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SUMMARY
Genital human papillomavirus (HPV) infection is common and the majority of 
infected individuals successfully clear with this virus. But in less than 5% of the cases 
the infection by high-risk HPV induces cervical cancer, which is preceded by a phase 
of persistent HPV infection during which the host immune system fails to eliminate 
the virus. Effective eradication of HPV-positive tumours may require both CD8+ and 
CD4+ T-cell-mediated immune responses. Specific CD4 T cell responses against the 
protein E6 of the HPV16 have been described in healthy subjects, but appear absent in 
patients with cervical cancer. This suggests the importance of specific CD4+ T-cell 
responses against E6 protein for the clearance of the virus.
The aim of this project was to investigate the m olecular interactions involved in T cell 
recognition of the HPV16 E6127-141 (DKKQRFHNIRGRW TG) peptide, in 
particular, mapping the im portant amino acids for T cell receptor (TCR) and MHC 
contact.
Initially, this was to be done directly by studying the biophysical interactions between 
soluble TCR and MHC molecules. Several constructs were made with the pBACgus 
expression vector in an attempt to generate soluble HLA-DR1/HPV16 E6127-141 
complexes. These vectors were used to generate recombinant baculovirus to infect 
insect cells, but unfortunately no stable M HCipeptide complexes were expressed ..
Since the biophysical approach was unsuccessful, the impact of changes in the 
peptide structure was assessed using functional T cell activation (IFN-y secretion). 
Two separate T-cell clones against HPV16 E6127-141 were tested against truncated 
versions of the peptide. The results show that the amino acids from the Cterminal end 
are essential for functional activation of both T-cell lines. Conversely, the amino acids 
from the Nterminal end do not appear to be as important. These variations in the 
responses induce by truncated peptides could be due to effects on TCR contact or 
MHC binding. However, m olecular modelling of the HPV16 E6127-141 associated 
with the MHC complex suggests that the Cterminal end of the peptide contributes to 
MHC binding.. These two clones were tested against variants of HPV16 E6127-141 
from different High risk HPV types (HPV31, 52, 33, 58, 67). Three types of response 
could be demonstrated. Indeed two peptides (HPV31, 52) have a null effect on the 
two T-cell clones, two others (HPV33, 58) have a partial agonist effect and one 
peptide (HPV67), has an antagonist effect on the T-cell clone. Based on these limited 
results, a model mechanism for viral immune evasion is proposed, whereby co- 
infection or sequential infection by different high risk HPV types could induce 
antagonistic effects on T cell responses. This could potentially inhibit effective 
clearance of a single HPV type, leading to viral persistence and disease.
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INTRODUCTION
5
In 1910 the first proof of a relationship between viruses and tumours was made. 
Then, Rous described a malignant chicken sarcoma, which could be propagated by 
transplanting its cells. These multiplied in their new hosts and formed tumours. The 
tumour cells yielded a causative virus (Rous 1967). This work was followed by the 
studies of Shope, who showed that the rabbit papillomavirus could induce giant warts on 
the skin and they might be true tumours (Shope 1966). Between 1960 and 1970 several 
studies demonstrated a viral aetiology for certain cancers (Southam 1963). In the 1970s, 
Harald zur Hausen postulated a role for, and then found HPV-DNA in cervical cancers 
(zur Hausen 2002, Haverkos, 2005). In the 1980s his group was the first to isolate HPV- 
16 DNA or HPV-18 DNA in more than 70% of cervical cancer biopsies from german 
patients (Durst, Gissmann et al. 1983; Boshart, Gissmann et al. 1984). It is now known 
that HPV-16 and HPV-18 play a major role in the aetiology of cervical cancer, the second 
most common cancer in women worldwide (Franco and Harper 2005), indeed 
Walboomers et al showed in a cervical cancer screening study that in 99.8% of cases 
HPV-16 or HPV-18 DNA could be detected (Meijer, Rozendaal et al. 2000).
1-PAPILLOMAVIRUSES:
Papillomaviruses (PV) were classified in a common family the papovaviruses, it 
was in the 1980s after sequencing and functional studies that the family 
“papillomaviruses” (Papillomaviridae) became officially recognized by the International 
Council on Taxonomy of Viruses (Bernard 2005). PVs have been found in more than 20 
different mammalian species, as well as in birds and reptiles and their classification is 
based on nucleotide sequence homology (Doorbar 2005). Because of their medical
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importance, HPV have been the most extensively studied, and more than 100 different 
types have now been identified. To qualify as a distinct HPV type, the nucleotide 
sequence of the HPV LI gene must differ from all other HPV types by at least 10% (de 
Villiers, Fauquet et al. 2004). The viruses are absolutely species specific and also 
exquisitely tissue tropic with a predilection for infection of either cutaneous or internal 
squamous mucosal surfaces (Stanley 2001). Furthermore the HPV can be separated into 
high or low risk types depending upon their oncogenic potential.
Table 1: Example of the most frequently studied papillomavirus types and their 
biological and clinical properties (Bernard 2005).
Types Properties
Low risk
-HPV-2, -27, -57 -Common skin warts, frequently 
in genital warts of children
-HPV-7, -40, -43 -Low risk mucosal and 
cutaneous lesions
-HPV-6,-11,-13, 
-44, -74
-Benign mucosal lesions. Some of 
these can progress malignantly
-HPV-1, -63 -Cutaneous lesions, frequently in 
footwarts
Hi eh risk
-HPV-16,-18-31, 
-33, -35, -52, 
-58.
-High risk malignant cervical 
HPV-16 most prevalent HPV type 
in cervical malignancy
-HPV-5, -8 -Cutaneous benign and malignant 
lesions in EV and immune- 
suooressed patients
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Infection of cutaneous epithelia with a low risk HPV leads to the formation of 
warts, which are hyperproliferative lesions. In this way common skin warts are frequently 
found in infection with HPV-2, -27, and -57 (de Villiers, Fauquet et al. 2004). Infection 
with a high risk HPV leads to the formation of carcinomas, for example HPV-5 and 
HPV-8 induce malignant lesions in epidermodysplasia verruciforms and immune- 
suppressed patients (Bernard 2005).
About 30 types regularly or sporadically infect the genital tract and they can be 
divided into those predominately associated with benign ano-genital warts or 
condylomata, HPV-6, -11 and those associated with ano-genital cancers and intra­
epithelial lesions particularly of the cervix (Stanley 2001). The first HPV types isolated 
directly from cancer biopsies of the cervix were the HPV-16 and -18 (zur Hausen 2002), 
since then greater than 99% of all cervical cancers have been found to be HPV positive 
with particular high risk HPV (-16, -18, -31, -45, -52, -58, etc) (Barnard and McMillan 
1999). The comparison of HPV type distribution in high-grade squamous intraepithelial 
lesion shows a prevalence o f the HPV-16 and -18 types. This could be interpreted either 
these types have a greater potential to induce malignant transformation or they have a 
greater potential to evade the host immune system (Clifford, Smith et al. 2003).
1-1-Epidemiology of the “high risk” HPV infections
Cervical cancer is the second most common cancer worldwide (471 000 annual 
cases, 233 000 deaths) (Parkin 2001), and high-risk HPV can be found in a growing 
proportion o f patients with cervical cancer, approaching 99%, but is not yet found in 
every patient with disease (Haverkos 2005). HPV is so common that more than half of all
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sexually active adults will be infected in their lifetime, although young, sexually active 
women bear the brunt of both infection and clinical complications (Ault 2006). In UK, as 
in other countries, the seroprevalence for high-risk HPV declines with increasing age. 
Nevertheless, even if the seroprevalence of the high-risk HPV is important in the young 
population in 80% of the cases the individual clears the infection, but it is not completely 
understood why some HPV lesions persist and progress in cancer. A number of genetic 
and/or immunological and environmental co-factors have been involved in increasing the 
risk of disease progression. Reproductive history, hormonal contraceptive use and 
smoking (Cotton, Sharp et al. 2007) can play a role in the progression of disease. 
Furthermore it has been demonstrated that high risks of squamous cell cervical cancer 
were associated with DRB1*1001, DRB1*1101 and DQB1*0301 and decreased risks 
were associated with DRB1*0301 and DRB1*13 (Madeleine, Brumback et al. 2002).
1-2-Genome of HPV:
Papillomaviruses are a group of small non-enveloped DNA tumour viruses with a 
virion size of approximately 55nm in diameter. All the viral particles contain a double­
stranded, circular DNA genome o f approximately 8 kb that can be divided into 3 major 
regions: early, late, and a long control region (LCR or noncoding region) (figure 1). The 
early region of HPV genomes occupies over 50% of the virus genome from its 5’ half and 
encodes six common open reading frames (Zheng and Baker 2006) that translate 
individual proteins named E l, E2, E4, E5, E6, and E7. The late region of the HPV 
genome, covering almost 40% of the virus genome, codes for the LI and L2 proteins. LI 
is the major capsid protein and L2 the minor capsid protein (Stanley 2001). The LCR
region, a segment of about 850 bp (10% of HPV genome), has no protein-coding 
function, but bears the origin o f replication as well as multiple transcription factor 
binding sites that are important in regulation of RNA polymerase II-initiated transcription 
from viral early as well as late promoters (Zheng and Baker 2006) The individual 
functions of each protein are briefly summarized in table 2.
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Figure l:G enom e organisation o f  high-risk HPV16. Early ORE'S are indicated in purple, w hile capsid genes are 
shown in blue (Stanley 2001)
Table 2: High-risk HPV protein functions
Protein Proposed functions Mode of action
El Viral genome replication
-DNA helicase and ATPase activity, 
necessary to unwind DNA at the OR 
allowing DNA replication (Chiang, Ustav 
et al. 1992; Hughes and Romanos 1993).
E2 Viral genome replication
-DNA binding transcription factor 
interacting with motifs within LCR 
(McBride, Romanczuk et al. 1991).
-Acts as either transcriptional repressor or 
activator (Bernard, Bailly et al. 1989; 
Demeret, Desaintes et al. 1997).
-Interaction with El protein vital for OR 
recognition (Chiang, Ustav et al. 1992).
E4 Cytoskeletal changes
-Interacts with the keratin cytoskeleton 
causing collapse of the cytokeratin matrix, 
which facilitates virion release (Doorbar, 
Ely et al. 1991).
E5
Cellular growth 
Immune evasion
-Interacts with epidermal growth factor 
receptor (Crusius, Auvinen et al. 1998). 
-Inhibits endosome acidification (Straight, 
Herman et al. 1995).
-Down regulates HLA class I and interferes 
with HLA class II expression (Zhang, Li et 
al. 2003; Ashrafi, Haghshenas et al. 2005).
E6
Inhibition o f apoptosis -Interacts with p53 leading to its 
degradation (Scheffner, Wemess et al. 
1990), with Bak, p300/CBP, MAGI-1... 
(Mantovani and Banks 2001)
Keratnocyte immortalisation -Induces telomerase activity (Klingelhutz, 
Foster etal. 1996).
E7
Activation of cell cycle 
Keratnocyte immortalisation
-Binds to Rb and induce its degradation 
resulting in the loss o f cell cycle control at 
the Gi/S-phase transition (Boyer, Wazer et 
al. 1996).
LI Viral capsid protein
-Major coat protein (360 copies per capsid) 
(Doorbar and Gallimore 1987).
L2 Viral capsid protein
-Minor coat protein (12 copies per capsid) 
(Doorbar and Gallimore 1987).
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1-3-Viral cycle of HPV:
Normal squamous human epithelia grow as stratified layers and only the cells of 
the basal layers are able to actively divide. During these mitoses one of the daughter cells 
migrates upward and starts her differentiation while the other remains in the basal layers 
(Hebner and Laimins 2006). As differentiation progresses, the cell begins to synthesize 
and accumulate high-molecular-weight keratins. This accumulation induces the nuclear 
envelope break down and the cell ceases to function and exists only as keratin-filled sacs, 
and is in the highest strata of differentiated epithelium.
HPV virions initially infect the basal layers of epithelia via micro-abrasions and 
enter cells via an unidentified receptor; however it is known that heparin sulphate 
mediates the initial attachment of virions to cells (Longworth and Laimins 2004). HPV 
infection of the cells leads to the establishment, as episomes, of viral genome in the 
cellular nucleus (Doorbar 2005). All these events result in the activation of the early HPV 
promoter and of a cascade of viral gene expression, which ends up with the production of 
approximately 20 to 100 extrachromosomal copies of viral DNA per cell. The expression 
of specific “early” viral genes (such as E5, E6 and E7) results in enhanced proliferation 
of the infected cells and their lateral expansion (zur Hausen 2002). In parallel, one of the 
infected daughter cells migrates into the upper layers of the epithelium and begins to 
differentiate, though it remains active in the cell cycle (Hebner and Laimins 2006). As 
HPV positive cells differentiate, the late promoter is activated and induces the expression 
of the late genes, which leads to high-level amplification of the viral genome. The virus 
continues its migration in the epithelium with the daughter cell and in the uppermost
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layers, viral DNA is packaged into newly formed capsid and progeny virions are released 
from the cell (Doorbar 2005).
In a model of mucosal PV infections (inoculation of dogs with COPV) these viral 
cycles result in the formation o f epithelial lesions, between weeks 8 and weeks 12 of 
infection there is an infiltration of lymphocytes and lesion regression takes place, and at 
week 16 the infected area has the appearance of uninfected epithelium (Nicholls, Moore 
et al. 2001). A similar pattern may also occur in humans and the importance of the 
immune system in controlling the spread of HPV-associated disease is well established, 
this will be described in section 3.
In absence of regression these lesions of the epithelium can persist and progress to 
cancer. When we observe the prevalence o f the HPV infection in general population the 
proportion of lesions that progress to cancer is very low, but when the patient does not 
successfully resolve this infection, such lesions can progress to cervical intraepithelial 
neoplasia grade 1 (CIN 1), and may progress further to CIN2, CIN3 and cancer (Doorbar 
2005). These cellular transformations are principally due to the E6 and E7 genes and their 
respective proteins.
The HPV viral cycle is summarized in figure 2 and figure 3 shows the expression 
of HPV genes during the cell differentiation.
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Figure 2 Viral cycle of H PV  from  W oodm an, 2007
Integration
HPV is thought to access the basal cell through micro-abrasions in the cervical epithelium. Following infection, the early HPV genes are 
expressed and the viral DNA replicates from episomal DNA (purple nuclei).In the upper layers o f  epithelium the viral genome is replicated 
further, and the late genes are expressed. LI and L2 encapsidate the viral genomes to form progeny virions in the nucleus. The shed virus can 
then initiate a new infection. The progression o f  untreated lesions to microinvasive and invasive cancer is associated with the integration of 
the HPV genome into the host chromosomes (red nuclei), with associated loss or disruption o f  E2, and subsequent up-regulation o f  E6 and 
E7 oncogene expression.
Virus Release
Packaging -/
Genome
Amplification
Proliferation
Genome
Maintenance
Figure 3 Expression of each H PV  genes during infection  (W oodm an 2007, D oorbar et al 2005)
1-4-The E6 and E7 genes and their proteins
The E6-E7 region is present in all PVs and contains genes that code for 
transforming proteins expressed in the initial stages of the infection, before the infected 
cells start to differentiate (Garcia-Vallve, Alonso et al. 2005).
The E6 proteins of high-risk HPVs contain approximately 150 amino acids and 
include 2 zinc finger-like motifs Cys-X-X-Cys (Longworth and Laimins 2004). The high- 
risk E6 proteins are localised to both the nucleus and the cytoplasm of HPV-infected 
keratinocytes (Hebner and Laimins 2006). The functions of the protein are principally to 
prevent the induction of apoptosis of the infected cells. In this goal the E6 protein is able 
to associate with the protein p53, which is a tumour suppressor factor involved in 
regulation of both the Gi/S and G2/M cell cycle check point (Oren 2003). E6 binds to p53 
in a ternary complex with the ubiquitin ligase, which induces the ubiquitination of p53 
and subsequently its degradation by the proteasome. The E6 protein can also induce the 
decrease of pro-apoptotic proteins including Bak or Bax (Mantovani and Banks 2001). As 
a consequence, the presence of E6 is considered a predisposition factor in the 
development of HPV-associated cancers, allowing the accumulation of risk errors in host 
cells DNA (Doorbar 2005). Furthermore E6 may contribute to the development of 
metastatic tumours by disrupting normal cells adhesion. A summary of the functions is 
presented in the figure 4.
The E7 proteins of high-risk are found predominantly in the nucleus of infected 
cells and are approximately 100 amino acids in size. In transgenic mice it has been shown 
that expression of this protein by itself is enough to transform cells at a low frequency 
(Riley, Duensing et al. 2003). One of the main functions of the E7 protein in the HPV
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cycle life is the binding and the degradation of the Rb family proteins (Hebner and 
Laimins 2006). The Rb protein is a negative regulator of the cell cycle that normally 
prevents the S-phase entry by associating with the E2F family of transcription factors. On 
progression from Gi into the S-phase, some cyclin-kinase complexes phosphorylate Rb, 
resulting in release of Rb from E2F complex and transcription of genes involved in the 
synthesis of DNA (Longworth and Laimins 2004). The E7 protein induces the destruction 
of the Rb protein by the proteasome and leads the cells in the cell cycle, the proposed 
model is E7 binds to and recruits calpain to Rb. E7 activates calpain cleavage Rb, which 
results in the release of E2F and the degradation of Rb by the proteasome (Darnell, 
Schroder et al. 2007). E7 can also bind other proteins involved in the cell proliferation 
including the histone deacetylalases and the cyclin-dependent kinase inhibitors (p21 cip 1 
and p27kipl), which leads the cell in cellular cycle.
1-5-The natural history of cervical HPV infection
In reality the period between the infection by HPV and the appearance of lesions 
is highly variable and can vary from weeks to months (Stanley 2001), and fortunately 
80% of HPV infections are transient (Schiffinan and Kjaer 2003). The natural history of 
cervical carcinogenesis may be summarised in the following schema:
Normal Infection  ^ HPV infected Progression pre- Invasion  ^ Cancer
cervix <-------------- cervix <-------------- cancer
Clearance Regression
Figure 4: An epidemiologic model of cervical carcinogenesis. The persistence of 
oncogenic HPV types is necessary for progression and invasion (Schiffinan and Kjaer 
2003).
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Sexual contact with an infected partner is necessary for the transmission of the HPV. 
HPV must be persistent in host epithelial cells during few months to few years before 
development of a cervical cancer (Ault 2006). During this phase no HPV DNA is 
detectable by conventional molecular tests, and in 80% of the cases there is a clearance of 
the pathogen. In uncommon cases, compared with clearance, the latency phase is 
followed by a phase of persistence, which is defined by the detection of the same HPV 
type or variant two or more times over a certain period (between few months and a year). 
During the persistence phase the lesions can progress to CIN with different grades (1 to 
3) (Woodman, Collins et al. 2007). In CIN 1 only the lower third o f the epithelium is 
affected, whilst in CIN 2 the lower two thirds of the epithelial structure is altered. In these 
low grade CIN the virus is still maintained as an episome in the keratinocytes and the 
early and late proteins are produced and some new virus is synthesised (figure 2). 
However, high grade lesions (CIN 3) are associated with an integration of the viral 
genome in the DNA of the host cell. In several cases this integration occurs in or close to 
known genes, most frequently in intronic regions (Wentzensen, Vinokurova et al. 2004). 
This integration is associated with a deregulated expression of HPV E6 and E7 genes in 
epithelial stem cells, which leads to major chromosomal instability and aneuploidy. The 
progression from CIN 3 to invasive cancer occurs when transformed cells breach the 
basement membrane of the epithelial tissue, allowing spread to other anatomical sites.
CIN 1 lesions can spontaneously regress without any treatment in 60% of cases, 
in contrast the CIN 3 lesions regression occurs in only 33% of the cases (Ostor 1993). For 
the patients with cervical cancer, the survival rates are closely related to the stage of
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disease. Following treatment, the 5 years survival rate of women with invasive cancer is 
-20%, whilst for women with very early stage the 5 years survival rate is 95%.
2-IMMUNE SYSTEM
Host defence is a partnership between innate immunity (phagocytes, soluble 
proteins as cytokines, complement, and epithelial barriers) and adaptive immunity 
(antibodies, cytotoxic effector cells, and auxiliary cells). Without coordination between 
both systems an efficient defence can not be observed. Indeed the innate immune system 
detects the pathogen and acts as the first line of defence.
2-1-Innate immunity
The innate immune response is not specific for pathogen; therefore it has evolved 
several strategies o f self/nonself discrimination, based on the recognition of molecular 
patterns demarcating infectious nonself, as well as normal and abnormal self.
In vertebrate animals three strategies of immune recognition can be described in 
terms of recognition of “microbial nonself’, recognition of “induced or altered se lf’ and 
recognition of “missing se lf’ (Medzhitov and Janeway 2002).
2-1-1-Recognition of “microbial nonself’ and “induced or altered self’
The basis of microbial nonself recognition lies in the ability of the host to 
recognize conserved products of microbial metabolism that are unique to micro­
organisms and are not produced by the host. Indeed pathogens express conserved 
molecules that are essential products for their physiology. These invariant structures are
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referred to as pathogen-associated molecular patterns (PAMPs). Some known examples 
of these conserved molecules are lipopolysaccharide (LPS) of the gram-negative bacteria 
and the peptidoglycan o f the gram-positive bacteria. These PAMPs are recognised by 
receptors of the innate immune system called pattern recognition receptors (PRRs). 
Nevertheless it is important to note that PAMPs are basically not unique to pathogens and 
are expressed by both pathogenic and non-pathogenic micro-organisms. This is due to the 
essential role of these molecules for microbial survival and they are incapable of 
sustaining mutations. The exact mechanisms that allow the host to ‘‘tolerate” non- 
pathogenic micro-organisms remain largely unknown. It has been hypothesized that 
compartmentalization (e.g., confinement of micro-flora to the lumina side of the intestinal 
epithelium), as well as anti-inflammatory cytokines, such as transforming growth factor-p 
(TGF- P) and interleukin IL-10, have an important role in this process (Medzhitov 2001).
The innate immune system uses various PPRs that are expressed on the cell 
surface, in intracellular compartments, or secreted into the blood stream and tissue fluids. 
Currently we can distinguish seven protein families: the C-type lectins, the leucine-rich 
proteins, the scavenger receptors, the pentraxins, the lipid transferases, the integrins and 
the toll like receptors (TLRs) (Medzhitov and Janeway 1997). The principal functions of 
these molecules are the activation of the leptin pathway of the complement, the 
opsonisation of the microorganism due to activation o f the classical complement 
pathway, phagocytosis, activation of pro-inflammatory signalling pathways and induction 
of apoptosis. Lot of PPRs are expressed on the cell surface on specialized antigen- 
presenting cells (APCs), such as dendritic cells (DCs), or macrophages and plays a 
critical role in the initiation o f the adaptive immune response (Medzhitov and Janeway
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2002). Indeed these molecules are able to recognize their own specific ligand, which 
induces the upregulation of cell-surface expression of co-stimulatory molecules (CD80 
and CD86) and of major histocompatibility complex class II (MHC II) molecules. TLRs 
also induce expression of cytokines (such as IL-12), chemokines, their receptors, and 
trigger many other events associated with DCs maturation. All these upregulations due to 
the TLRs contribute to the differentiation of activated T cells into T helper Thl effector 
cells. It is not yet known whether TLRs have any role in the induction of Th2 responses.
2-1-2-Recognition of “missing self’
This concept of “missing se lf5 was proposed to explain why natural killer (NK) 
cells preferentially kill target cells that express few or no MHC class I. These cells are a 
type of lymphocyte that mediates innate immunity against pathogens and tumours 
(Cerwenka and Lanier 2001). NK cells express on their membrane a vast number of 
receptors that control their activation. Indeed the activation of these cells will depend on a 
tuned balance between the activating and the inhibitory signals provided by a large 
number of cell surface receptors belonging to immunoglobulin (Ig)-like and C-type lectin 
receptor families (Andoniou, Andrews et al. 2006). During some viral infections a down 
regulation of class I MHC may be observed at the surface of certain cells, this kind of 
event can disturb the tuned balance between activating and inhibitory signals received by 
the NK cells and induce their activation, the same profile may be shown in cancer cells 
(Pena, Alonso et al. 1990). The activated NK cells will mediate their activities through 
the release of cytokines (IFNy, TNFa, IL-5, IL-10...) or cytolysis of the targets via the 
exocytosis of granzymes A and B, and have been believed unable to mount a recall or
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memory response when re-exposed to the same antigenic challenge (Andoniou, Andrews 
et al. 2006).
In conclusion all these recognitions of events also control innate or non-adaptive 
host defence mechanisms that keep infection in check during the several days required for 
adaptive immune response to become effective (Janeway 1992).
2-2-Adaptive immunity
Adaptive immunity is mediated by T and B-lymphocytes bearing clonally 
distributed antigen receptors and these responses are induced by the innate immunity 
(Medzhitov and Janeway 1997). The recognition of the PAMPs by the PRRs has two 
actions. In a first instance there is the induction of expression of co-stimulatory molecules 
on the APC surface, as CD80 and CD86, and the expression of other molecules such as 
adhesion molecules, which are evolved in the formation of the immunological synapse. In 
a second instance the production of pathogen-specific signals in the form of MHC- 
peptide complexes (Medzhitov and Janeway 1997). Furthermore the successful 
engagement o f innate immunity induces an inflammation with the secretion of different 
cytokines such as IL-1, type I IFNs (a and p), IL-6, TNFa, and IFNy, which are helpful 
for the activation of the T cells (Hoebe, Janssen et al. 2004). This cytokine environment 
associated with the interaction between the TCR and the MHC lead to the linear T 
lymphocytes differentiation into Thl or Th2 cells. Then in primary immune response 
activated T cells proliferate and, depending on the duration of stimulation by APCs and 
cytokines environment, reach hierarchical levels of differentiation characterized by
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distinct effector function, homing and survival capacity (Lanzavecchia and Sallusto
2000).
2-2-1-Processing and presentation of the antigen
In the absence of ongoing inflammatory and immune responses, DCs 
constitutively patrol through the blood, peripheral tissues, lymph and secondary lymphoid 
organs. In peripheral tissues the DCs take up self and nonself antigens, process them into 
proteolytic peptides, and load them onto class I or II MHC molecules (Guermonprez, 
Valladeau et al. 2002). Most o f the peptides loaded onto class I MHC are generated by 
proteasome degradation of newly synthesized ubiquitinated proteins. The resulting 
peptides are transferred to the ER by specialized peptides transporters, TAP, and load on 
a new class I MHC under the control of complex composed of several ER resident 
chaperons (including tapasin, calnexin, calreticulin) (Cresswell, Bangia et al. 1999). Once 
associated to peptides, class I MHC molecules are rapidly transferred through the Golgi 
apparatus to the plasma membrane (figure 6).
In parallel to this presentation of endogenous antigens by the class I MHC, 
another mechanism has been discovered 30 years ago (Bevan 1976), called cross- 
priming. This process is the presentation of exogenous peptides by the class I MHC 
(Basta and Alatery 2007). This occurs in the APCs and several mechanisms are proposed 
to explain this kind of event. One of them is the release of the pathogen to the cytosol 
from the phagosome or phagolysosome (Kovacsovics-Bankowski and Rock 1995).
Peptide loading on class II MHC occurs through a different pathway. Soon after 
synthesis in the ER, three a/p  MHC class II dimers associate with a trimer of invariant
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(Ii) chains, which ensure that ER derived proteins do not bind to the ER membrane 
anchored MHC II molecule (Cresswell 1996, Romagnoli, 1993). This nonameric complex 
exits the ER and pass through the Golgi apparatus before being transported to the 
endocytic pathway, under the influence of transport signals present in the cytoplasmic 
region of the Ii chain (Guermonprez, Valladeau et al. 2002). Like MHC I, during the 
formation of these complexes, calnexin is present to add stability to the newly formed 
molecule (Anderson and Cresswell 1994). Ii has a second function, which starts with the 
dissociation of MHC II from calnexin and results in the transport of the MHC II molecule 
from the ER to endosomal compartments for peptide loading. In order for peptide loading 
to occur, Ii must be removed from the MHC II peptide-binding groove. This is mediated 
through the activities of cathepsin S (Villadangos, Bryant et al. 1999), which cleaves Ii in 
a number of steps. Ii is then released from the MHC II molecule through the actions of 
the class II associated invariant-chain peptide (CLIP), which performs the final Ii 
cleavage. This also releases the MHC II molecule from the membrane. In order for MHC 
II to bind to endosomally derived proteins, an MHC-like molecule called DM must first 
associate. This association leads to the dissociation of CLIP from the MHC II peptide- 
binding groove, allowing endosomally processed peptide fragments to bind. MHC DM 
(Kropshofer, Hammerling et al. 1999) also facilitates a process termed “peptide-editing”, 
which ensures that only stable MHC II peptide complexes are expressed and transported 
to the cell surface for potential TCR interactions (Busch, Doebele et al. 2000) (figure 6). 
Like MHC I, many self-peptides are presented on the surface of APCs expressing MHC 
II. With this in mind, the control, or deletion of self-reactive T cells is vitally important 
for immunogenic tolerance.
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The APCs and principally the DCs, which are in contact with the pathogens prime 
and present the antigen to the T cells via the class I or class II MHC. These mechanisms 
induce the maturation of the DC, which is characterized by the up-regulation of a number 
of adhesion molecules, such as ICAM-1, ICAM-3 or LFA-3 as well as co-stimulatory 
molecules (B7.1 and B7.2), that are respectively required for the migration of the DC and 
the priming of T cells (Timmerman and Levy 1999).
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Figure 6: Model of the two pathways for the presentation of the antigen by the class I 
MHC and the class II MCH (adapted from Immunology, 4th edition, Janis Kuby, 2000).
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2-2-2-Genetics and structure of MHC class I
The human HLA region is located on the chromosome 6 and extends over 4xl06 
base pairs of DNA. It can be divided in 3 regions and the first contains the class I MHC 
with the HLA-A, -B, -C, -E, -F and -G. These molecules are able to present endogenous 
peptides derived from an intracellular pathogen to CD8+ T cells. MHC I comprise of a a- 
domain and p2-macroglobulin (p2m). p2m is comprised mainly of p-sheets, and it 
associates loosely with the MHC complex (Figure 7A). Peptides are presented in a 
groove between by the MHC a  1 and a2-domains formed from two long a-helices and a 
P-sheet domain, which provides the floor of the binding groove. The a3-domain, which is 
comprised mainly of p-sheets, is linked to the cell surface via atransmembrane-domain.
The peptide binding groove has been described in terms of pockets (A to F) which 
form important contacts with the peptide (Figure 7B). Generally, the B and F pockets are 
the most important in anchoring the N and C terminals, respectively, of the peptide. This 
interaction is often very selective, with only certain peptide residues in certain positions 
being compatible with the MHC binding groove. This anchoring stabilises the peptide, 
allowing central residues to bulge out away from the MHC surface for TCR recognition 
(Figure 7C) (Saper, Bjorkman et al. 1991; Reid, McAdam et al. 1996; Cole, Rizkallah et 
al. 2006).
2-2-3- Genetics and structure of MHC class II
These molecules are encoded by the chromosome 6 and are divided in 3 families 
HLA-DR, HLA-DQ and HLA-DP. These molecules are able to present exogenous 
peptides derived from an extra-cellular pathogen to CD4+ T cells. MHC II is very similar
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in overall structure to MHC class I, although they are formed from a a  and {3-chain, both 
with two distinct domains, rather than a three domains a-chain and p2m. (figure 8A). The 
a l  and pi-domains form the peptide binding groove, which is topologically similar to 
pMHC I. The main difference between the grooves is in the characterisation of the MHC 
II binding pockets. For MHC II molecules, the binding pockets are described as 1 to 9 
(Jones, Fugger et al. 2006) (Figure 8B), although the main concepts are similar compared 
to the defined MHC I pockets A to F. The a2 and p2-domains, which are comprised 
mostly of p-sheets, link the molecule to cell surface, via a transmembrane domain, and 
add to its overall stability. The main structural difference between the two molecules is in 
the peptide conformation. MHC II peptides are generally more buried within the groove 
and have a less prominent central bulge, resulting in a theoretically less favourable 
surface for TCR docking (Figure 8C) (Silver, Guo et al. 1992; Rudolph and Wilson 2002; 
Rudolph, Stanfield et al. 2006).
The structures of MHC complexes have provided answers to key questions 
concerning their overall conformation and antigen presentation. From such studies it has 
become clear that certain MHC types are restricted in terms of the peptide sequences they 
can successfully present. This is mostly due to the identification of important peptide 
anchor residues that form specific interactions with the MHC binding groove. In the case 
of pMHC I, for example, the interactions of peptide position 2 with the MHC B-pocket, 
and the terminal peptide residue with MHC F-pocket are of particular importance. 
Therefore, only certain residues at these positions will support stable antigen 
presentation.
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F igure 7: A -C ry s ta l structure o f  H L A -B 8 EB N A  to rep resen t the overall structure o f  
pM H C  (C ole, R izkallah  et al. 2006). pM H C  Is are com posed  o f  an a - c h a in  (brick  red) 
and (32m (green), w ith  the  pep tide (co loured  using W ilson B fac to r w hich  is a m easure o f  
residue flex ib ility  (red  to  blue, h igh to  low )) presen ted  in  a  ‘pep tide g roove’ form ed 
betw een tw o  a -h e lice s  o f  the a l  and a2 -ch a in s. B -T h e  M H C  b ind ing  pockets (A -F ) 
w hich  form  specific  in teractions w ith conserved  pep tide anchor residues. C -T h e  peptide 
conform ation  in M H C I m olecu les is characterised  by a  prom inent central bu lge w hich 
form s the  m ain  p la tform  fo r the antigen specific  T C R  interaction.
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F igure 8: A -C iy sta l structure o f  H LA-D R1 H A  to  represen t the  overall structure o f  
pM H C II (H ennecke, C arfi e t al. 2000). pM H C  I Is are  com posed  o f  a  a -c h a in  (green) and  
a  p-chain  (cyan), w ith  the pep tide (W ilson  B factor) p resen ted  in a  ‘pep tide g ro o v e’ 
form ed betw een  tw o a -h e lice s  o f  the  a l  and p i-ch a in s . B -T h e  M H C  b inding  pockets (1 - 
9) w hich  form  specific in teractions w ith conserved  pep tide ancho r residues. C -T h e  
peptide conform ation  in M H C  II m olecu les is flatter com pared  to  M H C I, although  the  
exposed  surface availab le  fo r antigen specific T C R  in teractions is sim ilar.
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2-2-4-Structure and functions of HLA class II
Polymorphism in HLA class II molecule, as well class I, is principally located in 
the amino acids of the peptide binding groove, which contribute to the formation of 
peptide binding pocket. This polymorphism induces spatial and chemical characteristics 
of the binding pocket and permits a preferential accommodation of the antigenic peptide 
in the groove of the HLA class II molecule (Nielsen, Lundegaard et al. 2004). The amino 
acids residues or the peptide epitopes that interact in the pockets of the binding groove 
are known as anchor residues and constitute the HLA allotype-specific binding motif. 
Due to this polymorphism antigen-specific CD4+ T cells exist at a very low frequencies 
in patient peripheral blood, frequently in the range of 1:6,000 to 1:100,000 (Nepom, 
Buckner et al. 2002). To identify and analyse these cells die traditional functional assays, 
such as antigen-induced proliferation or cytokine secretion, can be used. New techniques 
using MHC tetramers can now be added to the immunological toolbox to expand these 
types of assays, improving sensitivity and quantitation. Indeed different studies have used 
this technology for the enumeration of CD4+ T cells specific for viral, bacterial and auto­
antigens (Novak, Liu et al. 1999; Meyer, Trollmo et al. 2000; Reijonen, Novak et al.
2002).
Nevertheless this technology of tetramers can necessitate different approaches due 
to the complexity of the molecule. Class II molecules are non-covalent dimers of 
a  and p chains, which have a variable range of stability and solubility in solution. 
Detection of individual CD4+ T-cells based on their antigen specificity has been 
hampered by 2 significant barriers: the low frequency o f such CD4+ T cells in periphery 
and the low avidity of binding between the TCR and the MHC-peptide complex (Nepom,
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Buckner et al. 2002). A third difficulty results in the production o f the molecule, indeed 
three strategies can be used are: the expression of the a/p  chains by E. coli followed by 
the folding of the molecule in a buffer containing the peptide, the synthesis of the 
molecule associated with the peptide by insect cells or the production of the HLA class II 
by mammalian cells. All these techniques have different steps and the solubility of the 
molecule or the avidity of the peptide to the TCR, are as many difficulties in the 
production of a HLA class II associated with a peptide.
2-2-5-The T cell receptor (TCR)
The TCR is an antigen-specific membrane-bound molecule present on the surface 
of T-cells. Between 90 and 99% of peripheral blood T cells express TCR ap  chains, 
whilst the remaining population express TCR y5 chains. The TCR p-chain is encoded by 
four gene segments termed D (diversity), J (joining) and V (variable), which combine 
with the more conserved C (constant) region (Kronenberg, Siu et al. 1986) to make up the 
full p-chain under the influence of recombination activation genes (RAG1 & 2) and 
terminal deoxynucleotidyl transferase (TdT).
The DJ genes recombine first, involving the joining of the Dp gene segment to one 
of six Jp genes. There are two possible pools of genes that encode these segments (1 and 
2) from each chromosome pairing, so recombination can occur from either set. A Vpgene 
then recombines to the DpJp segment to encode the variable (V) region of the p-chain. 
This VpDpJp gene is then incorporated with the Cp segment to encode the full p-chain. 
Due to the presence of additional Dp and Jp segments upstream of the Cp segment, 
unsuccessful VpDpJp rearrangements, i.e. those that do not encode a functional p-chain,
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can be rescued by further rearrangements which increase the chance of successful p-chain 
expression. The p-chain then associates with a surrogate a-chain, pTa, to form a pre- 
TCR, which is transported to the cell surface (Figure 9B). During this maturation stage, T 
cells express both CD4 and CD8 (double positive). The a-chain forms in an identical 
manner to the p-chain, except that it lacks the D region. Therefore, VaJa recombination 
occurs first to encode the V domain, followed by VaJaCa recombination to encode the 
full a-chain (Krangel, Hemandez-Munain et al. 1998). Similarly to the p-chain, the a - 
chain may undergo rescue gene rearrangements if the initial recombination is 
unsuccessful. In fact, due to the presence of multiple Va and Ja genes spread over some 
80 kb o f DNA, the number of a-chain rearrangements that can occur is virtually endless 
and invariably results in either the production of a successful a-chain or the prolonged 
lack o f an activation signal leads to T cell death.
The V, D, J genes are clustered together at specific loci on chromosome 9. In 
order to splice these genes together during recombination, recombination signal 
sequences (RSSs) are required. These signals are composed of seven conserved 
nucleotides that reside next to the gene encoding sequence. These RSSs, present on the 
3’, or 5’ end of adjoining gene segments, are recognised by RAG1 and RAG2, which 
initiate the recombination. These segments are spliced together as an mRNA transcript to 
allow translation of the full length protein (Figure 9C). The two complete chains (a and 
P) combine, via disulphide bonds, to form a TCR capable of binding to peptide/self major 
histocompatibility complexes (pMHCs), presented by cortical epithelial cells, in the 
thymic stroma (Fink and McMahan 2000). Successfully binding T cells receive survival 
signals from these cells in a process called positive selection. Thymic nurse cells then
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present the naive T cells, now single positive for either CD4 or CD8, with self-antigens 
acquired during embryonic development in a process termed “central tolerance”. T cells 
that express TCRs that bind too strongly to these self-antigens are clonally deleted in the 
thymus. Negatively selected T cells must bind adequately weakly to these self antigens 
before migrating into the periphery (Sprent and Kishimoto 2002). Thus, a peripheral 
population o f T cells is generated with the ability to respond to foreign antigen, whilst 
generally remaining non-reactive to self-antigen (Figure 9D). The resulting T cells are 
responsible for identifying a range of antigens and responding to them appropriately.
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Figure 9: A-Gene locus o f the TCR a  and P-chains. The a-chain V domain is encoded by the V and J gene 
clusters, and the C domain is encoded by the C gene. The P-chain genes are similar to a-chain, except that 
the P-chain contains D gene. Furthermore, the a-chain contains a large number o f V and J genes that can be 
used to increase the number o f possible V domain rearrangements. B-T cells first express a P chain, which 
occurs via the rearrangement o f the Dp and Jp genes encoding the variable domain, involving the activities 
o f RAG1/RAG2 recombinase. Joining o f  these segments requires the activities o f TdT. Successful 
rearrangement o f the variable (Vp) domain precedes TdT mediated joining to the Cp region, which encodes 
the constant domain. The P-chain then associates with a surrogate a-chain (pTa) and CD3, creating a pre-T 
cell receptor, which is transported to the cell surface. C- RAG1 and RAG2 enzymes recognise RSSs that 
flank the gene encoding DNA segments at the 3’ and 5’ ends o f adjoining gene segments. The broken 
strands are then rejoined under the influence o f TdT to produce full a  or p-chain encoded by the spliced 
genes. D- T cells, under the influence o f  tyrosine kinase Lck, start to express CD4 and CD8 (CD4+CD8+ 
double-positive). Multiple a-chains are expressed until positive selection occurs via the binding o f the TCR 
to self-pMHC, presented by cortical epithelial cells in the thymic stroma. After positive selection, the 
developing T cells loose either CD4, or CD8 expression to become single positive adapted from Garland 
and Geoffrey.
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2-2-6-T-cells
The interaction between the TCR and a class I or class II MHC associated with a 
peptide result in T cell proliferation and differentiation into a variety of cell fates that 
determine the class of immune response (Lanzavecchia, 2000). The CD4+ T-cells can 
polarize toward T helper 1 (Thl) or T helper 2 (Th2). The CD8+ T-cells differentiate into 
cytotoxic cells (CTL) capable of killing virus-infected cells.
CD4+ T helper:
T-cell responses are initiated in the T-cell areas of secondary lymphoid organs, 
where naive T-cells encounter antigen-loaded DCs. The duration of TCR stimulation 
represents the driving force for T-cell activation, differentiation, and ultimately death 
(Lanzavecchia, Lezzi et al. 1999). Naive T-cells require stimulation for approximately 20 
hours in order to be committed to proliferate, if the cells receive excessive stimulation 
they die by activation-induced cell death, whereas cells receiving insufficient stimulation 
may remain non-fit and die by neglect. The fittest cells survive and enter the memory 
pool as central and effector memory T-cells (Lanzavecchia and Sallusto 2000). In 
presence o f pathogen many DC precursors are continuously recruited into inflammation 
site and from there continuously migrate to the draining lymph nodes where they arrive 
endowed with T cell-stimulatory and -polarizing capacity (Robert, Fuhlbrigge et al. 
1999). This stimulation of the naive CD4+ T-cells influences their differentiation in Thl 
or Th2 cells, indeed low doses of antigen favour Th2 development while higher doses 
favour Thl development. Peptides that bind with high affinity to the TCR induce a 
predominant Thl phenotype in subsequent effectors, while low affinity peptides induce
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Th2 cells (Noble 2000). Associated with these interactions between the TCR and the 
peptide/MHC complex, the cytokine micro-environment plays an important role in this 
polarization. Schematically, the APCs in response to the antigen type secrete IL-12, 
which leads to differentiate in Thl or IL-6, which leads to differentiate in Th2 (Kidd
2003). The Thl cells drive the type-1 pathway (“cellular immunity”) to fight viruses and 
other intracellular pathogens, eliminate cancerous cells, and stimulate delayed-type 
hypersensitivity (DTH) skin reaction. Th2 cells drive the type-2 pathway (“humoral 
immunity”) and up-regulate antibody production to fight extracellular organisms; type 2 
dominance is credited with tolerance of xenografts and of the foetus during pregnancy.
CD8+ T cells:
The development o f cytotoxic T lymphocyte (CTL) responses is necessary for the 
control of a variety o f bacterial and viral infection. The stimulation of naive CD8+ T-cells 
by a peptide/class I MHC in the lymph nodes induce their expansion and their migration 
to the infection site where these cells clear the pathogen by killing infected cells and 
secreting effector cytokines. After the resolution of the infection most of effector CTL 
die, leaving 5-10% of the original burst size as long-lived memory cells (Williams and 
Bevan 2007).
There is a great deal of evidence that during the stimulation of the naive CD8+ T- 
cells, CD4+ T-cell help plays an extremely important role in the generation of effective 
CD8+ T cell immunity (Clarke 2000). Keene and Forman (Keene and Forman 1982) 
proposed that the purpose of this three cells interaction was to facilitate delivery of short- 
range cytokines, such as IL-2, secreted by the CD4+ helper T cells to the antigen-specific
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CD8+ T-cell. A second hypothesis, that help for CD8+ T-cell activation is supplied 
indirectly, via CD4+ T cell-mediated up-regulation of APC co-stimulatory activity. 
Indeed the interaction between CD40L on activated CD4+ T-cells with the CD40 on 
APCs has been shown to induce a variety of co-stimulatory molecules (Clarke 2000).
The functions of the CTL are to kill infected cells or cancer cells, the interaction 
between the class I MHC associated with the restricted epitope induce a re-activation of 
the CTL which result in the death of the infected cell. The principal mechanism through 
which a CTL kills is release of pre-formed cytotoxic granules containing perforin and 
granzymes (Podack, Konigsberg et al. 1985). Perforin creates pores in the plasma 
membrane of the infected cell that firstly encourages osmotic lysis of the cell, and 
secondary permits the entrance of proteolytically active granzymes leading to apoptosis. 
CTL can also induce apoptosis of the target cells via the FAS/FAS-L pathway which 
activates the caspases (Rouvier, Luciani et al. 1993).
Regulatory T-cells:
In addition to the Thl and Th2 populations there is another CD4+ T-cell 
population named regulatory T-cells (Treg). These cells are considered to play a central 
role in self-tolerance (Pakravan, Hassan et al. 2007). They have been categorized into two 
major subgroups based on their ontogeny: the naturally Treg (FOXP3+, CD4+, CD25+), 
which develop in the thymus and are present in a naive mice and healthy individuals from 
birth, and the inducible Treg, which are generated in the periphery under various 
tolerogenic conditions.
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The natural Treg recognize self antigen via their TCR and their principal function 
is to suppress the activation of auto-reactive Thl, Th2 and CD8+ T-cells by cell-cell 
contact. The inducible Treg appear after encounter with antigen in presence of IL-10 and 
they have a very low proliferative capacity following activation (Roncarolo and Battaglia 
2007). These cells regulate immune responses through the secretion of TGFp and IL-10, 
thy will suppress both naive and memory T-cell responses and down-regulate the 
expression of co-stimulatory molecules and inflammatory cytokines by APCs 
(Roncarolo, Gregori et al. 2006).
yS  T-cells:
The majority of mature T cells expresses an aft TCR which recognizes peptides 
presented on the surface of antigen-presenting cells (APC) to CD8+ T cells by MHC class 
I or to CD4+ T cells by MHC class II molecules. In addition, a sizeable subset of CD3+ T 
cells carries an alternative TCR heterodimer composed of y and S chains. In the 
peripheral blood of healthy adult individuals, yS T cells account for 1-10% of circulating 
T cells, whereas yS T cells comprise a much higher proportion of T cells in other 
anatomical localizations, notably in the epithelia of the small intestine (Hayday, 2000). 
Two features are fundamentally different between conventional a(3 T cells and yS T cells. 
In contrast to a/3 T cells, human yd T cells do not (or only rarely) recognize peptides 
processed from complex protein antigens by professional APC but rather see 
unconventional antigens such as phosphorylated microbial metabolites and lipid antigens. 
These characteristics explain their role in innate immunity and not in adaptive immunity 
(Beetz, 2008).
40
2-2-7-B-cells and humoral responses
Humoral immunity is mediated by the production of antibodies by activated B- 
cells. This is the contact between the T-cells and the B-cells via CD40/CD40L, which 
induce the activation of the B-cells, and this is enhanced by antigen-receptor engagement 
and by interleukines such as IL-4 (Hodgkin and Basten 1995). This interaction undertakes 
a tightly regulated proliferation and differentiation program in which antigen-specific 
memory B cells and effector plasma cells are generated. The plasma cells secrete large 
amounts of antibodies, which are soluble but otherwise identical versions of the 
membrane-bound B cell receptor. In the first encounter with antigen, a primary antibody 
response is generated; later, a re-encounter with the same antigen causes a more rapid 
secondary response, producing high levels of antibodies with a high binding affinity for 
the target antigen (Bernard 2005).
3-IMMUNE SYSTEM AND HPV
Epidemiologic and natural history studies strongly suggest that the human 
immune response to HPV infection follows a similar pattern (Schiffinan and Kjaer 2003). 
Virtually all studies show that genital HPV infection is extremely common in young
sexually active women, with a prevalence as high as 80% in certain adolescent
populations (Moscicki, 2007). For most of these HPV infections DNA for a specific HPV 
type can no longer be detected. The time for this is between 8 and 14 mouths for HPV 16
infection and 5 to 6 months for low-risk HPV.
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3-1-Immunity against HPV
The cervical epithelium contains Langerhans cells (LC), which are a type of DC 
and act as the principal APCs into this site. LCs express HLA class I and HLA class II on 
their surface and react positively to HLA-DR antigens. They capture the HPV antigen 
and migrate to the the lymph nodes, where they present the antigen associated with a 
class I MHC or a class II MHC to the lymphocytes (Goncalves and Donadi, 2004). The 
role of T-cell immunity in controlling infection by various HPV types is further indicated 
by the increase incidence of HPV infections, HPV-associated warts, CIN lesions and 
cancers in immunocompromised patients such as transplant patients or HIV seropositive 
subjects (van der Burg, de Jong et al. 2002).
Furthermore different studies investigating the spontaneous regression of genital 
warts and cervical lesions have provided a more detailed picture of the immune response 
during the lesions clearance. Indeed Coleman et al. showed that regressing warts 
contained more T lymphocytes and macrophages than non-regressing control. They 
characterised these T cells and observed a predominance of CD4-positive lymphocytes 
with a greater expression o f activation marker in regression lesions (Coleman, Birley et 
al. 1994). It was shown that pro-inflammatory molecules, such as TNFa and IFNy, 
dominated the cytokine environment. Recent studies observed a correlation between a 
spontaneous regression of established HPV 16 high-grade squamous intraepithelial lesions 
of the cervix, and a HPV 16 E7 peptide-specific CD4+ T cell response (Peng, Trimble et 
al. 2007). Studies observed in HPV patients treated for CIN showed that recurrence-ffee 
survival is associated with a cellular immune response specific to synthetic peptides from 
the E6 and E7 proteins (Sarkar, Tortolero-Luna et al. 2005).
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3-1-1-CD4+ T-cell responses
Immunohistological studies on chronological series of biopsies from beagles 
experimentally infected with canine oral papillomavirus (Nicholls, Moore et al. 2001), 
indicate clearly that regression of infected lesions is associated with a Thl response but 
the viral antigens, which provoke this response, are not known (Stanley 2001). The Thl 
response is associated with a cytokine environment dominated by pro-inflammatory 
cytokines such as IL-12, TNFa or IFNy, and an up-regulation of the adhesions molecules 
required for lymphocytes trafficking on the endothelium of the wart capillaries (Bernard 
2005). Nevertheless there is no clear understanding regarding the relationship between 
the responses detected and the clearance or persistence of HPV disease, however some 
patterns are emerging.
Indeed different studies in healthy donors show a spontaneously CD4+ immunity 
against HPV 18 E6 epitopes or HPV 16 E6 epitopes (Welters, de Jong et al. 2003, 
Facchinetti, 2005, de Jong, 2004) which could be a memory response and associated with 
a clearance of the infection. Inversely the patients infected by HPV 18 or HPV 16 fail to 
demonstrate a Thl response against the E6 protein (Welters, van der Logt et al. 2006) or 
have response less high than in healthy donors (de Jong, van Poelgeest et al. 2004). These 
studies suggest that the absence of effective E6-specific CD4+ T-cells in early stage of 
HPV infection could contribute to the progression to cancer. Other studies observed a 
correlation between the tumour-infiltrating lymphocytes (TIL) in cervical cancer and the 
regression or progression of the tumours (Sheu, Chang et al. 2007). Clinically, a decrease
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in the number o f infiltrated CD4+ T cells is highly correlated with a rapid tumour growth 
and lymph node metastasis in cervical carcinoma (Sheu, Hsu et al. 1999).
Cross-sectional analysis of CD4+ T-cell responses against HPV 16 E7 protein, 
show exactly the inverse profile. Indeed Thl responses against E7 are not observed or 
rarely in healthy donors, but frequently occur in HPV 16 positive patients with cervical 
disease (van der Burg, Ressing et al. 2001). Longitudinal studies have provided evidence 
that Th responses against E7 could be correlated with progression to cancer or clearance 
of the infection (de Gruijl, Bontkes et al. 1998). It was proposed that the responding Th 
cells were generated in response to an increase in antigen exposure, which could arise 
from either lesion progression (increased burden with E7 expressing infected or 
transformed cells), or as result of detection and clearance of the HPV infected cells.
3-1-2-CD8+ T-cell responses
The profiles of the CTL responses against the E6 and E7 proteins seem 
contradictory between various studies, that is why the relationship between CTL 
responses and disease clearance or progression has not been resolved.
In some studies, CTL reactivity against both HPV 16 E6 and E7 was 
predominantly found in patients that cleared infection (Nakagawa, Stites et al. 2000). In 
other studies, especially patients with persistence infection or progressive disease 
displayed CTL reactivity (van der Burg, de Jong et al. 2002). Another study of our group 
has demonstrated previously that short-term in-vitro culture with the HPV 16 E7 (11-20) 
peptide, expanded E7-specific CD8+ T-cells to a greater extent in the PBMC from CIN3 
patients than from healthy donors (Youde, Dunbar et al. 2000). In contrast, Gurski et al.
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were able to detect HPV 16 E7 (n-20)-specific CTL responses in 3/6 healthy women but not 
in cervical cancer patients (Gurski, Schirmer et al. 1997). All these studies demonstrate 
the need for longitudinal studies using standardised immunological assays and containing 
larger cohorts of women with varying severity of cervical disease, to gain a better 
understanding of the role of HPV-specific CTL in protection from viral persistence and 
disease progression.
3-1-3-B-cell responses
The role of the humoral immune response in HPV infections has started to be 
clarified recently. Antibodies specific for HPV proteins LI and L2 can be detected from 
HPV experienced individuals using virus like particle (VLP) based ELIS As. IgG is the 
most abundant antibody isotype detected in serum, follow by IgA (Onda, Carter et al.
2003). The presence of IgG antibodies to HPV Ll-capsids is known to be a type-specific 
biomarker of past and present HPV infection (Matsumoto, Yasugi et al. 2006). A 
correlation between antibody responses to Ll-capsids induced by E6/E7 specific B cells, 
and the viral clearance has been observed in a longitudinal study of HPV infection 
(Nakagawa, Viscidi et al. 2002). In animal models, antibody responses to HPV Ll-capsid 
prevent animals from new infection, but do not induce tumour regression (Kimbauer, 
Chandrachud et al. 1996). The high level of IgG antibody to HPV 16 VLP has been 
reported to be associated with reduced risk for subsequent infection with HPV 16 and also 
in HPV31, -33, -35, -52 and -58 genetically related types (Sheu, Chang et al. 2007). 
Some studies show the presence of antibody against early proteins without evidence of 
pronostic significance (Stanley 2001).
45
In summary antibody responses against HPV are the basis of the current 
prophylactic vaccines but the natural antibody response is weak, takes a long time and 
only 46% of women have a seroconvertion (Viscidi, Kotloff et al. 1997). Therefore 
detection of serum antibodies is not a reliable indication of HPV infection.
3-2-Immune escape
Even if the immune system is really efficient against HPV infection, in rare cases 
the infection progress to cancer and it almost always involves accidental integration of 
the viral genome in the cellular DNA. This kind of rare event implies that the virus is able 
to escape from immune system at various steps.
3-2-1-Low profile
One of the first mechanisms of immune-evasion resides in the life cycle of the 
virus. Indeed the replication of viral DNA in undifferentiated cells and subsequent 
particle formation in external differentiated epithelial cells reduces exposure to the host 
immune system. In addition, the virus cycle is non-lytic and therefore does not elicit any 
pro-inflammatory signals that activate the LCs (Kupper and Fuhlbrigge 2004). 
Furthermore the virus encodes only non-secreted proteins, expressed at low levels and 
primarily in the nucleus of infected cells (Kanodia, Fahey et al. 2007). At the end the 
production of highly immunogenic capsid proteins is limited to the terminally 
differentiated outer layer, which is shed from the epithelium (Cason, Patel et al. 1989). 
Finally a third way used by the virus to escape immune system is the different codon 
usage of HPV and human genes. Indeed the extensive third-position degeneracy of the
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genetic code permits ample variation in the set of codons preferred by viruses with 
respect to that prevalent in human cells. By this codon bias HPV prevent compromising 
viability of the host cell by excessive viral early protein expression, as well as to evade 
the immune system (Cid-Arregui, Juarez et al. 2003).
Thus the first strategy used by the vims to escape from immune system is to 
maintain a very low profile.
3-2-2- Modulation of antigen presentation
It is now known that HPV mediates deregulation of antigen processing 
machinery, which results in down-regulation of peptide-MHC complexes on the surface 
of infected cells and protects them from immune attack. Immunogenic peptides from both 
E6 and E7 proteins are not efficiency processed and presented by HPV+ tumour cells and 
it is correlated with reduced expression of human leukocyte antigen (HLA) class I and the 
TAP 1 and 2 in cervical carcinoma cell lines (Evans, Borysiewicz et al. 2001). Then the 
E7 protein of HPV is mostly found in the nucleus of infected cells and in the case of 
HPV 16 and 18 it represses the promoter for MHC class I heavy chain expression 
(Kanodia, Fahey et al. 2007). Furthermore Connor et al. have observed changes at 2 
alleles which were at both HLA-A and -B  loci and which permit the loss of class I MHC 
expression in cervical carcinoma (Connor and Stem 1990). The HPV 16 E5 mediates 
alkalinization of the Golgi complex and endosomes, inhibits endosome acidification, 
leads to dismption of the exocytic and endocytic trafficking. Furthermore the Ii chain of 
the class II MHC needs an acidic endocytic compartment for its sequential degradation, 
and the alkalinization of endosomes by E5 blocks the formation of mature MHC class II
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complex with the antigenic peptide. This suggests that as well as interfering with CTL 
and NK cell recognition of infected cells, HPV may inhibit CD4+ T-cell recognition 
through down-regulation of MHC class II molecules and thereby evade the immune 
system. The HPV 16 E5 protein was recently shown to selectively down-regulate the cell 
surface expression of HLA-A and HLA-B due to its interactions with the HLA I heavy 
chain (Ashrafi, Haghshenas et al. 2006), thereby potentially decreasing viral peptide 
presentation to CD8+ T-cell (Ashrafi, Haghshenas et al. 2005). These interactions 
between HLA I heavy chain and E5 protein, which result in the retention of HLA-A and -  
B in the Golgi apparatus, do not occur with HLA-C and -E  the natural killer cell inhibitor 
ligands (Ashrafi, Haghshenas et al. 2005). The absence of pro-inflammatory signals 
associated with HPV infection, together with the immune evasion strategies employed by 
the viral proteins, permit the virus to establish infection by temporarily evading the 
immune system.
3-2-3-Interference with IFN
Barnard and McMillan (Barnard and McMillan 1999) showed that the E7 protein 
of HPV 16 inhibits the induction of IFNa-inducible genes, therefore interfering with the 
effective elimination of HPV. Indeed this IFN is synthesized by infected cells, which 
combat the replication of the viruses in the host cells. It acts by stimulating the synthesis 
of a protein-kinase that blocks the initiation of translation of viral proteins by activating 
endoribonuleases and allows the degradation of the viral and cellular mRNA. It also 
activates the synthesis and expression of MHC class I molecules (Goncalves and Donadi
2004). The inhibition of this IFN is one of the immune escape mechanisms of the HPV.
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3-2-4-Inhibition of cytokines and chemo-attractants
Identified as one of the first chemokines, MCP-1 attracts a variety of cells types 
including monocytes, memory T-cells and NK cells. A study shows that after infection 
the expression of MCP-1 is suppressed (Rosl, Lengert et al. 1994). The mechanism by 
which HPV suppresses MCP-1 production is not known, but E6  and E7 from “high-risk” 
HPV have been shown individually and together to suppress MCP-1 expression in 
primary epithelial cells derived from the female genital tract (Kanodia, Fahey et al. 
2007). The E6  and E7 proteins are able to inhibit the transcription of IL-8 , which is a 
chemo-attractant for neutrophils, basophils and T-cells (Huang and McCance 2002).
Finally HPV modulate the expression of IL-18, an interleukin, which helps to 
prime CD8 + T-cells, indeed the E6  protein binds IL-18 and might degrade it via the 
ubiquitin pathway (Cho, Kang et al. 2001). Alternatively E6  and E7 proteins 
competitively bind to IL-18 receptor and thus may inhibit IL-18 induced IFNy production 
(Cho, Kang et al. 2001).
Therefore the modulation or inhibition of cytokines or chemo-attractants is one of 
the mechanisms used by HPV against immune attack.
3-2-5-Other mechanisms used by HPV
Studies have shown other mechanisms used by the HPV to evade immune system 
but their understanding remains vague. A switch to Th2 polarity has been associated with 
a progression to cancer (Kanodia, Fahey et al. 2007). A modulation of adherence 
molecules on the surface of APCs such as LCs, decreases the contact between these cells
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and infected cells. There is an inhibition of APC migration in lymph nodes dues to a 
reduction of MIP-3a production induced by E6  and E7 (Guess and McCance 2005).
4-VACCINATION AGAINST HPV
The causal link between HPV infection and malignant transformation in cervical 
neoplasia provides a unique opportunity for both prophylactic and therapeutic vaccination 
(Stem 2005).
4-1-Prophylactic vaccination
Prevention of persistent infection with HR HPVs should have a major impact on 
the prevalence of malignant cervical lesions and it is from this observation that the first 
studies on VLPs have started. These VLPs are morphologically similar to infectious 
virions, present LI and L2 epitopes that are highly immunogenic, but lack viral DNA 
(Stem 2005). Safety and immunogenicity trials in healthy volunteers have been done with 
HPV 16 LI VPLs produced from baculovirus infected insect cells (Harro, Pang et al.
2001) and from yeast (Koutsky, Ault et al. 2002). These have established that the 
vaccines are well tolerated and generated strong immune responses that are several orders 
of magnitude higher than those exhibited by naturally infected population. Following 
studies which included 25, 000 women several efficacy trials demonstrated protection 
against persistent infection with HPV 16 and 18 and against the development of precursor 
lesions to cervical cancer (Gissmann and Muller 2007). All these studies have permitted 
the production of prophylactic vaccines against HPV, which reduce the incidence of 
genitals warts and the risk of developing cervical cancer. But the vaccine can only be
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used for systemic vaccination of young girls aged 9-15 years before the first infection by 
HPV and can not be used in infected population (Garcia Carranca and Galvan 2007). 
Furthermore, even if this vaccine is a very important advance against HPV infection, it is 
a prophylactic vaccine, which cannot be used in patient already infected by HR HPV, 
only therapeutic vaccines can be used in this case.
4-2-Therapeutic vaccines
The ideal HPV therapeutic vaccine would appropriately stimulate or redirect the 
immune response so as to eradicate infected tissue or mediate regression of malignant 
lesions. The chosen targets in therapeutic vaccines depend of the grade of infection, 
indeed immunisation with specific early proteins, such as El or E2, are promising for 
benign or low grade HPV induced disease (Stanley 2002). Vaccines encoding El or E2 
genes modified to increase antigen expression, protect against challenge in dog model 
with live virus (Stanley 2006).
In cervical cancer and most CIN 2/3, viral gene expression is deregulated and the 
E6  and E7 genes are constitutively expressed because they are essential for maintenance 
of the malignant phenotype, making them ideal targets for different immunotherapies. 
Furthermore E6  and E7 are the only viral proteins that will be expressed in all high 
grades of infection (Stanley 2002). Therapeutic vaccines against HPV are summarised in 
the table 3.
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4-2-1-Peptides or recombinant proteins
The goal of this strategy is to predict immunodominant or subdominant peptides 
of viral antigens that would associate with particular HLA allelic products and are 
recognized by T-cells. The advantages of this approach are cost effectiveness, as peptide 
vaccines are cheap to produce and immunological responses following vaccination are 
relatively straightforward to measure (Stem 2005). Studies using a HLA-A2 associated 
with HPV 16 E7 peptide in phase I or phase II clinical trial have shown an immunogenic 
role of these molecules which are able to enhance the CTL response against HPV 16 
(Steller, Gurski et al. 1998; Campo 2002).
Recombinant proteins have the advantage over peptide approaches in delivery of 
all potential epitopes to the antigen processing cells of the immune system. The 
challenges involve the production and purification of the viral proteins including fusions 
with molecules like heat shock proteins and their formulation with appropriate adjuvants 
in order to elicit the necessary processing and subsequent activation of T cells 
(Goldstone, Palefsky et al. 2002).
Different assays have been done with various fusion proteins. TA-GW fusion 
protein (HPV6L2E6) shows a good protection against recurrence of warts (Lacey, 
Thompson et al. 1999). TA-CIN fusion protein (HPV 16 L2/E6/E7) induces in mice 
models E7 specific CD8 + T-cell immune response and tumour protection (de Jong, 
O'Neill et al. 2002). Various studies with heath shock protein fused to E7 (hspE7), show a 
protection in mice against challenge with an E7-expressing murine tumour cell line and in 
phase II o f clinical trial a protection was observed too (Chu, Wu et al. 2000, Mahdavi, 
2005).
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Overall the experience from the various polypeptide vaccines is that they are 
apparently safe, but immunogenicity has only been shown in a fraction of patients and 
does not correlate with limited clinical outcome data (Stem 2005).
4-2-2-Plasmid DNA-vaccines
Due to the weak intrinsic potency of naked DNA vaccines, various strategies have 
been developed to enhance their immunogenicity, one of them is to use an encapsulated 
HPV DNA vaccine. Garcia et al. (Garcia, Petry et al. 2004) reported on the use of 
encapsulated plasmid DNA-encoding fragment derived from E6  and E7 of HPV 16 and 18 
in biodegradable particle (ZYClOla). This study design was double-blinded, randomised, 
and placebo-controlled (saline placebo) and was carried out in multiple centres in U.S. 
and Europe. Patients received three injections at 0 , 3 or 6  months of either 100pg or 
200pg of the vaccine. The results showed a statistically significant higher rate of CIN2 or 
CIN3 resolution in the <25 years of age group (placebo, 23%; lOOpg, 67%; and 200pg, 
72%). However there was no difference in resolution rates between vaccine and placebo 
in the group>25 years old. Now this vaccine has been acquired by MGI Pharmaceuticals 
and further studies are planned (Mahdavi and Monk 2005). A recent study showed that a 
DNA vaccine encoding a fusion of IL-2 and E7 proteins induces a strong E7-specific 
CTL response (Lin, Tsai et al. 2007).
Nevertheless this kind of strategy has two disadvantages: the first one is the low 
immunogenicity of the DNA, and the other one a possible insertion o f the HPV DNA 
which could enhance the expression of oncogenes.
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4-2-3-DC-based vaccines
A study demonstrated that recombinant, full-length, E7-pulsed, autologous DCs 
could elicit a specific CD8 + CTL response against autologous tumour target cells in three 
patients with HPV 16 or 18 positive cervical cancer (Santin, Hermonat et al. 1999). 
Another group has pulsed autologous monocyte-derived DCs with recombinant HPV 16 
E7 or HPV 18 E7 and used its for the treatment of 15 patients (Ferrara, Nonn et al. 2003). 
Specific cellular immune responses were detected in four of the 15 patients.
4-2-4-Viral Vector Vaccine
This strategy has the advantage of being highly immunogenic and having different 
immunogenic properties of viruses. Several studies have shown that immunotherapy 
targeting E6  and/or E7 using vaccina vector generates strong CTL activity and tumour 
responses in preclinical studies. Indeed a phase I/II trial in 8  patients with late stage 
cervical cancer using a recombinant vaccinia virus expressing the E6  and E7 proteins of 
HPV 16 and 18 (TA-HPV), has permitted the development of HPV-specific antibody 
response in each patient and HPV-specific CTL response in one patient (Borysiewicz, 
Fiander et al. 1996). A 2002 study on the same TA-HPV vector confirmed the safety and 
immunogenicity of the vaccine, with 4 patients who develop HPV-specific CTL response 
(Kaufinann, Stem et al. 2002).
Another recombinant vaccine composed of modified vaccinia virus Ankara 
(MVA) expressing the E2 of bovine papillomavirus has been recently tested to treat flat 
condyloma lesions associated with oncogenic HPV in men. After 4 weeks of treatment,
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93% of the patients showed no lesion or presence of papillomavirus as diagnosed by 
coloscopy and brush examination (Albarran, de la Garza et al. 2007).
4-2-5-“prime-boost” strategies
Prime-boost strategies use a priming immunisation (e.g. DNA plasmid or viral 
protein) followed by a heterologous boost with a different viral vector encoding the 
immunogenic epitope (Mahdavi and Monk 2005). Different assays have been done with 
this kind of strategy and the most impressive was the assay of Baldwin et al. (Baldwin, 
van der Burg et al. 2003). They vaccinated with a fusion protein of HPV16 L2E6E7 12 
women with high grade HPV positive vaginal or vulval intraepithelial neoplasia. In 42% 
of the cases a decrease in lesion size, average 40% reduction, was observed. Whilst this 
result is promising, the absence of placebo control group complicates interpretation, as 
the naturally occurring oscillations in lesion size have not been account for.
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Table 3: Published clinical trials of therapeutic HPV vaccines (adapted from (Winters, Roden et al. 
2006).__________________________________________________________________________________
Delivery
system
Antigen Participants Key findings Phase
Viral vector (Smith, Tristram 
et al. 2005)
TA-HPV, Xenova 
E6-E7 fusion protein
11 patients CIN3, 
VIN3, VAIN
5 patients made novel HPV 
specific T cell responses after 
vaccination. No clinical 
responses
Phase I/II
(Corona 
Gutierrez, 
Tinoco et al. 
2004)
M V A E 2  
recombinant vaccinia
36 women CIN 1, 
2 and 3
34/36 complete responses Phase I/II
(Hallez, Simon 
et al. 2004)
Fusion protein PD- 
E7. E7 linked to 
Hemophilus 
influenza
7 patients with 
CIN1 and 3
5/7 CTL responses Phase I/II
(Davidson, 
Boswell et al. 
2003)
TA-HPV, Xenova, 
E6-E7 fusion protein
18 women with 
high grade VIN
8 women had partial clinical 
responses, 13 women had 
HVP specific immune 
responses after vaccination. 
Correlation between response 
and pre-vaccination local 
immune status
Phase II
(Kaufmann, 
Stem et al. 2002)
TA-HPV, Xenova, 
E6-E7 fusion protein
29 women stage 
lb  or 2 a cervical 
cancer prior to 
radical 
hysterectomy
HPV specific CTL in 4 
women 
Serological response in 8 
women
Phase I/II
Peptide (Chu, Wu et al. 
2000)
HPV 16 E7 peptides 15 women with 
advanced cervical 
cancer
T helper responses in 4 
patients, No specific CTL 
responses
Phase I/II
(Frazer, Quinn et 
al. 2004)
Protein/I sco matrix 
adjuvant E6E7-IMX, 
CSL
31 women with 
CIN randomized 
to vaccine or 
placebo
Most developed antibody 
responses, about half 
developed new CTL 
responses
Phase I
(de Jong, O'Neill 
et al. 2002)
TA-CIN L2, E6, E7 
Fusion protein, 
Xenova
40 healthy 
volunteers 
randomized to 
vaccine or placebo
TA-CIN specific IgG 
antibody and T cell 
proliferative responses in 
majority
Phase I
Prime boost (Smyth, 2004) TA-HPV + TA-CIN, 
Xenova
29 women with 
high grade VIN
Antibody and CTL 
responses, no simple 
correlation with the clinical 
responses
Phase I/II
DNA (Garcia, Petry et 
al. 2004)
Plasmid DNA  
encoding fragments 
derived from E6 and 
E7 proteins in 
microparticules
161 women with 
CIN2/3 
randomized to 
vaccine/placebo 
prior to cone
43% o f  vaccinated women 
cleared disease versus 27% 
o f placebo recipients (not 
statistically significant).
Phase I/II
DC (Ferrara, Nonn et 
al. 2003)
Autologus DC pulsed 
with recombinant 
HPV16 E7 and 
H PV18E7
15 women stage 
IV cervical cancer
Specific cellular responses in 
4/11
Phase I/II
Abbreviations: CIN, cervical intraepithelial neoplasia; IFA, incomplete Freund’s adjuvant; LEEP, loop 
electrosurgical excision procedure; MVA, modified vaccinia Ankara; PD, hemophilus influenza protein D.
56
PROJECT AIMS
Infection with HPV, in particular HPV 16 and 18, is the causative factor in the 
development of cervical cancer because the immune system fails to eliminate the virus. 
Our understanding of the mechanisms which prevent the clearance of HPV remains poor. 
Some studies on the T-cell responses against HPV show a relation between the failure to 
clear the infection and a weak E6 -specific Thl response. Indeed some healthy donors 
seem to induce a better CD4 immunity against HPV-18 E6  epitopes than the patients 
(Facchinetti, Seresini et al. 2005). In the infection by HPV-16, the failure of CD4+ T-cell 
function in E2- and E6 -specific immunity seems to be associated with cervical disease 
(de Jong, van Poelgeest et al. 2004). Conversely lymphoproliferative responses to 
specific HPV-16 E6  and E7 peptides appear to be associated with the clearance of HPV 
infection and the regression of CIN (Kadish, Ho et al. 1997). Therefore these data suggest 
the necessity of a better understanding of the immune response against HPV 16 E6  
antigen. One of the ways, which could be explored, is the activation of the CD4+ T-cells 
by this antigen, and then the molecular interaction between the TCR and the class II 
MHC associated with a peptide derived from the E6  protein. Indeed these interactions are 
the basis of an efficient immune response against HPV. In this goal the laboratory has 
already identified a target in the E6  protein (HPV 16 E6127-141: DKKQRFHNIRGRWTG), 
which can induce some CD4+ responses in healthy donors. Furthermore it has been 
demonstrated HLA-DR*0101 presents E6127-141 (Gallagher and Man 2007), and two 
clones (CD4+), specific for this peptides have been generated, belxl and belx2. These 
two clones have two different TCR; indeed they express the same a  chain but not the 
same P chain, belxl expresses the TRBV14 and belx2 expresses the TRBV4-2. The 
responses of these clones to HPV 16 E6127-141 in terms of IFNy secretion are not similar,
indeed belx2 secretes more IFNy than belxl. The explanation for these variations in the 
functional characteristics of these two clones could be due to their different TCRs. Indeed 
the interaction between the TCRs and the HLA-DR*0101 -HPV 16 E6127-141 complex 
could be dissimilar. In order to understand a part of the mechanisms which regulate this 
kind of events it is necessary to construct the soluble molecules and to study their 
interactions.
Therefore the principal objectives of this project were:
-The construction of soluble HLA-DR1 protein associated with HPV 16 
E6127-141 to allow biophysical studies.
-Investigate the functional importance of changes in the peptide structure 
using T-cell clones against HPV 16 E6127-141.
-Investigate the functional effect of natural HPV type variation of peptide 
sequences on T-cell responses.
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MATERIALS AND METHODS
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1-CONSTRUCTION OF THE HLA-DRB*0101 GENES
To produce HLA-DRB*0101 associated with peptide E6127-141 several steps were 
necessary. First we have generated the DNA sequence of the a  chain by amplification of 
cDNA (provided by Dr J. Boulter) corresponding to the extracellular domain and the wild 
type signal peptide of HLA-DRA*0101 from a B cell line (figure 10). In parallel we 
amplified the fos  leucine zipper attached to the biotinylation tag. Finally we have 
proceded to the amplification of all the chain corresponding to the extracellular domain of 
HLA-DRA*0101 attached to the fos  leucine zipper and the biotinylation tag for a. The 
construction of the DRB*0101 chain was generated in four steps. First the cDNAs 
corresponding to the extracellular domain of HLA-DRB*0101 from B cell line were 
amplified and attached to the linker by overlapping PCR. Secondly the amplification of 
the jun leucine zipper sequence was performed, following by the amplification of the 
wild type signal peptide for the secretion of the molecule associated with the HPV 
peptide, for p. Thirdly the amplification of the complete chain has been done. Finally the 
sites of the restriction endonuclease Bglll were added to the DRA*0101 and the 
restriction endonuclease sites, BamHl, were added to the DRB*0101. A similar construct 
with the CLIP peptide instead of the HPV16 E6127-141 peptide was also generated.
All these amplifications have been done by Polymerase Chain Reaction (PCR), or 
overlapping PCR. The final concentrations of reagents in PCR mixture (50pl) were: 0.3 
mM dNTPs (Bioline, London, UK), 1 mM MgCL (Bioline), 25 pmol o f forward and 
reverse primers, and 2.5 U of Taq DNA polymerase (Bioline) in PCR buffer (Bioline, 
16mM (NH4)2So4, 0.01% Tween-20, 67 mM Tris-HCl pH 8 .8 ). Typical cycling 
conditions are shown in table 4. All PCRs were performed using a Biometra Tpersonal
61
thermocycler (Glasgow, UK). PCR products were purified by DNA-binding columns 
(QIAquick® PCR purification kit, Qiagen, Valencia, California, USA) and following the 
manufacturer’s instructions. Briefly, the PCR products were purified on a column with 
different buffers, provided by the kit, and several steps of centrifugation at maximum 
speed with a bench centrifuge. The samples were eluted with the buffer provided in the 
kit and the quantity of DNA was directly measured by spectrometry at ratio 260/280 nm.
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F igure 10: S chem a o f  the  construc tion  o f  a  and  P chains to express a  so luble H L A - 
D R*0101 associa ted  w ith H PV 16 E 6127-141 peptide.
Extraction o f  the mRNA 
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Table 4: Typical cycling conditions
Steps T°C Time Number of cycles
Initial denaturation 95 °C 5 min 1
Denaturation 94°C 40 sec
Annealing a55-68°C 40 sec 30
Extension 72°C bl-3 min
Final extension 72°C 10 min 1
a The annealing temperature depends on the melting T°C of primers. 
b The extension time depends on the size of the PCR product.
The different primers used for these constructions and for the sequencing of the DNA 
are presented in the table 5.
64
Table 5: List of the primers used for the construction
Name Sequence Use
485F 5 ’-gaagatctatggccataagtggagtccctg-3 ’ Extracellular domain of a - 
chain plus wild type signal 
peptide for the secretion.487R 5 ’ -agcatcaaactcccagtgcttgag-3 ’
487F 5 ’-ctcaagcactgggagtttgatgctcccgggggtctg-3 ’
fos leucin zipper.
486R 5 ’-gaagatcttaatgccattcgattttctgagcttc-3 ’
488F 5 ’-cgggatccatggtgtgtctgaagctccctg-3 ’
493R 5 ’ -ttatgaaatctttgttttttatcagccaaagccagt-3 ’ Wild type signal peptide
494R 5 ’ -gtccatcgtccacgaatattatgaaatctttgt-3 ’ for the secretion and the 
E6 127-141 HPV peptide or 
CLIP peptide.495R 5 ’ -gtgagccaccaccagatccagtccatcgtccacgaa-3 ’
23F 5’-gtagtccggaccagttagtaagatgcgaatggcaactcctctgct-3’
24R 5 5 -gtagtccggatgcttgcataagcagaggagttgccat-3 ’
491F 5 ’ -cggggctctggaggtgggtccggggacacccga-3 ’
Extracellular domain of
490R 5 ’ -tgctctccattccactgtgagag-3 ’ the p-chain associated 
with a linker.
492F 5 ’ -tggatctggtggtggctcactagtgccacggggctc-3 ’
490F 5 ’ -ctctcacagtggaatggagagcacccgggggtagaa-3 ’
jun  leucine zipper489R 5 ’ -cgggatccttaccatggatcctagtagtccatg-3 ’
M13F 5 ’-tcgtgactgggaaaac-3 ’
M13R 5 ’ -caggaaacagctatgac-3 ’
ASbasicprom 5 ’-tgcatcgtcgcaaaacgg-S ’
1629 DWN 5 ,-ctgtgcgttgttgatttacag-3 ’
sequencing
485F 5 ’-gaagatctatggccataagtggagtccctg-3 ’
488F 5 ’-cgggatccatggtgtgtctgaagctccctg-3 ’
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2-CLONING OF THE a  AND P HLA-DRB*0101 IN THE PCR®2.1-TOPO®
Purified PCR products were subcloned into the pCR@2.1-TOPO® vector (TOPO TA 
Cloning ® kit, Invitrogen, Paisley, UK). The pCR2.1-TOPO cloning vector (figure 11) is 
a linear plasmid with single 3’-thymidine (T) overhangs, allowing the direct cloning of 
PCR products due to the production of single 3’-adenosine (A) overhangs by Taq DNA 
polymerase. The selection o f transformed bacteria is based on ampicillin resistance 
introduced by the vector.
The ligation mixture (10 pi final volume) contained 10 ng of purified PCR 
product, 50 ng of pCR2.1-TOPO vector, 1 pi of 10X ligation buffer (300mM Tris-HCl 
(pH 7.8 at 25°C), lOOmM MgCl2, lOOmM DTT and lOmM ATP), 1-3U of T4 DNA 
ligase (Promega, Southampton, UK) and sterile water to a total of 10 pi. The mixture was 
incubated at 16°C overnight. This product of ligation was used to transform E. coli cells, 
strain DH5a. One to ten ng of DNA (ligation product) were added to 50 pi of Subcloning 
Efficiency™ DH5a™ Competent Cells (Invitrogen) and incubated on ice for 30 minutes. 
The cells were heat shocked for 20 seconds at 42°C in a water bath without shaking and 
placed immediately on ice for 2 minutes. After transformation 950 pi of SOC medium 
(2% (w/v) Bacto-Tryptone, 0.5% (w/v) Yeast extract, lOmM NaCl, 2.5mM KC1, lOmM 
MgCl2, 20mM Glucose, pH7.0) were immediately added, and the cells were incubated at 
37°C for 1 hour at 225 rpm in an orbital shaker (Sanyo, UK). After 1 hour 20 pi to 200pl 
from the transformation were spread on Luria Bertani (LB)/ agar plates (1% (w/v) Bacto- 
Tryptone, 0.5% (w/v) Yeast extract, 172 mM NaCl, pH 7.7/1.5% (w/v) Agar) containing 
100 pg/ml ampicillin (Sigma, Poole, UK) and incubated at 37°C. The following day, the
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clones were screened by PCR (see tables 4 and 5). Then the DNA sequence of the 
positive clones were checked by sequencing.
3-DNA SEQUENCING OF POSITIVE CLONES
After the PCR screening the positive clones were collected from petri dishes and 
grown in 5 ml of LB medium plus ampicillin in 25ml tubes (Sterilin, Staffordshire, UK) 
(100 pg/ml, Sigma) at 37°C overnight. Plasmid extraction from each clone was carried 
out by using the QIAprep® spin miniprep kit (Qiagen) according to the manufacturer’s 
instructions. Each DNA insert was checked by PCR sequencing using the ABI Prism® 
Big Dye™ Terminator Cycle Sequencing Ready Reaction kit with AmpliTaq® 
Polymerase FS (Perkin and Elmer, Waltham, Massachusetts, USA). The PCR mixture (15 
pi) contained 700 ng of each plasmid, 5 pmol of primer and 3 pi of Terminator mixture, 
containing the enzyme, the buffer, the dNTPs and the Big Dye Terminators. Thermal 
cycling (25 cycles) conditions were: denaturation, 96°C for 30 seconds; annealing, 50°C 
for 15 seconds; extension, 60°C for 4 minutes. Following thermal cycling the PCR 
products were precipitated by adding 1.5 pi of 3 M CFECOONa, pH 5.4 and 45 pi of 
ethanol (Fisher, London, UK) and incubating for 20 minutes at -70°C. The samples were 
then centrifuged at 13,000 rpm for 20 minutes at room temperature, and precipitated 
DNA was washed with 75% (v/v) ethanol. DNA sequencing was carried out in our DNA 
sequencing facility (Central Biotechnology Services, CBS) by using an automated ABI 
377 DNA sequencer (Applied Biosystems, Warrington, UK).
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i3CZa ATG
M13 Reverse Primer
CAG GAA A.CA GCT ATG AC
GTC CTT TGT CGA TAC TG
Hind III K m  I Sac I BamH I Spe II I I I I
ATG ATT ACG CCA AGC TTG GTA CCG AGC TCG GAT CCA CTA 
TAC TAA TGC GGT TCG AAC CAT GGC TCG AGC CTA GGT GAT
BstX I teoR  I EcoR I
GTA ACG GCC GCC AGT GTG CTG GAA TTC GCC C T T j 2 5 F I H ! ! m 5 P AG GGC GAA TTC TGC
CAT TGC CGG CGG TCA CAC GAC CTT AAG CGG G A a l 8 | | l | i | f l 8 i T T C  CCG CTT AAG ACG
EooR V B s iX \ Not I Xho  I Ns: I Xba I Apa  I
AGA TAT CCA TCA CAC TGG CGG CCG CTC GAG CAT GCA TCT AGA GGG CCC AAT TCG CCC TAT 
TCT ATA GGT AGT GTG ACC GCC GGC GAG CTC GTA CGT AGA TCT CCC GGG TTA AGC GGG ATA
♦
T7 Promoter M13 Forward (-20) Primer
AGT GAG TCG TAT TAC AAT TCA 
TCA CTC AGC ATA ATG TTA AGT
CTG GCC GTC GTT TTA CAA CGT CGT GAC TGG GAA AAC 
GAC CGG CAG CAA AAT GTT GCA GCA CTG ACC CTT TTG
p C R ® 2 .1 -T O P O
3.9 kb
Figure 11: Map of the circularized vector, pCR®2.1. The arrow indicates the start of 
transcription for the T7 RNA polymerase (from Invitrogen).
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4-CLONING INTO TRANSFER VECTOR PACAB3
After analysing and checking of the sequence the HLA-DR*0101 a  and p chains 
were cloned in pAcAB3 (kindly provided by Dr N. Pumphrey, Avidex, Oxon, UK), 
which is a multiple plasmid transfer vector used for expression of up to three proteins of 
interest. This vector is an AcNPV (Autographa califomica nuclear polyhedrosis virus) 
polyhedrin locus-based vector, which contains an E. coli origin of replication, an 
ampicillin resistance marker, a copy of the AcNPV polyhedrin promoter, two copies of 
the AcNPV plO promoters, a cloning region downstream from each promoters and a 
large tract o f AcNPV sequence to facilitate homologous recombination (figure 12).
Before cloning of the two different chains into pAcAB3, each TOPO vector 
containing the a  and p chains was digested by the endonuclease Eco RI (Invitrogen). 100 
ng of vector was digested by adding 30 U of Eco RI in reaction buffer 4 (Invitrogen) 
(final volume 15 pi) and placing the reaction at 37°C for 1 hour.
The products o f these digestions were resolved on a 1% (w/v) agarose 
(Invitrogen) gel in TAE buffer (40mM Tris Acetate pH 7.2, 1 mM EDTA). Agarose was 
dissolved in TAE buffer by boiling. The solution was allowed to cool to approximately 
55°C before ethidium bromide (Sigma, dorset, UK) was added at a final concentration of 
50ng/ml. The solution was poured into the gel casting tray of an Electro-4 gel tank 
(Hybaid Ltd, Hampshire, UK), and left for at least 30 minutes to set. The gel was 
transferred to the gel tank and TAE buffer was added. Before loading, DNA products 
were mixed with DNA loading buffer (0.25% (w/v) bromophenol blue, 30% glycerol in 
dH20) at a final DNA product: loading buffer ratio of 10:1. Electrophoresis was carried 
out at constant voltage (100V) until separation of the DNA fragments. The SmartLadder
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(Bioline) was used as a DNA size marker. DNA products of digestion were cut out from 
the gel and visualized using an UV transilluminator lamp. DNA was purified using a 
DNA-binding column (QIAquick® gel extraction kit, Qiagen) and following the 
manufacturer’s instructions. Briefly the agarose with the DNA was dissolved at 52°C in 
presence of a buffer provided bin the kit. After this step the DNA was purified on a 
column as for the PCR products (see part 1).
A second digestion was performed for each chain: the a  chain was digested by the 
endonuclease Bgl II (NEB, London, UK) and the p chain by the endonuclease Bam HI 
(NEB). For each digestion lOOng of DNA was digested by adding 30 U of enzyme in the 
buffer provided by the manufacturer and left 90 minutes at 37°C and each product of 
digestion was purified using QIAquick® PCR purification kit (Qiagen) and stored a -  
20°C.
In parallel the digestion of pAcAB3 by Bgl II was performed, and followed by a 
dephosphorylation of its 5’ phosphorylated ends produced by the endonuclease digestion. 
In this goal an alkaline phosphatase (Promega) was used to catalyse the hydrolysis of 5’- 
phosphate groups from DNA, which prevents re-circularization and religation of 
linearized cloning vector DNA. This was performed by adding 1U of alkaline 
phosphatase to the digestion products and leaving for 1 hour at 37°C. After the reaction 
the linearized pAcAB3 was purified using QIAquick® PCR purification kit (Qiagen), and 
a ligation was performed overnight with the a  chain. Following the ligation, DH5a cells 
were transformed with product of ligation and spread on LB/agar plates containing 
lOOpg/ml ampicillin. On the following day, the bacteria colonies were screened for 
inserts and their orientation to the promoter by PCR screening.
The same experiments were performed with the (3 chain. The construct amplified 
in TOPO vector was digested by EcoRI, purified, digested by BamHl and purified. In 
parallel the pAcAB3, containing the a  chain, was digested by BamHl and a ligation 
between the p chain and the vector was performed overnight. DH5a cells were 
transformed by product of ligation and spread on LB/agar plates. The following day, the 
bacteria were screened by PCR screening, to check the presence of the insert and the 
orientation of the insert compared with the promoter.
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Figure 12: The pAcAB3 is a 10.0 kb AcNPV polyhedrin locus-based vector that 
contains a copy of the AcNPV polyhedrin promoter and two AcNPV plO promoters. 
Dwonstream of the first plO promoter are a Sma I and a Bam HI cloning site, followed 
by polyhedrin locus-derived terminal sequences. Upstream of this, an inverted 
polyhedrin promoter has been inserted containing a Xba I and a Stu I cloning site, 
followed by a second plO promoter, a Bgl II insertion site and an SV40 terminator. 
The two plO promoters are in opposite orientations. Using pAcAB3, three foreign 
genes can be simultaneously expressed during the very late phase of the Baculovirus 
infection cycle (from PharMingen, London, UK).
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5-CLONING INTO TRANSFER VECTOR PBACGUS4X-1
pBACgus4x-l is a baculovirus transfer plasmid (Novagen, Nottingham, UK) 
designed for cloning and co-expression of up to four target genes or multiple copies of 
the same gene in insect cells. The plasmid contains two polyhedrin promoters and two 
plO promoters, each of which is upstream of unique cloning sites for sequential insertion 
of target genes. The plasmid also carries the gus gene encoding p-glucuronidase under 
control of the late basic protein promoter, which serves as a reporter to verify 
recombinant viruses by staining with X-gluc (figure 13).
The protocol is exactly the same as cloning in pAcAB3, we first digested the vector by 
Bgl II, carried out dephosphorylation, performed a ligation between the a  chain and the 
vector, checked the direction of the insert by PCR screening and sequencing, and 
proceeded to the insertion of the p chain.
6-EXPRESSION OF HLA- DR*0101 IN INSECT CELLS
6-1-Generating recombinant baculoviruses by co-transfection with BD 
Biosciences system
The principle of this technique is shown in the figure 14. Basically baculogold is 
an Autographa califomica nuclear polyhedrosis virus (AcNPV) baculovirus DNA, which 
contains a lethal deletion and does not code for viable virus. Co-transfection of the 
baculogold DNA with a complementing baculovirus expression vector rescues the lethal 
deletion by homologous recombination.
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Figure 13: Map of the pBACgus4x-l transfer plasmid (from Novagen)
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Figure 14: Principle o f the co-transfection o f baculovirus and recombinant transfer 
vector
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The co-transfection of the BD BaculoGold™ (BD Biosciences, Oxford, UK) 
linearized baculovirus DNA and the complementing transfer vector construct, pAcAB3, 
was done in Spodoptera frugiperda Sf9 cells (Novagen). Sf9 cells were seeded at 2xl06 
cells per well in a 6 wells plate (Falcon, Loughborough, UK) in BacVector® Insect Cell 
Medium (Novagen) with an initial cell density which should be 50-70% confluent, and 
left approximately 15 minutes at 27°C to allow the insect cells to attach firmly to plate. 
Subsequently the medium was removed from the plate and 1ml of Transfection buffer A 
(BD Biosciences) was added. In parallel, 0.5pg o f BD BaculoGold™ (BD Biosciences) 
and 2pg o f recombinant pAcAB3 were mixed in a sterile 1.5 ml tube and left for 5 
minutes at room temperature before adding 1 ml of Transfection buffer B (BD 
Biosciences). Then the mixture was added drop-by-drop to the insect cells on the tissue 
culture plate, and the plate was incubated 4 hours at 27°C. Following incubation the 
transfection solution was removed and 3 ml of insect cell medium were added and the 
plate was rocked back and forth several times, before once again removing the medium 
and adding 3 ml of fresh medium. Finally the plate was incubated for 4 to 5 days at 27°C 
and the supernatant was collected and used for amplification of virus. The control vector 
pVL1392-XylE (BD Biosciences) was used as positive control for the co-transfection and 
the negative control was a co-transfection without recombinant vector.
6-2-Amplification of recombinant baculovirus with BD Biosciences system
To obtain a high titre stock solution of recombinant baculovirus we had to amplify 
the recombinant virus after co-tranfection. To this end, freshly seeded insect cells should 
be infected at a multiplicity of infection (MOI) of >1. This was done by infecting 5xl06
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Sf9 cells per 10 cm plate (approximately 60% confluent) with 500pl of transfection 
supernatant in 15ml of insect cells medium. The cells were incubated for 3 days at 27°C 
before harvesting the medium.
6-3-Plaque assay to titre recombinant virus with BD Biosciences system
Sf9 cells, 70-80% confluent, were seeded at 2x106 cells per well in 6  wells plate 
(Falcon) and left 5 minutes at room temperature to allow the cells to attach. At the same 
time serial dilutions ( 1 0 '4- 1 0 '7) o f our amplified co-transfection virus supernatant were 
made and 1 ml of each serial dilution was added per well. We left the infection occur for 
4 hours at room temperature on a rocker and prepared a 2% solution of plaque assay 
agarose (Novagen) in sterile water by heating mixture in a microwave oven to 60°C and 
keeping it at 42°C. Following infection the agarose solution was mixed with Sf9 medium 
1% Foetal Calf Serum (FCS) (Invitrogen) to obtain a final agarose concentration of 1%. 
The medium was removed and the cells were overlaid with 2ml of the 1% agarose 
solution and left for approximately 10-15 minutes at room temperature until the agarose 
was completely hardened. The plate was incubated at 27°C during 5 to 7 days in a humid 
atmosphere. After 7 days 1ml of neutral red solution (25% neutral red diluted in PBS, 
Sigma) was added to each well and plate was incubated at 27°C for 2  hours. Following 
incubation the neutral red solution was removed; the plate was inverted, wrapped in foil 
and left overnight at room temperature. The plaques were counted the day after under a 
microscope with a magnification o f 20X.
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6-4-Generating recombinant baculoviruses by co-transfection with Nogaven
system
The principle is exactly the same as BD Biosciences system but with another 
transfer vector, pBACgus4x-l. Insect cells were seeded at lxlO6 cells per well in 6  wells 
plate (Falcon) and incubated at 27°C for 1 hour. Co-tranfection mix was prepared during 
incubation by adding in the following order; 1ml of insect cell medium, 5 pi of insect 
genejuice transfection reagent (Novagen), 5 pi of BacMagic™ DNA (100 ng total) and 
5pi of pBACgus4x-l (500 ng) in a sterile 6  ml polystyrene tube. The co-transfection mix 
was incubated for 15-30 minutes at room temperature to allow complexes to form. After 
incubation of insect cells the medium was removed and 1ml of transfection mixture was 
added dropwise to center of well. The plate was placed in humidified container at 27°C 
overnight. After 1 day 1ml of medium was added and the plate was incubated for 5 days 
in total at 27°C. Supernatant was then collected in the dark at 4°C. The transfection 
control vector (Novagen) was used as a positive control and the negative control was a 
co-transfection without recombinant vector.
6-5-Amplification of recombinant baculovirus with Novagen system
100 to 200 ml of cultures of Sf9 cells, at an appropriate cell density in log phase 
growth (e.g., 2xl0 6 cells /ml), were infected at a low MOI (<lpfu/cell) in an 1 1 flask 
(Coming, Schiphol-Rijk, The Netherlands) with 0.5 ml of recombinant vims. The flask 
was incubated for 4-5 days at 27°C in an orbital shaker at 150 rpm. Then cell culture 
medium was collected and centrifuged at lOOOg for 20 minutes at 4°C. The supernatant 
was removed aseptically and stored in the dark at 4°C.
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6-6-Titration of the recombinant virus with FastPlax™ Titer from Novagen
Sf9 cells resuspended in 2ml of medium containing a total of lxlO6 cells were 
added to a single well and left for about 30 minutes at 27°C to allow the cells to attach to 
the plate. During this step the virus dilutions (10'5-10'7) were made. After 30 minutes of 
incubation the medium was removed from the well and 1ml of virus dilution was added. 
The plate was incubated for 60 minutes at room temperature (RT) and 2ml of fresh 
medium was added to each well. Subsequently the plate was incubated at 27°C for 26-27 
hours in humid atmosphere. After this incubation the medium was removed, and the well 
was washed twice by adding 2ml per well of PBS. Cells were fixed by adding 2  ml of 
3.7% formaldehyde solution (Sigma) diluted in PBS for 10-15 minutes. Each well was 
washed twice with PBS and 2ml of 1% gelatin solution in IX TBST (Novagen) was 
added to block the cells for 30 minutes. The gelatin solution was removed and cells were 
washed twice with 2 ml PBS. Following this, 1 ml of FastPlax™ antibody diluted 
1:10,000 in IX TBST (Novagen) was added to the well for 60 minutes with gentle 
rocking at RT. The well was washed three times with 2 ml of IX TBST and each wash 
was incubated for 10 minutes. Then 1 ml of goat anti-mouse P-gal conjugate antibody 
(Novagen) diluted 1:100 in IX TBST (Novagen) was incubated for 1 hour with gentle 
rocking, the well was washed three times with 2 ml IX TBST (Novagen) and each wash 
was incubated for 10 minutes. After the last wash 2ml of developing solution (60pl X- 
Gal Novagen, 60pl NBT Novagen in 15ml PBS, 5mM MgCh) was added and the plate 
was incubated at 37°C for 15 to 60 minutes. To stop colour development two more 
washes with 2ml of IX TBST were done. The infected cells and foci were counted
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immediately using a dissecting microscope and the titer was calculated using the 
following formula:
Pfu / ml (MOI) = 10 x (# infected cells or foci) x (dilution factor)
This formula was used for each well and an average was done to determine the final 
titer.
6-7-Expression of HLA-DRB*0101 in High 5 cells
We used another insect cell line for the expression of the HLA-DRB*0101, the 
High 5 cells, due to their ability to express molecules at higher rates than sJ9 cells. For the 
expression, cells had to be infected at a high MOI to ensure all cells were infected 
simultaneously and the culture was synchronous. After optimization of the expression, 
200 ml culture o f High 5 cells in Express Five® SFM medium (Invitrogen) were 
prepared at an appropriate cell density in log phase growth (2.5 x 106 cells/ml). This 
culture was infected by the recombinant baculovirus at a MOI of 10 and incubated at 
27°C in shake incubator for 5 days. Following incubation the culture was centrifuged at 
453g for 2 0  minutes at 4°C, the supernatant was harvested, filtered using a 0.45pm filter 
in a first instance, then a 0.22pm filter and the purification of the HLA-DRB*0101 was 
done.
6-8-Purification of HLA-DR*0101
HLA-DRB*0101 was first purified by passing the filtered supernatant on anion 
exchange column. A Poros50HQ™ column was equilibrated first in buffer B (lOmM 
Tris, 1M NaCl) and secondly in buffer A (lOmM Tris), the supernatant was loaded onto 
the column and eluted using the buffer A. Different fractions were collected, concentrated
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to 0.5 ml, using centrifugal concentrators (Sartorius, Stedim, Australia), and purified 
using gel filtration column. A Superdex200HR™ (GE Healthcare, UK) was equilibrated 
in PBS, the sample was loaded onto the column using a 2  ml injection loop and eluted 
using PBS. The factions were analysed by gel (SDS-Page, Invitrogen), concentrated and 
stored at -80°C. For the gel, 8  pi of sample were mixed to 2 pi of 5X loading buffer 
(0.313M Tris-HCl, pH 6 .8  at 25°C, 1 0 % SDS, 0.05% bromophenol blue and 50% 
glycerol) or 2 pi of 5X reducing loading buffer (loading buffer plus 0.5M DTT), the 10 pi 
were loaded on aNuPAGE® Gel (Invitrogen), 5 pi of SeeBlue® Plus2 Pe-stained Standard 
(Invitrogen) were used as marker of molecular weight protein. The electrophoresis was 
carried out at constant voltage (150V) during 1 hour, the gel was washed twice in 
distilled water, stained in SimplyBlue™ SafeStain (Invitrogen) for 30 minutes and de­
stained overnight with water and lOmM NaCl.
6-9-Biotinylation of HLA-DR*0101
Briefly, HLA-DRB*0101 with a biotinylation sequence tag, was treated with 400 
pM biotin, 5 pM ATP, 200 pM PMSF, 1 pM leupeptin, 1 pM pepstatin and 15 pi of 
BirA enzyme. The mixture was incubated overnight at room temperature and gel filtered 
using a Superdex200HR™column to remove free biotin (see paragraph 6 -8 ).
6-10- Surface Plasmon Resonance (SPR)
The binding analysis was performed using a BIAcore 3000™ equiped with a 
CM5 sensor chip. Briefly, chip coupling solutions containing 100 pi of lOOmM NHS and 
100 pi of 400mM EDC were used to activate the CM5 sensor chip prior to streptavidin
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binding (110 (j.1 of 200 pg/ml in lOmM acetate pH 4.5). 100 pi of 1M ethanolamine 
hydrochloride was used to deactivate any reactive groups. Biotinylated HLA-DRB*0101 
at ~1 pM was then coupled to the streptavidin coated chip. For MHC coupling, 
approximately 600-3000 RU of protein was attached to the CM5 sensor chip. L243 
antibody (anti-HLA-DR) or soluble TCR samples were concentrated to around ImM. For 
equilibrium analysis, ten serial dilutions were carefully prepared in triplicate for each 
sample, which were injected over the relevant sensor chips at 25°C. All experiments were 
carried out in triplicate using the same chip on the same day. Results were analysed using 
BLAevaluation 3.1™ (BIAcore) and Microsoft Excel™. The equilibrium binding constant 
(Kd) values were calculated using a nonlinear curve fit (y = (Pix)/(P2 + x)).
7-PRODUCTION OF HLA-DRB*0101 IN ECHERICHIA COLI (E.COLI)
7-1- Inclusions bodies production and purification
Between 200 and 500 pg of expression plasmid pGMT7 (kindly provided by Dr J 
Boulter) containing the sequence of either the a  chain or the (3 chain of HLA-DR*0101, 
were used for the transformation of Rosetta BL21 (DE3) competent cells (Novagen). The 
bacteria were mixed with the plasmid and incubated at 42°C for 45 seconds and incubated 
for 2 minutes at 4°C, the transformed cells were cultured in LB medium for 1 hour at 
37°C and spread on LB/agar plates. The day following the transformation a single colony 
was used to inoculate 1 L of warm TYP media (16 g tryptone, 16 g yeast extract, 5 g 
NaCl, 2.5 g K2HPO4) containing lOOpg/ml ampicillin, the culture was incubated at 37°C, 
220 rpm. When the cells were in exponential phase (OD reached approximately 0.5 at 
600nm) the inclusion bodies were inducted by adding 0.5ml of 1M IPTG (Sigma) in
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culture media for 3 hours. Following this, the transformed cells were harvested by 
centrifugation (151 Og for 20 minutes at 4°C), the supernatant was discarded. The pellet 
was dissolved in 40ml of lysis buffer (lOmM TRIS pH 8.1, lOmM MgCU, 150mM NaCl, 
10% glycerol). The dissolved pellet was sonicated (Sonicator W-385 heat system, ultra 
sonics, UK) on ice at 20% power for 20 minutes using a 2 second interval, following 
200pi of 20mg/ml DNase I (Invitrogen) was added and shaken at RT for 30 minutes. The 
sonicated pellet was then treated with 100 ml of triton wash buffer (0.5% w/v Triton 
X100, 50mM TRIS pH 8.1, lOOmM NaCl, lOmM EDTA) and centrifuged for 20 minutes 
at 3775g, this step was repeated 3 times. The pellet was then treated with 100ml of re­
suspension buffer (50mM TRIS pH 8.1, lOOmM NaCl, lOmM EDTA) and centrifuged 
for 20 minutes at 3775g. Finally, the inclusion bodies (IBs) were dissolved in the smallest 
possible volume of guanidine buffer (6 M guanidine, 50mM TRIS, 2mM EDTA, lOOmM 
NaCl) and stored in 15ml falcon tube at -80°C. Prior to refolding, protein concentration 
was estimated using a Coomassie Plus reagent kit™ (Pierce™) using BSA as a standard. 
Furthermore a NuPAGE® Gel (Invitrogen) was run to check the expression of 
recombinant proteins.
7-2-Refolding of HLA-DRB*0101
For refolding of HLA-DR*0101, 60mg of a  chain IBs and 30mg of p chain IBs 
were diluted to a final concentration of lOmg/ml in guanidine buffer (6 M guanidine, 
50mM TRIS, 2mM EDTA, lOOmM NaCl). This was incubated at 37°C for 15 minutes 
with lOmM DTT, and added to cold refold buffer (50mM TRIS, pH 8 , 2mM EDTA, pH 
8 , 2.5M urea), the oxydo-reduction couple was added at the last minute (0.74g/l
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cysteamine, Sigma, and 0.83g/l cysteine, Sigma). Each refold reaction was incubated 
with mixing at 4°C for at least 1 hour before dialysis. Dialysis was performed at 4°C over 
two days with 2 0  volumes of dialysis buffer (changing the dialysis buffer once) until the 
conductivity of the refolds was under 2000pS/cm. The HLA-DRB*0101 refolds were 
filtered and ready for the purification steps as it is described in the section 6 -8 .
8-PRODUCTION OF TCR IN ECHERICHIA COLI (E.COLI)
8-1- Inclusions bodies production and purification
Between 200 and 500 pg of expression plasmid pGMT7 (kindly provided by Dr J 
Boulter) containing the sequence o f either the a  chain or one of the two P chain of TCR, 
were used for the transformation of Rosetta BL21 (DE3) competent cells (Novagen). The 
bacteria were mixed with the plasmid and incubated at 42°C for 45 seconds and incubated 
for 2 minutes at 4°C, the transformed cells were cultured in LB medium for 1 hour at 
37°C and spread on LB/agar plates. The day following the transformation a single colony 
was used to inoculate 1 L of warm TYP media (16 g tryptone, 16 g yeast extract, 5 g 
NaCl, 2.5 g K2H P04) containing lOOpg/ml ampicillin, the culture was incubated at 37°C, 
220 rpm. When the cells were in exponential phase (OD reached approximately 0.5 at 
600nm) the inclusion bodies were inducted by adding 0.5ml of 1M IPTG (Sigma) in 
culture media during 3 hours. Following this, the transformed cells were harvested by 
centrifugation (151 Og for 20 minutes at 4°C), the supernatant was discarded. The pellet 
was dissolved in 40ml of lysis buffer (10mM TRIS pH 8.1, 10mM MgCL, 150mM NaCl, 
10% glycerol). The dissolved pellet was sonicated (Sonicator W-385 heat system, ultra 
sonics, UK) on ice at 20% power for 20 minutes using a 2 second interval, following
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200jj.1 of 20mg/ml DNase I (Invitrogen) was added and shaken at RT for 30 minutes. This 
sonicated pellet was then treated with 100 ml of Triton wash buffer (0.5% w/v Triton 
X100, 50mM TRIS pH 8.1, lOOmM NaCl, lOmM EDTA) and centrifuged for 20 minutes 
at 3775g, this step was repeated 3 times. The pellet was then treated with 100ml of re­
suspension buffer (50mM TRIS pH 8.1, lOOmM NaCl, lOmM EDTA) and centrifuged 
for 20 minutes at 3775g. Finally, the inclusion bodies (IBs) were dissolved in the smallest 
possible volume of guanidine buffer (6 M guanidine, 50mM TRIS, 2mM EDTA, lOOmM 
NaCl) and stored in 15ml falcon tube at -80°C. Prior to refolding, protein concentration 
was estimated using a Coomassie Plus reagent kit™ (Pierce™) using BSA as a standard. 
Furthermore a NuPAGE® Gel (Invitrogen) was run to check the expression of 
recombinant proteins.
8-2-Refolding of TCR
For refolding of TCR, different mixtures of a , p chains and redox couples have 
been tested (see table 8  chapter 3) . Each refold reaction was incubated with mixing at 
4°C for at least 1 hour before dialysis. Dialysis was performed at 4°C over two days with 
2 0  volumes of dialysis buffer (changing the dialysis buffer once) until the conductivity of 
the refolds was under 2000pS/cm. The HLA-DRB*0101 refolds were filtered and ready 
for the purification steps as it is described in the section 6 -8 .
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9-TISSUE CULTURE
9-1-Tissue culture media
For the culture of cells, which were not CD4+ T cells 10% FCS-RPMI media was 
used. RPMI 1640 (Invitrogen) was supplemented with 100 U/ml of penicillin, 100 pg/ml 
of streptomycin (Invitrogen), 25 mM of HEPES (Sigma), 2mM of L-glutamine 
(Invitrogen), and 10% of foetal calf serum (FCS, Invitrogen). For the culture of the clones 
bexll and belx2 CD4+ T cells AB-RPMI media 5% of heat inactivated human AB serum 
(Welsh Blood Transfusion Service) was used. For the clones HC3 and HC6  RPMI X- 
VIVO 15 media (Lonza, Tewkesbury, UK) 5% of heat inactivated human AB serum 
(Welsh Blood Transfusion Service) was used. RPMI 1640 (Sigma) was supplemented 
with lOOU/ml of penicillin, 100 pg/ml of streptomycin (Invitrogen), 25 mM of HEPES 
(Sigma), 2mM of L-glutamine (Invitrogen).
For all washes during the isolation of peripheral blood mononuclear cells 
(PBMC), thawing, and when the APC were pulsed with peptides, a serum-free RPMI 
media was used. It was the RPMI 1640 (Invitrogen) supplemented as above but without 
adding FCS.
All the cells were cryopreserved using a freezing mix with 10% dimethyl 
sulphoxide (DMSO, Invitrogen), 40% RPMI 1640 (Invitrogen) and 50% FCS 
(Invitrogen). Cells were thawed rapidly using a 37°C water bath. After thawing, cells 
were washed in serum-free RPMI media, centrifuged at 425g for 5 minutes and 
resuspended in the appropriate serum containing RPMI media (10% FCS or 5% AB- 
serum). After thawing a T-cell line, the cells were plated out in AB-RPMI media 
supplemented with lOng/ml of human recombinant IL-7 (Genzyme, Oxford).
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9-2-Tissue culture vessels
All standard plasticware were obtained from either Nunc (Loughborough), 
Greiner (Stonehouse), Fisher (Loughborough) and Coming (Loughborough), with the 
exception of 48 well plates from Falcon (Loughborough).
10-BLOOD SAMPLES, PBMC CULTURE AND EXPANSION OF T-CELLS
10-1-Blood donors
The blood used in the screening for p37 (HPV16 E6  peptide) responses was 
collected by the Welsh Blood Transfusion Service (WBTS). All the buffy-coats came 
from female donors and were tested for HIV, HBV and HCV by the WBTS. Due to the 
anonymous character o f the donation it was impossible to know the age of the donors, or 
whether they had history of cervical dysplasia or neoplasia.
The blood used as feeders was collected from laboratory staff (into 50 ml Falcon 
tubes containing lOU/ml of heparin) without any restriction of age or gender. Blood was 
taken with informed consent. Since donors were healthy volunteers, no ethical approval 
was required.
10-2-Isolation of PBMC from whole blood
PBMC were enriched from whole blood by density gradient centrifugation. 
Briefly, blood was layered upon an equal volume of Ficoll-Hypaque (Histopaque-1077, 
Sigma) in a 50ml Falcon tube. Blood was centrifuged with the brake inactivated for 2 0
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minutes at 755g. This resulted in the formation of a distinct monolayer, enriched with 
PBMC and platelets at the surface between Histopaque and plasma. This monolayer was 
harvested with a pastette (Alpha, Hampshire, UK) into a 50 ml Falcon tube and serum- 
free RPMI media was added until 50 ml. Enriched PBMC were centrifuged at 612g for 
10 minutes and serum-free RPMI media was then used to wash them, with the first 2 
washes centrifuged at 425g for 5 minutes and the final spin at 272g for 5 minutes so as to 
reduce the platelet content of pellet.
10-3-Stocks of peptides
All the peptides were obtained from Mimotopes (Heswall, UK), dissolved in 
DMSO (Sigma) to give a stock of lOOmg/ml. From this, aliquots of lOpg/pl were done 
by dilution in DMSO (Sigma) and stored at -20°C.
10-4-Expansion of Belxl and Belx2 clones using allogenic feeder system
Belxl and belx2 clones, CD4+ T-cells specific for HPV16 E6127-141 peptide, were 
expanded in a T75 flask. 2xl07 irradiated PBMC feeders mixture (from 3 donors) were 
cultured in 50ml AB-RPMI medium supplemented with 20U/ml of IL-2, 0.5pg/ml 
Purified Phytohaemagglutinin (PHA). 1 x 106 T-cells were added to the flask which was 
placed into a 37°C incubator tilted at 45° so as to enhance cell-cell contact. On day 5 of 
expansion, half of the medium was removed and replaced with the same volume of AB- 
RPMI medium supplemented with 20U/ml of IL-2. Cells were re-suspended and cultured 
for further 2 days upright. Cells were then harvested and plated out in fresh AB-RPMI 
medium supplemented with 20U/ml of IL-2, at 2xl06 cells/well, in 24 well plates. Every
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2-3 days when media turned yellow, half of the media was replaced by AB-RPMI 
medium supplemented with 20U/ml of IL-2.
10-5-Expansion of HC3 and HC6 clones using allogenic feeder system
HC3 and HC6  clones, CD4+ T-cells specific for influenza peptide (HA 100 and 
HA107), were expanded in a T75 flask. 2xl07 irradiated PBMC feeders mixture (from 3 
donors) were cultured in 50ml X-VIVO 15 RPMI medium supplemented with 20U/ml of 
IL-2, 0.5pg/ml PHA. lxlO6 T-cells were added to the flask which was placed into a 37°C 
incubator tilted at 45° so as to enhance cell-cell contact. On day 5 of expansion, half of 
the medium was removed and replaced with the same volume of X-VIVO 15 RPMI 
medium supplemented with 20U/ml of IL-2. Cells were re-suspended and cultured for 
further 2 days upright. Cells were then harvested and plated out in fresh X-VIVO 15 
RPMI medium supplemented with 20U/ml of IL-2, at 2 x 106 cells/well, in 24 well plates. 
Every 2-3 days when medium turned yellow, half of the medium was replaced by X- 
VIVO 15 RPMI medium supplemented with 20U/ml of IL-2.
11-DETECTION OF PEPTIDE SPECIFIC T-CELLS RESPONSE BY IFNy ELISA 
ASSAY
To measure the IFNy secretion induced by peptides, some co-cultures of T-cells in 
presence of APC and peptides were done. T-cells were plated out at 5xl04 cells/well in 
48 well plates. B-LCL cells were added at a ratio of 2:1 in a final volume of 0.5 ml of 
AB-RPMI. Cells were cultured in the presence of different concentrations of peptides 
(Opg/ml to 10fig/ml). Cells were incubated at 37°C overnight, 1 OOjllI of supernatant was
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collected from each well and used for ELISA and 300|l l 1 of supernatant was harvested and 
stored at -80°C.
For ELISA, a 96 well flat-bottom Maxisorp plate (Nunc) was coated with 50jnl of 
anti-human IFNy antibody 1-D1K (diluted with coating buffer (0.04M Na2C0 3 , 0.06M 
NaHCC>3 pH 9.6) to 2 pg/ml, Mabtech, Nacka Strand, Sweden) and incubated overnight at 
4°C. The plate was washed twice with 200pl/well of PBS and lOOpl/well of blocking 
buffer (PBS 1 /o FCS) was added and incubated for 1 hour at room temperature (R' 1 '). 
Plate was then washed 5 times with ELISA wash buffer (PBS 0.05% Tween) and the 
collected supernatants were added in triplicate at 100pl/well. For each experiment the 
IFNy standard (Mabtech) was used according to manufacturer instructions. Briefly, IFNy 
standard was reconstituted to give lOpg/ml stock solution, which was then aliquoted and 
stored at -20°C. One aliquot of lpl was thawed and diluted 1 in 10,000 with dilution 
buffer to give a final solution at lOOOpg/ml, 200pl of the standard solution was added in 
triplicate to the first wells and lOOpl of this was used to generate V2 serial dilutions of 
IFNy using dilution buffer. The plate with the supernatants and the standard was 
incubated at RT for 2 hours and then washed 5 times with 200pl/well ELISA wash 
buffer. The antibody 7-B6-1-biotin (Mabtech) was diluted in dilution buffer (PBS, 0.1% 
BSA) at lpg/ml, added at 50pl/well and incubated for 1 hour at RT. After the incubation 
the plate was washed 5 times and 50pl/well of substrate mix (equal volume o f substrate 
reagent A and substrate reagent B mixed at RT, BD biosciences) were added and 
incubated in the dark for 10 to 30 minutes, until the standard had clearly developed. The 
reaction was stopped by adding 50pl/well of ELISA stop reagent (1M phosphoric acid).
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The optical density was then analysed using a Bechenmark Microplate reader (Bio-Rad, 
Watford, UK) at 450nm. A standard curve was created with Graphpad Prism® using the 
serially diluted IFNy standard, allowing the determination of the IFNy concentration in 
the collected samples.
12-PROLIFERATION ASSAY
To compare the cellular activation induced by the different peptides proliferation 
assays were performed. lxlO5 BLCL cells were loaded with 10pg/ml of HVP16 E6127-141 
in 1ml of RPMI 1640 (Invitrogen) supplemented with 100 U/ml of penicillin, 100 pg/ml 
of streptomycin (Invitrogen), 25 mM of HEPES (Sigma), 2mM of L-glutamine 
(Invitrogen) for 1 hour at 37°C. Following this incubation BLCL cells were washed once 
and 15 ml of 10% FCS-RPMI (Gibco) was added. The BLCL were gamma-irradiated at 
3000 rads. BLCL were plated in a 96 well plate and belxl or belx2 cells were added at 
5xl04cells/well. The co-culture was incubated in 10% FCS-RPMI for 3 days at 37°C. At 
day 2, lpCi of [methyl-3H]Thymidine (GE healthcare) was added to each well. The 
following day the cells were harvested on a paper filter using a cell harvester (Tomtec, 
UK), the filter was wet with scintillant (Fisher) and the radioactivity was counted with a 
liquid scintillation and luminescence counter (Wallac, UK). PMA was used as a positive 
control and the BLCL/belxl or BLCL/belx2 was used as background o f the experiment.
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13-CALCIUM SIGNALLING
13-1-Calcium signalling of a cellular population
BLCL cells were incubated at a concentration of lx l0 6/ml with lOpg/ml of 
HPV16 E6127-141 for 1 hour at 37°C. In parallel, belx2 cells were incubated at lx l0 6 
cells/ml with 2pM of acetoxymethyl ester of Fura-2.AM (Calcium sensitive fluorescent 
probe), for 1 hour at 37°C in the dark. Following the incubations each type of cell was 
washed and resuspended in RPMI 1640 without phenol red (Invitrogen), 10% FCS. 
IO O jllI of each type of cell were collected in a round bottom 96 well plate and centrifuged 
at 735g for 5 minutes. Following this centrifugation the cells were re-suspended in 25 pi 
of 0.1% Triton X-100 (Fisher) in RPMI without phenol red (control for the maximum of 
fluorescence), or 0.1% Triton X-100 plus 5mM EDTA (Fisher) in RPMI without phenol 
red (control for the minimum of fluorescence), or RPMI without phenol red. The belx2 
cells, loaded with Fura-2.AM, were plated in a black 96 well plate (Greiner) and the plate 
was placed in the plate reader rack. BLCL were injected 20 seconds after the beginning 
of reading with Fluostar™ fluorescence reader with excitation at 340 and 380 nm.
13-2-Calcium signalling of one cell
As previously the BLCL and belx2 were loaded with respectively HPV16 E6127- 
i4i (lOpg/ml) and Fura-2.AM (2pM). The cells were incubated on ice after loading and 
washed in 10% FCS-RPMI. With the kindly help of Professor Hallett, BLCL cells were 
set down on a slide and left under a fluorescence microscope. After a few seconds, when 
the BLCL stopped moving, the belx2 cells were added and the calcium flux was observed 
on the camera connected to the microscope.
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14-FLUORESCENCE CYTOMETRY
14-1-Staining with the ultimer from pro-immune
To observe the binding of the HLA-DR*0101/HPV16 E6127-141 ultimer to its 
TCRs and its specificity various cell lines or clones have been stained. lxlO 5 cells were 
incubated at 37°C with 10 pi of the ultimer (for 1, 2 or 3 hours). Following this incubation 
cells were washed and stained with a 2 pi of mouse anti-human CD4-FITC antibody 
(Serotec, Kidlington, UK) for 20 minutes at 4°C. The cells were washed twice in PBS 
0.1% FCS and re-suspended in 200pl of PBS 0.1% FCS. The samples were directly 
acquired and analysed on FASCcalibur (BD biosciences), using the software 
CellQuestPro™ and analysed using the software CellQuestPro™.
14-2-Staining of the TCR
To observe the down-regulation of the TCR on belx2  cell clone a staining of the 
TCR was performed. 3xl0 5 BLCL cells were loaded with different concentration of 
peptides (0.001 to lOpg/ml) for 1 hour at 37°C in 10% FCS-RPMI. BLCL cells were 
washed and incubated with 1.5x10s belx2 cells at 37°C for 4 hours in FACS tubes 
(Falcon). Following this incubation the reaction was stopped by addition in excess of cell 
wash buffer (BD biosciences) and the cells were washed and co-stained with 2pl of 
mouse anti-human TCR PAN ALPHA/BETA:RPE antibody (Serotec) and 2pl of mouse 
anti-human CD4-FITC antibody (Caltag, Buckingham, UK) for 20 minutes at 4°C. The 
cells were washed twice in PBS 0.1% FCS and re-suspended in 200pl of PBS 0.1% FCS. 
The samples were directly acquired and analysed on FACScalibur (BD biosciences), 
using the software CellQuestPro™.
RESULTS
1-SOLUBLE HLA-DRB*0101 AND SOLUBLE TCR
The E6  and E7 proteins are constitutively expressed in both high grade CIN and 
cervical cancer, making them ideal tumour-specific antigens for investigation. Previous 
studies from our laboratory have shown that CD4+ T cell responses against HPV16 
peptides were detected in nearly 50% of healthy young women. These T-cell responses 
were tested against different pools of HPV16 E6  peptides and in two healthy donors the 
E6  response was mapped to HPV16 E6127-141. Then two clones, belxl and belx2, were 
generated from the PBMC of one of these donors (Gallagher and Man 2007). These 
clones could be phenotypically differentiated based upon their expression o f either TRBV 
14 or TRBV 4-2 (P chain of their TCR). Furthermore the two lines were different in their 
capacity to secrete IFNy in response to HPV16 E6127-141; belxl demonstrated an inferior 
IFNy response to HPV16 E6127-141 compared to belx2, but both of them recognized 
HPV16 E6127-141 presented by HLA-DR1.
One o f the explanations for the functional variation observed between these two 
clones against the HLA-DR1 HPV16 E6127-141 complex could be due to differences in 
their TCR expression.
To investigate this at a molecular level, recombinant soluble TCR and MHC- 
peptide complexes would be generated. The affinity of interactions between soluble TCR 
and MHC-peptide complexes could then be measured using surface plasmon technology 
(BIAcore™) (Cole, Rizkallah et al. 2006). From these biophysical studies it was hoped 
that:
-Critical peptide residues could be identified that influenced TCR, MHC 
interactions or both.
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-Optimised peptides could be designed as vaccine candidates.
-Stable MHC-peptide complexes could be generated in order to produce 
fluorescent multimeric molecules suitable for detecting HPV specific T-cells directly 
from blood.
1-1-Construction of the HLA-DR*0101
Dr J. Boulter defined the cloning scheme for the construction of the a  and 
P chains, according to literature (Gauthier, Smith et al. 1998). The DRA1*01 chain 
construct was generated in three steps: (1) amplification of complementary DNA strands 
corresponding to the extracellular domain and the wild type secretion signal peptide of 
HLA-DRA1*01 from a B cell line, (2) the amplification of the fos leucine zipper attached 
to the biotinylation tag, (3) the amplification of all the domains corresponding to the 
extracellular domain of HLA-DRA1*01 attached to the fos  leucine zipper and the 
biotinylation tag, figure 15.
The construction of the DRB*01 chains were generated in four steps: (1) 
amplication of the complementary DNA strands, corresponding to the extracellular 
domain of HLA-DRB1*01 which was then attached to a linker by overlapping PCR, (2) 
the amplification of the jun leucine zipper sequence, (3) the amplification of the wild type 
signal peptide for the secretion of the molecule associated with the HPV peptide by 
overlapping PCR, (4) the amplification of the complete chain. The sites of the restriction 
endonuclease BglH was added to the DRA1*01 construct and the restriction 
endonuclease site, BamHI, was added to the DRB1*01 construct, figure 15. The results of 
these constructs are showed in figure 16. In parallel to this construct another one was
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generated with the CLIP peptide sequence instead of the HPV16 E6127-141 sequence.
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Figure 15: Schem a o f  the construction  o f  a  and  P chains to  express a  so lub le H LA - 
DR*0101 associated  w ith H PV  16 E6127-141 peptide.
HLA-DRA*0101
AGATCTATGGCC..............CCCGGGGGTCT GACTGAT.......................................TCCGGTGGT
M A  P G G L T D  S G G
B g ll l  ■<----------  D R A *0101  ► + -------------- Jos L eucin  zipper --------------
GGTCTGAAC...................T GGC ATT AAGATCT
G L N  W H
Biotin tag *  Bgl II
HLA-DRB*0101
GGATCCATGGTGTGT....................GCTTTGGCTGATAAAAAA.............. TGGACTGGATCTGGTGG
M V C  A L A  D K K W T G S G G
BamH 1 + ------- Signal peptide for secretion —   Peptide  >  •*-------------
 GAAT GGAGAGCACCCGGGGGTAGA.............A
E W R A P G G R
D R B *0101 *  jun  L eucin
ACTACTAGGATC 
N Y .
Zipper — > BamH 1
Figure 16: Construction of a  and p chains of the HLA-DR*0101
T................ GGGTCCGGGGACACC
G S G D T 
Linker---------------------► < -------------
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At each step of the construction, PCR screening was implemented to check the presence 
of the insert in the vector, and sequencing was performed m order to check the sequence 
of the insert for both a  and p chain constmcts. An example of PCR screening confirming 
that cloning was correct is presented in figure 17.
Positive clones for the 
p chain in the vector 
pBACgus4x-l.
Figure 17: An example of screening: screening of different DH5a colonies after their 
transformation by the product of ligation between the p chain and pBACgus4x-l.
1-2-Production of recombinant virus in insect cells
Initially, recombinant baculovirus was produced using a BaculoGold kit from BD 
bioscience. The three constructions of the a  and p chains (with HPV 16 E6127-141 or CLIP 
peptide) were cloned in the transfer vector pAcAB3, using the Bglll and BamHl 
endonuclease restriction sites respectively. After checking the correct orientation of each 
insert in the transfer vector, recombination with the BaculoGold was performed at room 
temperature, using the kit provided by BD bioscience. Following this step, sf9 cells were 
infected by the recombinant vims, the vims was amplified and an assay of vims titration 
was carried out. We used neutral red staining to count the plaques of cellular lysis,
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because neutral red stains the lysomes of the living cells (figure 18 A). Nevertheless, it
was difficult to distinguish a true lysis plaque from a false positive just by the staining
with neutral red alone. In order to identify the true lysis plaques and to define the viral
titre of the initial stock, 6  well plates sf9 were infected by various dilutions of the initial
viral stock from 1 to 10‘7, and each infection was performed between 3 and 10 days.
Unfortunately, after coloration with neutral red it was not possible to visualise significant
differences in lysis plaque formation between each well.
*
Due to these difficulties, it appeared necessary to use different systems which 
were available from Invitrogen and Novagen. The system from Invitrogen offered the 
expression of one gene, therefore the co-expression of two chains (a  and p) was not 
possible. The system from Novagen offered co-expression of up to four genes and 
staining of the infected cells due to expression of p-glucuronidase, which could then be 
stained with X-gluc. The cloning of the a  and p (with HPV 16 E6127-141 or CLIP) chains 
was performed in the transfer vector pBACgus4X-l, using the Bglll and BamHI 
endonuclease restriction sites, and the recombination was performed using the BacMagic 
DNA at room temperature, using the buffer from the kit provided with the BacMagic and 
the transfer vector. In order to test if there was any recombinant virus in the media, a 
staining with X-gluc was performed. Indeed, recombinant gus-containing virus expressed 
P-glucuronidase (gus) and after contact with the X-gluc the media stained blue (data not 
shown). The positive supernatant was collected, used for an amplification o f the 
recombinant virus and a viral titre assay was done with FastPlax™ Titer Kit, figure 18B. 
FastPlax Kit takes advantage of the appearance of detectable levels of AcNPV gp64 
glycoprotein, the major envelope glycoprotein of the baculovirus, on the cell surface, as
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early as 8  to 24 hours post-infection. Detection is based on a high affinity monoclonal 
antibody against gp64, which is added directly to fixed cells. Antibody binding is 
detected with Goat Anti-Mouse IgG p-Galactosidase conjugate followed by enhanced 
colour development with X-Gal/NBT substrates. This system was more effective than the 
BD bioscience system because only the cells infected could express the AcNPV gp64 
protein and there were no false positives. Different assays were done to observe the 
specificity of the technique showing that the staining of the cells was proportional to the 
time of infection. After 24 hours of infection, only a few isolated cells were stained, 
compared to 48 hours post-infection, in which the staining of groups of infected cells, 
could be observed, figure 18B.
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Figure 18: Detection o f sf9 cells infected by recombinant virus. A-Staining using neutral red after 
infection during 5 days by recombinant virus using the BD system. We distinguished some light plaques 
and with a higher magnification we could observe cellular debris (red line) near living cells (yellow line). 
Nevertheless we could not be sure this represented a real lysis plaque caused by the virus. B-Staining o f  
sf9 cells expressing viral AcNPV gp64, the envelope glycoprotein o f the baculoviruses, to their surface 
using FastPlax™ Titer Kit. The cells were infected for 24 or 48 hours, fixed using 3.7% formaldehyde 
solution and stained directly. Positive cells appeared purple to black and the negative cells stayed white.
103
1-3-Expression of HLA-DR*0101 in insect cells
Following the previous experiments the viral titre was defined by using the 
formula:
Pfii/ml = 5 x (# infected cells and foci) x (dilution factor)
An average of 3 dilutions, in duplicate, were used to obtain the final viral titre.
Two viral amplifications were performed to obtain a viral stock with a good viral 
titre: 1.36xl08 pfu/ml, although after the recombination of the transfer vector with the 
baculovirus and the first infection the viral titre was too low to be detected by the 
FastPlax™ Titer Kit. The amplified viral stock was then used to infect High5 cells to 
obtain good expression of HLA-DR*0101- HPV16 E6127-141 or HPV-DR*0101 -CLIP. 
Different assays were performed using various multiplicity of infection (MOI) and time 
points, the following table recapitulate the various conditions for the optimisation of the 
expression of the HLA-DR*0101 in High5 cells.
Table 6 : setting of the expression of the HLA-DR*0101 in High5 cells
MOI 2 2  ml of supematant/ 6 6  ml of media/170x106 cells (samples 
taken at 48, 72, 96 hours and 5 days)
MOI 5 5.2 ml of supematant/62.8 ml of media/170x106 cells 
(samples taken at 48, 72, 96 hours and 5 days)
MOI 1 0  10 ml of supematant/58 ml o f media/170x106 cells (samples
taken at 48, 72, 96 hours and 5 days)
Each condition was tested and each supernatant was collected, filtered with 0.45pi 
filter and purified by ion exchange. The harvested fractions from the purification were
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tested on a SDS-PAGE gel and the positive ones (60 kD) were further purified by gel 
filtration. These experiments showed that a MOI of 2  was not sufficient to induce the 
production of soluble HLA-DR*0101, indeed no peaks were detectable after purification 
on ion exchange column of the supernatant (data not shown). A MOI of 5 was sufficient 
to produce a very small amount of protein after an infection of 5 days, figure 19. The best 
conditions for good expression of HLA-DR*0101 were infection with a MOI of 10 for 96 
hours, the infection of 5 days induced the production of less soluble HLA-DR*0101 and 
more cellular proteins (data not shown). Following these experiments, an infection of 
High5 cells in a bigger volume was implemented and after 96 hours the supernatant was 
collected and purified by ion exchange and gel filtration, figure 2 0 .
In order to test the conformation of the soluble HLA-DR*0101 associated with 
HPV 16 E6127-141 or CLIP obtained from High 5 culture, surface plasmon resonance assays 
were performed. Soluble HLA-DR*0101-HPV16 E6127-141 or HLA-DR*0101-CLIP was 
immobilised on a CM5 chip via the interaction between its biotin tag and the streptavidin 
on the chip, and L243 antibody (specific for the a  chain of HLA-DR1) was injected, 
figure 21. A biotinylated HLA-DR*0101-HA (with influenza peptide) was used as 
positive control on the flow cell number 2 (Fc 2), a class I MHC (A2) was used as 
negative control, Fc 1, and the biotinylated HLA-DR*0101-CLIP was on Fc3. 
Unfortunately no binding was observed after different assays with different concentration 
of L243 antibody or soluble HLA-DR*0101, the figure 21A shows the best observed 
response. Nevertheless low amounts and impure HLA-DR*0101-CLIP was generated, 
figure 2 IB. The results shown low amount of class II MHC binding the L243 antibody
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compared to the positive control with HLA-DR*0101-HA (kindly provided by Dr Cole, 
and generated from CHO cells).
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Figure 19: Expression of HLA-DR*0101 in High 5 cells after infection with a viral 
stock of MOI 5. The cells were cultured at 2.5x106 cells/ml and virus was added to 
obtain a MOI of 5. Following 5 days of infection the supernatant was collected and 
filtered at 0 .45 j l l 1. The sterile solution was purified by anion exchange and gel filtration. 
The positive fractions were collected and a SDS-PAGE gel was performed. The sample 
was loaded on the gel with a non-reducing buffer (NR), band at 60kD and with a 
reducing buffer (R). Due to the low expression of DR1, other MOIs and times of 
infection were tested.
aP dimers
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Figure 20: Expression of the HLA-DR*0101 in High5 cells. A-Purification using an 
anion exchange column of supernatant from High5 cells infected during 96 hours at 
MOI 10. B-SDS-PAGE of the two fractions chosen due to their molecular weight 
(~60kD), after purification by anion exchange column, in non-reduced conditions (NR) 
and reduced conditions (R). C-Purification using a gel filtration column (S200) of the 
two fractions. D-SDS-PAGE of the fractions collected after the gel filtration 
purification in non-reduced conditions (NR) and reduced conditions (R).
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Figure 21: BIAcore assays. A-Assay with HLA-DR*0101-HPV16 E6127-141. The biotinylated HLA-
DR1 (0.25mg/ml) was immobilised on the CM5 chip via the interaction between its biotin tag and the
streptavidin which was immobilised on the chip. L243 antibody was injected at 0.4mg/ml. B-Assay
with HLA-DR*0101-CLIP. The biotinylated HLA-DR1 (0.25mg/ml) was immobilised on the CM5
chip via the interaction between its biotin tag and the streptavidin which was immobilised on the chip
(green line). L243 antibody was injected at 0.4mg/ml. HLA-DR*0101-HA (0.25mg/ml) was used as
positive control (blue line). Some specific binding was observed. . no
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1-4-Expression of HLA-DR1*0101 and its TCR in E.coli
The benefits of protein expression with baculovirus can be summarized as: 
eukaryotic post-translational modification (proper proteolysis, N- and O-glycosylation, 
acylation, amidation, carboxymethylation, phorphorylation, and prenylation), proper 
protein folding and function, high expression levels (up to 30% of the total cell protein), 
high-density suspension culture and safety. Despite these potential advantages, particular 
patterns of post-translational processing and expression must be empirically determined 
for each construct. Different problems can explain the poor results obtained for few 
proteins. Indeed it is possible to have an inefficient secretion, poor refolding of the 
molecule due to intracellular aggregates caused by the infection cycle, or species-specific 
or tissue-specific modifications that do not occur. These disadvantages could explain why 
no binding between the soluble HLA-DR*0101-HPV16 E6127-141 and the L243 antibody 
was observed.
A number of other protein expression systems exist including E.coli, yeast and 
mammalian expression systems, table 6 . The mammalian system is generally expensive 
and produces smaller yields, although it has the potential to provide all the post- 
translational modification required for the production of soluble protein. The yeast 
expression, which could be a good alternative to the insect cell expression system is time 
consuming and is not a technique used by the laboratory. The E.coli expression system is 
robust, low cost and produces high yields of proteins. Furthermore this expression system 
was already used in the laboratory. In this system target genes were cloned into pGMT7 
plasmids under the control of T7 transcription signals. The E. coli bacteria, BL21 DE3, 
were transformed by either a-pGMT7 (D Rla) or p-pGMT7 (DRip). BL21 have the
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advantage of being deficient in both Ion and ompT proteases and DE3 indicates that the 
host is a lysogen of ADE3, and therefore carries a chromosomal copy of the T7 RNA 
polymerase gene under control of the lacUV5 promoter. Such strains are suitable for 
production of protein from target genes cloned in pGMT7 vectors by induction with 
isopropyl-P-D-l-thiogaiactopyranoside (IPTG). IPTG binds to repressor of the lac operon 
and inactivates it, but is not a substrate for P-galactosidase and it cannot be metabolized 
by E. coli. Its concentration remains constant and the rate of expression of lac p/o- 
controlled genes, is not a variable in the experiment. In addition, IPTG is transported 
efficiently, independent o f whether the lacY gene is functional.
The a  and p chains o f HLA-DR*0101 or the a  or p chains of the TCRs specific 
for the recognition of the HPV 16 E6 i27-i4 i-HLA-DR* 0 1 0 1  were cloned in the expression 
vector pGMT7, and BL21 DE3 E.coli cells were transformed with the constructs for the 
production o f each chain (D R la, DRlp, TCRa and TCRP). Following induction by 
IPTG, the inclusion bodies were collected purified and the in vitro refolding of the 
different molecules was performed. The denaturated inclusion bodies were purified by 
anion exchange and different fractions were collected, concentrated and purified by gel 
filtration. Fractions were analyzed by SDS-PAGE (figure 22). From this gel, fractions 11 
to 13 for the a  chain and 11 to 14 for the p chain were chosen due to their purity and the 
high concentration of soluble molecules. Different refolding conditions (table 7) were 
tested and analysed by SDS-PAGE (figure 23) but no in-vitro refolding attempt generated 
a molecule with the correct molecular weight which was 60kD, an example of the 
refolding result is presented figure 23.
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Table 6: Comparison of Expression Systems (adapted from Genway).
Characteristics
Complexity of Growth Medium
Expression Level
Protein Folding
O-linked Glycosylation
Acetylation
gamma-Carboxylation
Yield (mg) (per liter culture)
Success Rate (%) (soluble or 
functional
- Reject Cost
Recommended Use
Disadvantage
E coli Yeast
Minimum Minimum
Low
High
Refolding Usually 
Required
Refolding May Be 
Required
None
No Yes
No Yes
No No
4 0 -6 0 5 0 -70
Antigen protein, 
Protein standards, 
Functional proteins
Antigen protein, 
Protein standards, 
Functional proteins
:, tow cost, good
Least PIM* Longer time, less PIM
Insect cells 
Slow (18-24 H)
Complex
Low-High 
Secretion to Medium
Proper Folding
Yes
Yes
Yes
No
5 0 -7 0
Proteins with 
glycosylation, Assay 
standards, Secreted 
form.
Relatively hi^ Ter yield, 
better PIM
Longer time, higher 
cost
Mammalian cells
Complex
Low- Moderate 
Secretion to Medium
Proper Folding
Gon^ bt
Yes
Yes
Yes
Yes
Yes
O.MOO
80 -95
Functional study, PIM  
study, Assay standards, 
Characterization
FTM
Hgjiest cost, lower 
yield
PTM = Post-Translational Modification such as glycosylation
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Figure 22: Expression of the a  (33kD) and p (28kD) chains of HLA-DR*0101 in 
BL21/DE3. Inclusion bodies were induced by addition of IPTG for 4 hours. After 
different washes with lysis and denaturating buffer the a  and P chains were purified 
by anion exchange and by gel filtration. Different fractions were collected and a 
SDS-PAGE analysis was performed.
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Table7: Different refolding conditions used to test the production of soluble HLA-DR*0101-HPV16 
E6 127-hi complex
TCEP
Glycerol
GSH/GSSG
Metals
TCEP
Metals
GSH/GSSG
Glycerol
TCEP
Glycerol
EDTA
GSH/GSSG
GuHCl
TCEP
Metals
GSH/GSSSG
PEG6000
TCEP
L-arg
EDTA
GSH/GSSG
EDTA
Cyclodexdrm
TCEP
Glycerol
EDTA
Cyclodextrin
GSH/GSSG
L-arg
Cyclodexdrin
TCEP
Metals
Cyclodextrin
GSH/GSSG
Glycerol
Cyclodextrin
TCEP
GuHCl
Cyclodextrin
GSH/GSSG
EDTA
Cyclodexdrin
TCEP
lOOmM
NaCl
EDTA
GSH/GSSG
lOOmM
NaCl
TCEP
PEG6000
lOOmM
NaCl
GSH/GSSG
lOOmM
NaCl
TCEP
lOOmM
NaCl
GSH/GSSG
PEG600
lOOmM
NaCl
TCEP
GuHCl
lOOmM
NaCl
EDTA
GSH/GSSG
GuHCl
Cyclodexdrin
TCEP
GuHCl
lOOmM
NaCl
Cyclodextrin
GSH/GSSG
GuHCl
lOOmM
NaCl
TCEP
GuHCl
lOOmM
NaCl
Cyclodextrin
GSH/GSSG
lOOmM
NaCl
Cyclodextrin
TCEP
lOOmM
NaCl
Cyclodextrin
GSH/GSSG
Glycerol
lOOmM
NaCl
Cyclodextrin
TCEP
L-arg
lOOmM
NaCl
Cyclodextrin
GSH/GSSG
Metals
lOOmM
NaCl
TCEP
PEG6000
250mM
NaCl
GSH/GSSG
PEG6000
lOOmM
NaCl
Cyclodextrin
TCEP
Metals
250mM
NaCl
GSH/GSSG
EDTA
lOOmM
NaCl
Cyclodextrin
TCEP
GuHCl
250mM
NaCl
GSH/GSSG
EDTA
lOOmM
NaCl
Cyclodextrin
TCEP
PEG6000
lOOmM
NaCl
EDTA
GSH/GSSG
Cyclodextrin
lOOmM
NaCl
Cyclodexdrin
TCEP
250mM
NaCl
Cydodextrin
GSH/GSSG
Glycerol
250mM
NaCl
TCEP
PEG6000
250mM
NaCl
Cyclodextrin
GSH/GSSG
GuHCl
250mM
NaCl
TCEP
GuHCl
250mM
NaCl
GSH/GSSG
EDTA
PEG6000
250mM
NaCl
TCEP
250mM
NaCl
GSH/GSSG
Glycerol
250mM
NaCl
TCEP
metals
250mM
NaCl
Cyclodextrin
GSH/GSSG
EDTA
250mM
NaCl
Cyclodextrin
TCEP
L-arg
250mM
NaCl
Cyclodextrin
GSH/GSSG
metals
250mM
NaCl
Cyclodextrin
TCEP
250mM
NaCl
GSH/GSSG
EDTA
Cyclodextrin
250mM
NaCl
Cyclodextrin
TCEP
250mM
NaCl
Cyclodextrin
GSH/GSSG
PEG6000
L-arg
EDTA
250mM
NaCl
Cyclodextrin
Cyclodextrin
L-arg
250mM
NaCl
Metals
L-arg
250mM
NaCl
" w m m m .
Glycerol 250mMNaCl
lOOmM
NaCl
PEG6000
250mM
NaCl
Cyclodextrin
GSH/GSSG
GuHCl
Cyclodextrin
EDTA
250mM
NaCl
Glycerol
Cyclodextrin
EDTA
250mM
NaCl
PEG6000
Metals
L-arg
EDTA
250mM
NaCl
L-arg
lOOmM
NaCl
Glycerol
250mM
NaCl
Cyclodextrin
L-arg
lOOmM
NaCl
GuHCl
250mM
NaCl
Cyclodextrin
PEG6000
Cyclodextrin
GuHCl
NaCl
Cyclodextrin
Glycerol
Cyclodextrin
Metals
250mM
NaCl
Cyclodextrin
Metals
lOOmM
NaCl
Cyclodextrin
Metals
Buffer only
lOOmM
NaCl
EDTA Buffer only
lOOmM
NaCl
Metals
Buffer only lOOmMNaCl Buffer only
250mM
NaCl ddH20
lOOmM
NaCl
Cyclodextrin
GlycerolV
ddH20
lOOmM
NaCl
Cyclodextrin
PEG6000 
^ .....................
Empty
y
lOOmM
NaCl
Cyclodextrin
GuHCl
Empty
V
pH 7.0 pH 7.5 pH 8.0 pH 8.5 
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Figure 23: Different refolding conditions were analysed by SDS-PAGE for 
identification of bands at size corresponding to the HLA-DR*0101 
(~60kD). Only bands corresponding to the a  and P chains complexed 
could be observed (33kD for a  chain and 28kD for the P chain).
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The same experiments were performed with the a  and p chains of the TCRs 
specific for the HLA-DR*0101-HPV16 E6127-141. Dr J. Boulter performed the 
amplification, sequencing of the TCR a  and P chains from belxl and belx2 T cells, and 
cloning in pGMT7. He found three different TCR chains, one a  (plasmid: pJMB154 with 
the a  chain TRAV17) and two p (pJMB155 with the p chain TRBV 14 with corresponded 
to belxl and pJMB156 with the p chain TCRBV4-2 which corresponded to belx2). The 
E. coli protein expression system was used to produce the different chains, using the 
expression vector pJMB154, pJMB155 and pJMB156 to transform BL21DE3 E. coli 
bacteria. After induction, the inclusion bodies were washed, solubilized, and the 
expression of recombinant proteins was checked by SDS-PAGE gel, figure 24. The 
expression of the a  chain from pJMB154 and of the p chain from pJMB156 was 
successful, but no expression of the p chain from the vector pJMB155 was observed. 
Different refolding conditions were used in order to produce soluble TCR, which were 
purified by anion exchange and gel filtration, table 8 . Each refold was checked by SDS- 
PAGE for species with the correct molecular weight for the TCR (50 kD). However, no 
potential bands with the correct molecular size were observed.
Despite several attempts, no refolded HLA-DR*0101-HPV16 E6127-141 peptide 
complex or TCR was produced. Therefore to move the project forward, an HLA- 
DR1*01/HPV16 E6127-141 ultimer was ordered from Pro-immune (Oxford, UK). This 
company has successfully synthesized other HLA-DR1 ultimers e.g. HLA-DR1 
complexed to a hemagglutin peptide.
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Figure 24: Expression and refolding of recombinant proteins. A-Expression of the recombinant TCRs a  
and P chains after purification of inclusion bodies from BL21 DE3, the expected size for the a  chain was 
23kD and for the P chain 27kD (due to its extra loops). B-Left part is another assay for the expression of 
the pJMB155 vector in the BL21DE3, on the right is the incorrect refolding of the TCR and we can 
observe that the bands do not correspond to the expected size of the TCR dimer, or a  or p chains. C- 
Refolding of a TCR specific for influenza peptide, the aP dimer of TCR was observed at ~50kD and the 
a  and P monomer were observed at 23kD and 27kD, correct refolding of a TCR specific for influenza 
peptide is presented to show the expected results (SDS-gel profited by D. Cole).
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Table 8: Conditions tested for the refolding of TCRs specific of the HLA-
DR*0101-HVP16 E6127-141
pH 8 8 8.5 8.5 8.5
Tris 50mM 50mM 50mM 50mM 50mM 50mM 50mM
EDTA m m 2mM 2mM . 2mM 2mM
Urea 2.5M 2.5M 2.5M 2.5M 2.5M 2.5M 2.5M
Cysteamine 3.7g/l 3.7g/l 3.7g/l 3.7g/l 3.7g/l 3.7g/I 3.7g/l
Cystamine 0.83g/l 0.83g/l 1.245g/l 0.83g/l 0.83g/l 0.83g/l 1.245g/l
L-arginine none none none 200mM none 200mM none
a  chain 60mg/l 30mg/l 60mg/l 60mg/l 60mg/l 60mg/l 60mg/l
p chain 30mg/l 30mg/l 30mg/l 30mg/l 30mg/l 30mg/l 30mg/l
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1-5-Staining of Belxl and Belx2 by HLA-DR*0101 ultimer
Soluble HLA class II peptide ultimers are predicted to bind to the TCR of peptide 
specific T-cells. Since these complexes are fluorescent, binding can be detected by flow 
cytometry. To test the specificity of the HLA-DR*0101-HPV16 E6127-141 ultimers made 
by Proimmune, the ultimers were used to stain two HPV16 E6127-141 specific T-cell clones 
(belxl and belx2), and the parental T-cell lines (figure 25). It was predicted that the line 
D1 would not have a high percentage of stained cells, line 46 would have a better 
staining, and the belxl and belx2 clones would have the highest staining (between 90 and 
1 0 0 %). A first batch sent by Proimmune was tested using several different conditions 
(figure 26). The staining was done at 37°C for 1 2 0  or 180 minutes, nevertheless no 
staining by the HLA-DR*0101-HPV16 E6127-141 ultimer was observed. We have tested a 
second batch from Proimmune, also with negative results (data not shown).
In order to test the functionality of the cells an IFNy ELISA was performed with 
belxl and be 1x2. B-LCL cells, expressing HLA-DR1*01, were loaded with the different 
concentration of HPV16 E6127-141 peptide at 37°C for 1 hour, washed and co-cultured 
with either belxl or belx2 overnight. The IFNy ELISA was performed the following day, 
figure 27. This assay demonstrated the specificity and the response of each clone for the 
peptide. This response was dependant on the concentration of the peptide and was 
characteristic for each clone; indeed belx2  showed a better response than belxl with a 
higher secretion of IFNy and a response with smaller concentration of peptide than belx l.
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Figur 25: Overview of the process by which peptide HPV16 E6 i27_14i-specific T-cell lines were 
generated from healthy donor (adapted from K.Gallagher thesis).
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Figure 26: Staining of the different lines or clones by an antibody against CD4 and the ultimer from 
pro-immune (first batch). The cells were incubated at 37°C during 60 or 180 minutes with the 
ultimer, washed and incubated 20 minutes at 4°C with the CD4+FITC antibody. The cells were not 
fixed and directly used for Facs.
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Figure 27: Titration of the specific response against HPV16 E6127-14 generated by the clones 
Belxl and Belx2. The CD4+ T-cells were co-cultured with B-LCL loaded with peptide at 
37°C overnight and the supernatant were collected and tested by IFNy ELISA.
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1-7-Discussion
It was proposed that the functional variation between belxl and belx2, was caused 
by different TCR avidity or affinity. To investigate this, at a molecular level, attempts 
were made to generate recombinant soluble TCR and MHC peptide complexes. 
Nevertheless no soluble TCR or HLA-DR*0101-HPV16 E6 127-141 molecules were 
obtained only a low amount of soluble HLA-DR*0101-CLIP was produced.
A variety of expression systems were used to prepare recombinant class II MHC- 
peptide complexes (table 9). Each method has its advantages and its disadvantages. E. 
coli expression is the method of choice for the production of class I MHC proteins, and 
can provide a large quantities of highly purified protein. However, the folding conditions 
for class II MHC proteins need to be optimized individually for each species and 
allotypes and at present only four different class II MHC proteins have been produced 
using E.coli system (Vollers and Stem 2008). The most common recombinant expression 
system for class II MHC proteins is the co-expression in baculovims infected insect cells. 
However, each generated DR1 molecule, in E. coli or insect cells systems, was associated 
with an influenza peptide, which is known to promote a high stability of the molecule. 
The stability between the HPV16 E6127-141 peptide and HLA-DR*0101 is not known and 
it is possible that it is much lower than for influenza peptide. Furthermore it is important 
to know that the choice of methodologies for the production o f class II MHC-peptide 
complexes will depend on the particular alleles of interest and previous experience in 
protein expression (Cameron, Norris et al. 2 0 0 2 ).
123
Table 9: Class II MHC proteins used in MHC tetramer staining of antigen-specific CD4+ T- 
cells in human.
MHC protein Allotype Expression
system
Modification References
DR1 DRB1*0101 E  coli 
E. coli
Insect
Insect
Mammalian
Covalent
peptide
Zipper
Covalent and 
zipper
(Cameron, Norris et al. 
2 0 0 2 ) 
(Cunliffe, Wyer et al. 
2 0 0 2 ) 
(Cameron, 2002) 
(Danke and Kwok 
2003)
(Day, Seth et al. 2003)
DR2 DRB1*1501 Mammalian Covalent and 
zipper
(Day, Seth et al. 2003)
DRB5*0101 Mammalian Covalent and 
zipper
(Day, Seth et al. 2003)
DR3 DRB1*0301 Insect Zipper (Bronke, Palmer et al. 
2005)
DR4 DRB1*0401
DRB 1*0402 
DRB 1*0404
Insect
Insect
Mammalian
Insect
Mammalian
Covalent
peptide
Zipper
Covalent and 
zipper
(Meyer, Trollmo et al. 
2000) (Kotzin, Falta et 
al. 2 0 0 0 ) 
(Novak, Liu et al. 
1999)
(Day, Seth etal. 2003)
(Veldman, Eming et al. 
2007)
(Gebe, Novak et al. 
2 0 0 1 )
DR5 DRB1*1101 E. coli 
Insect
Covalent
peptide
Zipper
(Cunliffe, Wyer et al. 
2 0 0 2 )
(Moro, Cecconi et al. 
2005)
DR6 DRB1*1302 Insect Zipper (Laughlin, Miller et al. 
2007)
DR7 DRB 1*0701 Insect Zipper (Danke and Kwok 
2003)
DQ6 DQA1*0102 
DQB 1*0602
Insect Zipper (Kwok, Liu et al. 2000)
DQ2 DQA1*0501
DQB1*0201
Insect Zipper (Quarsten, McAdam et 
al. 2 0 0 1 )
DP4 DPA1*0103 
DPB 1*0401
Insect Covalent and 
zipper/Ig
(Zhang, Renkvist et al. 
2005)
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We were able to produce the recombinant baculovirus as observed by the 
colouration of the cellular supernatant by X-gluc. The staining of the cells expressing the 
viral gp64 after amplification showed that the sf9 cells were sensitive to the infection by 
the recombinant virus. The purification of the soluble class II MHC by anion exchange 
and gel filtration showed that the High 5 cells seemed to produce intact molecules. 
However the BIAcore assay demonstrated that no binding was observed between HLA- 
DR*0101-HPV and L243 (anti-HLA-DR antibody), although a binding of a low amount 
of HLA-DR*0101-CLIP was observed. The expression of each unit for HLA-DR*0101 
in E. coli was successfully performed, but no correct refolding was observed. One 
explanation for these results could be the weak stability of the class II MHC in presence 
of the HPV peptide, compared to the CLIP peptide which is naturally used by the cell to 
stabilise the class II MHC before loading of exogenous peptides.
Studies featuring CD4+ T cell staining by class II tetramers has became more 
common but there are still very few studies compared to the thousands done with class I 
MHC tetramers (Vollers and Stem 2008). Production of class II MHC tetramers remains 
complicated, and there are several different methods dependant on the class II molecule 
studied. Nevertheless there are other limits to the staining of the CD4+ T cells by 
tetramers including: the low frequency of antigen specific CD4+ T-cells and 
complications potentially caused by low TCR/pMHC II affinity. Lucas et al. overcame 
the low frequency obstacle, by using microbeads to enrich the target population (Lucas, 
Day et al. 2004). Before enrichment, no distinct population of HA-specific CD4+ cells 
could be detected in fresh PBMCs, although a population of CD4+ DR1-HA+ cells was 
clearly visible after enrichment with anti-PE microbeads. Another strategy chooses to
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detect cells after class II MHC tetramer staining is the ex-vivo expansion of the target 
cells (Lemaitre, Viguieretal. 2004). However highly enriched (including clonal) 
populations of antigen specific T-cells were used in the current study. Therefore the 
failure of the commercially produced ultimers to bind must be due to other factors. It is 
possible that antigen specific T-cells are not stained by class II MHC tetramers because 
the TCR affinity for soluble MHC/peptide complexes is too weak (Vollers and Stem 
2008). By contrast, TCR avidity for MHC-peptide complexes on live antigen specific 
cells may be influenced by other cell surface molecules. This might explain the lack of 
binding of the Proimmune ultimer, despite clear functional specificity of the tested cells.
Despite using several different conditions, no binding of the Proimmune ultimer 
to T-cells could be detected. The technical team at Proimmune could not offer any 
explanation for the results. It is possible that either unstable or incorrectly folded 
molecules were produced but without knowledge of the exact composition of the 
commercial product it was not possible to assess this with protein biochemistry 
techniques. The company would not provide any technical details about manufacture of 
the ultimer, but did offer a full refund.
No biophysical measurements for TCR/MHC/peptide interactions were obtained 
in this project (figure 28). It was not possible to make either soluble MHC/HPV16 E6127- 
141 complexes or TCRs, and no binding could be detected for commercially produced 
MHC/peptide complex. Therefore to move the project forward it was decided to 
investigate the functional difference between belxl and be 1x2  at a cellular level using in 
the first instance truncated versions of HPV16 E6127-141 and in a second instance some 
peptide variants derived from other HPV types.
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2-STUDY OF THE RESPONSES INDUCED BY TRUNCATED VERSION OF 
HPV16 E6 12714i.
Previous studies in the laboratory defined HPV16 E6127-141 as a new 
epitope that may be useful in investigating protective T-cell responses against HPV. Two 
clones belxl and belx2 were generated and defined which HLA presented the peptide; 
HLA-DRB1*01. From this data Dr. Istvan Bartok, Imperial College, London carried out 
molecular modelling. The HPV 16 E6127-141 epitope was superimposed onto the 
crystallised structures of HLA-DRBl*0 1 -HA3O6-3i8 (Stem, Brown et al. 1994), of HLA- 
DRB1*01-HTV1 gag35_47 (Zavala-Ruiz, Strug et al. 2004) and of HLA-DRB1*01-Triose 
Phosphate Isomerase23-27 (Sundberg, Sawicki et al. 2002), figure 29. From these models it 
appears that HPV 16 E6127-141 “sat” in the binding groove of the HLA-DR molecule in a 
similar way to the known and well-characterised epitopes. The epitope HPV 16 E6127-141 
(DKKQRFHNIRGRWTG) was aligned based upon the HLA-DRB1*01 binding motif 
with P1=F, P4=I and P6 =G. In figure 30A the epitope is shown with the HLA-DR 
molecule removed for clarity. The amino acids at positions 1, 4, 6  and 9 face down and 
are the anchor residues that bind in HLA-DRB1*01 specificity pockets. The three 
arginine residues (R, positively charged at positions P-l, P5 and P7), the glutamine 
residue (Q, position P-2), the tryptophan residue (W, position P8 ) and the glycine residue 
(G, position P 1 0 ) protmde on the water accessible surface of the bound peptide. It is 
possible that one or more of these residues could form contacts with CDR3 loops of the 
TCR structure, and therefore be relevant to the recognition of the epitope by the T-cell, 
figure 29B. The CDR3 region of the a  chain (TRAV 17: 
CATDAGTGNQFYFGTGTSLTVIP) identified from the belxl and belx2  T-cell clones,
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contains a negatively charged aspartic acid (D), which could in theory form electrostatic 
interactions with a positively charged arginine. At the end molecular modelling of 
HPV16 E6i27-i4i-HLA-DRBl*01 complex suggests that this epitope binds the HLA-DR 
molecule in similar fashion to other well characterised HLA-DRB 1*01-restricted 
peptides. The anchor residues predicted by binding motif for this HLA-DR allotype 
appear to fit well in the binding groove. This model identified several amino acid residues 
that could be involved in TCR recognition and provides a basis for our study 
investigating the effect of amino acid truncation or substitutions in HPV 16 E6127-141 on T- 
cell recognition.
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Influenza A HA jo6-3i« 
PK Y VKQNTLK.L AT
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HIV-1 gag 35-47 
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Figure 29: H PV 16 E6127-141 ep itope superim posed onto the  m odels o f  H A 306-3i8, HIV1 
gag35-47? and triose phosphate isom erase23-37 peptides com plexed  w ith  H LA -D R B 1*01 
(defined from  X ray crystallisation  studies). The E6 pep tide  is show n in red  ribbon  w hilst 
the reference peptides are show n in grey ribbon.
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Figure 30: A -H P V 16 E6i27-i4iepitope dep icted  in “ball and  stick” w ith  th e  H LA - 
D R  m olecule excluded for clarity . T he anchor residues p roposed  to  sit in the 
specific pockets are labelled as P I ,  P4, P 6 and P9. W ater accessib le  residues w hich  
m ay potentially  contact the T C R  are h igh ligh ted  w ith  dashed  arrow s. M odels w ere 
constructed  on a silicon graphics octane 2 w orstation  using  insigh t II m odelling  
suite (M SI/A ccelrys). The first th ree  am ino acid residues D K K  w ere excluded  
from  analysis to sim plify the m odelling . B -3D  structure o f  th e  in te raction  betw een  
H PV 16 E6127-141 peptide and TCR . T he red  loop show n in ribbons rep resen ts the 
CD R3 region o f  the a  chain and the b lue  loop represen ts the  C D R 3 reg ion  o f  th e  P 
chain. This m odel w as created by Istvan Bartok, Im perial C ollege, L ondon.
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2-1-Effect of amino acid truncation in HPV16 E6127-141 on belxl T-cell 
recognition
In both  class II and class I M H C , po lym orphism  pockets in the  b ind ing  site 
p rov ide the basis fo r the preference o f  d ifferen t a lleles o r d iffe ren t pep tide sequence 
m otifs, bu t a t least tw o m ore pockets accom m odate pep tide  side chains in  class II than  in 
class I m olecules (S tem , B row n et al. 1994). T hese d ifferences allow  the  b ind ing  o f  
peptide w ith  d ifferen t size for each M H C . Indeed in c lass II M H C , th e  g roove is open  at 
either end, and the pep tide term in i a re  no t fixed so tha t bound  pep tides are usually  
significantly  longer than in class I M H C . In c lass II M H C , the pep tide  te rm in i, 
particularly  the N -term inal ex tension (P -4  to  P - l) ,  can play a  m ajo r ro le  in  the  T C R  
in teraction  (R udolph, S tanfield  et al. 2006).
In order to  study the im pact o f  H PV 16 E6127-141 te rm in i, d iffe ren t trunca ted  
pep tides w ere designed  accord ing  to  th e ir  pu ta tive T C R  con tac t residues o r  pu ta tive  
M H C  anchor residues from  H PV  16 E6127-141 (table 10). T hese pep tides w ere  te sted  in 
functional assays (IFN y release) w ith  tw o T -cell c lones (b e lx l and  belx2).
Table 10: L ist o f  the  truncated  peptide designed  from  the H PV 16 E6127-141 epitope.
Peptides Sequences
HPV16 E6127-141 D K K Q R F H N I R G R W
1 K K Q R F H N I R G R W
2 K Q R F H N I R G R W
3 Q R F H N I R G R W
4 R F H N I R G R W
5 D K K Q R F H N I R G R W
6 D K K Q R F H N I R G R W
7 D K K Q R F H N I R G R
8 Q R F H N I R G R W
Putative T C R  contact residues Putative MHC anchor residues
T
T
T
T
T
T
T
G
G
G
G
G
G R  C M
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2-1-1-Effect of the Nterminai truncation of HPV16 E6 1 2 7 - 1 4 1  on T-cells
The effect of removing 1 to 4 amino acids from the N terminus of HPV 16 E6127- 
141 was tested using belxl T-cells. These T-cells recognized the HPV16 E6127-141 peptide 
in a dose dependent manner (figure 31) from 0.05|iig/ml to lOpg/ml, confirming previous 
results from the laboratory.
Four peptides were studied for the truncation of the N terminus end; the first 
designed peptide was deleted of the aspartic acid (D) in position P-5, peptide 2 was 
deleted of aspartic acid plus the lysine (K) in position P-4, peptide 3 was deleted of the 
first three amino acids; the aspartic acid, and the two lysines (D=P-5, K=P-4 and K=P-3) 
and peptide 4 was deleted of four amino acids, the D (P-5), the two K (P-4 and -3) and 
the glutamine (Q) in position P=-2.
The first three peptides induced similar responses. A dose dependent secretion of 
IFNy was observed from 0.05pg/ml to lOpg/ml, which was similar to the wild type 
peptide, nevertheless this secretion was lower in term of quantity of IFNy. The profile of 
the response for peptide 4 was different from the previous responses. Indeed the IFNy 
secretion was detectable from lpg/ml to lOpg/ml and lower than 500pg/ml (figure 31).
The impact of the deletion of amino acids from the Nterminai end did not seem to 
have a big impact on the IFNy secretion by belxl, indeed the profiles of the responses 
induced by the peptides 1, 2 and 3 were similar to the response against HPV 16 E6127-141 
peptide. Only peptide 4 had a different profile with a decreased response.
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2-1-2-Effect of the Cterminai truncation of HPV16 E6127-141 on T-cells
The next couple of truncations were the deletion of amino acids from the Cterminai 
end. The peptide 5 was deleted of the glycine (G) in position P10. The peptide 6  was 
deleted of the G plus the threonine (T) in position P9 and the peptide 7 was deleted of G, 
T and tryptophan (W) in position P8 . Peptide 5 induced a response from 0.5|ag/ml to 
lOpg/ml (the response observed at O.lpg/ml was not considered positive due to the high 
standard deviation), which was very late compared to the wild type peptide (0.05pg/ml). 
Furthermore the IFNy secretion was lower than for HPV 16 E6 127-141, the maximum value 
was 601.67pg/ml (figure 31). The deletion of this G seemed to induce a response less 
specific and with an intracellular signalling lower than wild type peptide. The profiles of 
the response for peptides 6  and 7 were exactly the same; no responses were observed for 
any concentration.
Contrary to the responses observed for the Nterminai end, the Cteiminai seemed to 
have greater effect on T-cell recognition by belxl.
In order to study the impact of a longer Cterminai end to the response by belxl, 
peptide 8  was tested. This peptide was truncated of the first three amino acid at the 
Nterminai end (D, K, K), and three residues were added; an arginine R, a cysteine C and a 
methionine M. The results showed a secretion of IFNy from 0.005pg/ml to lOpg/ml (the 
secretion of IFNy for the wild type peptide was observed from 0.05pg/ml). It seemed that 
the addition of these three residues could affect the response generated by belxl, indeed 
the response seemed better with peptide 8  than the peptide HPV 16 E6 127-141.
134
2-2-Impact of the deletions on T-cell in term of % of response
There was variation in the amount of IFNy produced by belxl T-cell clone in 
response to the peptide variants. Therefore to allow comparison with response to the wild 
type peptide the responses were standardised to the maximum response for each peptide 
or the maximum response for HPV16 E6127-141 (figure 31). For this standardisation each 
experiment was performed three times using triplicates. Furthermore the concentration 
(T50) of peptide necessary to obtain 50% of the maximum response for each peptide was 
determinated (table 1 1 ).
Four groups could be defined from these analyses; group one with the peptides 2 
and 3, group two with peptides 1, 4 and 5, group three with peptides 6  and 7 and the last 
group with peptide 8 . In the first group the peptides reached their T50 at concentration 
lower than HPV 16 E6 127-141 which could indicate these peptides are better binders than 
the wild type. Nevertheless these peptides were not able to induce the same level of IFNy 
secretion as the wild type, indeed the amount of IFNy secreted did not reach 50% of the 
quantity secreted in response to the wild type peptide. Group two, contained the peptides 
1, 4 and 5, these peptides had similar T50 compared to HPV16 E6127-141 but induced 
secretion of lower amounts of IFNy. These results indicated these three peptides could 
interact in the same manner as the wild type peptide but they were less efficient at 
inducing T-cell activation. No T50 could be calculated for peptide 6  and 7 because they 
did not induce IFNy secretion. These data confirmed the major role of the Cterminal amino 
acids for the interaction of the TCR and pMHC complex and for the activation of the T 
cells. Peptide 8  had a T50 smaller than HPV16 E6127-141 and reached 50% of maximum
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secreted IFNy induced by HPV 16 E6 127-141 at lower concentration, the peptide seemed to 
be a better binder or cellular activator than the wild type.
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Figure 31: IFNy ELISA performed on Belxl. B-LCL cells were loaded with the peptide at 
different concentrations during I hour at 37°C, and then the cells were washed and co­
cultured with Belxl CD4+ T cells overnight at 37°C. The supernatants were collected and 
tested by ELISA. Each ELISA was performed in triplicate three times, from these 
experiments a % of response has been calculated compared to the maximum response of each 
peptide (A and C) or compared to the maximum response of HPV16 E6 1 2 7 .1 4 1  (B and D).
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2-3-Effect of amino acid truncation in HPV16 E6 1 2 7 - 1 4  on belx2 T-cell 
recognition
In order to study the impact of HPV 16 E6 127-141 termini, different truncated 
peptides were designed according to their putative TCR contact residues or putative 
MHC anchor residues from HPV 16 E6 127-141 (table 10). These peptides were tested in 
functional assays (IFNy release) with the T-cell clone belx2. Previous studied have 
demonstrated that belx2 has higher “avidity” for HPV 16 E6 127-141- Furthermore be 1x2 
expresses a different TCR to belxl. Each peptide was tested at different concentration, 
0 .0 0 1  pg/ml to 1 0  pg/ml in triplicates, to obtain a dose/response and to compare the 
specificity and the affinity of each peptide.
2-3-1-Effect of the Nterminai truncation of HPV16 E6 1 2 7 . 1 4 1  on T-cells
The effect of removing 1 to 4 amino acids from the N terminus of HPV 16 E6127- 
141 was tested using belx2 T-cells. These T-cells recognized the HPV 16 E6127-141 peptide 
in a dose dependent manner (figure 32) from 0.005pg/ml to 10 pg/ml, confirming 
previous results from the laboratory.
Four peptides were studied for the truncation of the N terminus end; the first 
designed peptide was deleted of the aspartic acid (D) in position P-5, peptide 2 was 
deleted of aspartic acid plus the lysine (K) in position P-4, peptide 3 was deleted of the 
first three amino acids; the aspartic acid, and the two lysines (D=P-5, K=P-4 and K=P-3) 
and peptide 4 was deleted of four amino acids, the D (P-5), the two K (P-4 and -3) and 
the glutamine (Q) in position P=-2.
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The first three peptides induced a similar response, indeed for all of them belx2 
recognized the peptide in a dose dependent manner from 0.005pg/ml to 10 pg/ml. The 
profile of IFNy secretion in response to these three peptides was similar to the response 
induced by the wild type peptide. The profile of the response for peptide 4 was not 
similar to the wild type, indeed a dose/response could be observed but there was a big 
shift of this titration to the high concentration. The secretion of IFNy appeared from 
0 .1  pg/ml and was less than to 500pg/ml (for the wild type peptide a response inferior to 
500pg/ml was obtained for a concentration of 0.005pg/ml).
As for belxl the deletion of amino acids from the Nterminai end did not seem to 
have a big impact on the IFNy secretion by belx2, indeed the profiles o f the responses 
induced by peptides 1, 2  and 3 were similar to the response against HPV 16 E6127-141 
peptide. Only peptide 4 had a different profile with a decreased response compared to 
HPVI6 E6127-141 (figure 32).
2-3-2-Effect of the Cterminai truncation of HPV16 E6 1 2 7 . 1 4 1  on T-cells
The next couple of truncations were the deletion of amino acids from the Cterminai 
end. Peptide 5 was deleted of the glycine (G) in position P10. Peptide 6  was deleted of 
the G plus the threonine (T) in position P9 and peptide 7 was deleted of G, T and 
tryptophan (W) in position P8 . For peptide 5 a response appeared from 0.05pg/ml to 
10pg/ml and a plateau was reached at 1 pg/ml. In response to peptide 6  a secretion of 
IFNy was observed from 1 pg/ml to lOpg/ml. As for belxl no IFNy secretion was 
observed in response to the peptide 7 (figure 32).
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Contrary to the responses observed for the Nterminai end, the Cterminai seemed to 
have a predominant role in the interaction of the peptide with the class II MHC and/or the 
TCR, then in the activation of the cell and at the end in the secretion of IFNy.
In order to study the impact of a longer Cterminai end to the response by belx2 
peptide 8  was tested. This peptide was truncated of the first three amino acid at the 
Nterminai end (D, K, K), and three residues were added; an arginine R, a cysteine C and a 
methionine M. The results showed a secretion of IFNy from 0.005 (xg/ml to 10pg/ml. The 
plateau was reached at 0.05pg/ml, which was the same concentration as the wild type 
peptide (figure 32).
2-4-Impact of the deletions on T-cell in term of % of response
There was variation in the amount of IFNy produced by belx2 T-cell clone in 
response to the peptide variants. Therefore to allow comparison with response to the wild 
type peptide the responses were standardised to the maximum response for each peptide 
or the maximum response for HPV16 E6127-141 (figure 32). For this standardisation each 
experiment was performed three times using triplicates. Furthermore the amount of 
peptide (T50) necessary to obtain 50% of the maximum response for each peptide was 
determined (table 1 1 ).
From this standardisation three groups could be defined for belx2; one group with 
peptides 1, 3, 4, 5, and 6  which had a higher T50 to the T50 of the wild type peptide (1.6- 
20 fold higher). These results indicated than HPV16 E6127-141 was a better binder or 
cellular activator than these 5 peptides. Another group, containing peptides 2 and 8 , had a 
T50 lower than the wild type (4.5-12 folder lower). It could implicate these peptides are
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better binders or more efficient at activation than the wild type. Nevertheless neither 
peptide 2 nor peptide 8 , were able to induce a higher level of IFNy secretion than the wild 
type. Peptide 7 did not have a calculated T50 because it did not induce IFNy secretion.
Summarising the results in terms of % response (Table 11) demonstrated the 
differential effect of peptide truncation on belxl and belx2 , with belxl being less 
sensitive to peptide truncation. Furthermore it appeared that the Cterminai end was more 
important that the Nterminai end for both belxl and be 1x2. Deleting residues decreased the 
response (peptide 7) while adding residues increased the response (peptide 8 ).
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Figure 32: IFNy ELISA performed on Beix2. B-LCL ceils were loaded with the peptide at 
different concentrations during 1 hour at 37°C, and then the cells were washed and co­
cultured with Belx2 CD4+ T cells overnight at 37°C. The supernatants were collected and 
tested by ELISA. Each ELISA was performed in triplicate three times, from these 
experiments a % of response has been calculated compare to the maximum response of each 
peptide (A and C) or compare to the maximum response of HPV16 E6 1 2 7 -1 4 1  (B and D).
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Table 11: T50 o f HPV16 E6127-141 and peptides 1 to 8 .
T50 (pg/ml)
Peptides Belxl Belx 2
HPV16 E6127-141 1 0.052
1 1 0.10
2 0.11 0.011
3 0.5 0.073
4 1.5 1
5 1.07 0.083
6 none 1.01
7 none none
8 0.3 0.0042
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2-5-Discussion
In this chapter the terminal ends of the HPV16 E6127-141 peptide were modified by 
truncation (or addition) and the impact on the T cell response was studied. The molecular 
modelling predicted that the first three residues of the Nominal (127-129; DKK) were not 
crucial for MHC binding. It was hoped that by truncating peptides at both ends of the 
peptide, some insight into the role of individual residues in TCR or MHC binding 
interactions could be gained.
For the two clones, belxl and belx2 it was demonstrated that the Ctenninai end had a 
greater impact important on the IFNy secretion than the Ntenninai end. Indeed the deletion 
of first three amino acids of the HPV16 E6127-141 peptide did not affected the response; 
similar profiles of response and quantities of IFNy were observed in each case. These 
results were consistent with the molecular modelling. Peptide 4 (deletion of 4 residues 
from Ntenninai end) induced different responses for the two clones; for belxl an 
abolishment of the response was observed but for belx2 the response was reduced 
compare to wild type peptide response. A first explanation for these responses was that 
peptide was too short to bind the class II MHC. The deletion of four amino acids 
generated a 1 lmer which is smaller than the majority of the loaded peptides on a class II 
MHC (12 to 18 mer). However the belx2 clone could respond, proving that the peptide 
could bind. A second explanation was the impact of the deletion of the Q in P-2, this 
residue was a putative TCR contact residue. The major difference in belxl and belx2 was 
their TCRs, indeed the two clones had the same a  chain but not the same p chain. One of 
the characteristic of the TCRs is their ability to differ in their ap  chain pairing, such that 
the pseudo Va/Vp twofold angle, which currently varies from 166° to 188°, can
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contribute to the variation in TCR orientation on the pMHC (Rudolph and Wilson 2002), 
and potentially could have relevance to TCR signalling if  the pairing changes propagate 
to the constant domains or are tranduced to accessory proteins (Garcia 1999). 
Furthermore few studies have demonstrated that the Vp chain of the TCR recognizes the 
Ntenninai end of the peptide with CDR1 and 3 (Garcia 1999) (Garcia, Scott et al. 1996) 
(Garboczi, Ghosh et al. 1996) (Garcia and Teyton 1998) (Garcia 1999) (Reinherz, Tan et 
al. 1999) (Tsurui and Takahashi 2007). The deletion of the Q could generate a change in 
the twofold angle when the pMHC interacted with the TCR, only in presence of the Vp 16, 
and it could affect the intracellular signalling. It is possible that the Vp7 chain was less 
affected by the lost of residue. In general the peptide truncations had less effect on belxl 
compared to belx2, which is consistent with the idea that the respective TCRs have a 
different orientation on the pMHC complex.
By contrast the deletion on the Germinal end of the HPV16 E6 127.141 peptide had an 
important impact on the response of each clone. Each deletion was associated with either 
a putative TCR contact residue or a putative MHC anchor residue. The deletions 
generated peptides that potentially were not able to bind HLA-DR*0101 or to not interact 
with the TCR. Furthermore the P10 position has been identified as minor or auxiliary 
anchor residues in several pMHC (Ferrante and Gorski 2007).
Finally the deletion of the first three residues and the addition of the three 
following amino acid; R, C, M had an impact on belxl and belx2. Peptide 8  was a better 
cellular activator for the lower concentrations, indeed its T50 is lower than the T50 
observed for HPV16 E6 127-141 peptide. It is possible that this tail which does not bind the 
MHC or the TCR could provide a peptide conformation that stabilises the interactions
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between the Cterminai end of the peptide and the MHC or the TCR. It would be interesting 
to perform molecular modelling with this peptide, and also to test whether it would be 
more effective in the generation of soluble MHC:peptide complexes.
In summary the Nterminai of HPV16 E6127-141 peptide does not seem crucial for the 
interactions with the MHC or the TCR, which was predicted by the molecular model. By 
contrast the Ctemiinai end seems crucial for the interactions, due to its contact with the 
MHC, or the TCR or both, and this is also consistent with predictions from the molecular 
model. A minimum peptide epitope of HPV16 E6130-141 was defined that provided the 
basis for further experiments looking at the effect of amino acid substitutions at 
individual positions within the core of the epitope.
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3-RESPONSES OF T-CELL CLONES AGAINST PEPTIDE FROM OTHER HPV 
TYPES
Previous results have showed that the Cteminai end of the HPV 16 E6127-141 peptide 
had an important impact on the response of each T-cell clone but the deletions at Ntenninai 
end did not seem to have an effect. The T cell clones were able to recognise a minimum 
epitope comprising HPV 16 E6130-141 (QRFHNIRGRWTG). In order to have a better 
understanding o f the molecular mechanisms which govern the interactions between 
peptide, MHC and TCRs, the presentation of peptides from other HPV types was studied. 
Indeed women are often infected by several HPV types including HPV 16, HPV 18, HPV 
33 (Hoory, Monie et al. 2008). All these variants are found in histology tests of women 
with cell carcinoma, adenocarcinoma or normal cytology in various percentages (Bosch 
and de Sanjose 2003) or detected by PCR (Hoory, Monie et al. 2008). The immunological 
effects of infection with multiple HPV types have not been well-studied. For example, 
can cross-reactive T-cell responses be generated against closely related HPV types? 
Alternatively, could infection by HPV type A have a negative effect on immune 
responses against HPV type B? In order to study, in-vitro, these kinds of events different 
peptides were designed (table 12). The chosen strategy was to compare the sequence of 
HPV 16 E6 127-141 to the E6  sequence of other HPV types and define which types o f HPV 
were most closely related to the HPV16 E6127-141 sequence. Five peptides from five 
different HPV types have been chosen; all of them are “high-risk” viruses and are able to 
induce cancer. The first difference in the sequence of these peptides, compared to HPV 16 
E6 127-141, was the substitution of the Q in position P- 2  to a K. In order to check if this 
substitution affected the response generated by belxl and belx2 peptide p9 was designed.
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From the previous results it was observed that truncations at the Nterminai end did not have 
a major effect on the T-cell response, so peptide plO was designed to see if it was the 
case for a peptide with the substitution in P-2. From these first set of data the other 
peptides were designed. Comparison of the aligned peptide sequences suggested that the 
amino acid variation might have an impact on TCR recognition (table 12).
Table 12: Sequences of the variant peptides
Peptides Sequences
16 E6i27-141 D K K Q R
9 D K K K R
10 K R
HPV31 K R
HPV52 K R
HPV58 K R
HPV33 K R
HPV67 K R
F
F
F
F
F
F
F
F
H N 1 R
H N 1 R
H N I R
H N I G
H N I M
H N I S
H N I S
H N 1 s
G
G
G
G
G
G
G
N
R W 
R W 
R W 
R W 
R W 
R W 
R W 
R W
T
T
T
T
T
T
A
T
G
G
G
G
G
G
G
G
Putative TCR contact residues Putative MHC anchor residues
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3-1-Effect of amino acid substitutions on T-cell recognition:
Each peptide was tested, by IFNy El^ISA, at different concentration, 0.001 pg/ml 
to 10 pg/ml in triplicates. To obtain a dose/response and to compare the specificity and 
the affinity of each peptide two T-cell clones (belxl and belx2) with different avidities 
for HPV 16 E6 127-141 were tested.
3-1-1-Belxl
9 and 10 (DKKKRFHNIRGRWTG and KRFHNIRGRWTG):
The responses induced by these peptides had similar dose/response profiles to that 
generated by HPV 16 E6127-141 (figure 33). Furthermore the quantity of secreted IFNy was 
similar to the quantity induced by the wild type peptide for the higher concentrations, 
nevertheless for the lower concentrations such as 0.05pg/ml the quantity of secreted IFNy 
was inferior. These results provided the basis for the next experiments with different 
substitutions because they showed that neither the substitution of the Q to a K nor the 
truncation had an impact on the response of the T-cells.
HPV3L 52, 58, 33, 67:
All the responses induced by these peptides had exactly the same profile; a- 
complete abolishment of the IFNy secretion. No IFNy secretion was observed even for 
the highest concentration of peptide which was lOpg/ml. It seemed belxl was very 
sensitive to the substitutions generated in the designed peptides and there was no 
evidence of cross-reactivity.
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Figure 33: IFNy ELISA performed on belxl. B-LCL cells were loaded with the 
peptide at different concentrations of peptide during 1 hour at 37°C, then the cells 
were washed and co-cultured with belxl CD4+ T-cells overnight at 37°C. The 
supernatants were collected and tested by IFNy ELISA. 152
3-l-2-Belx2
9 and 10 (DKKKRFHNIRGRWTG and KRFHNIRGRWPG):
The T-cell responses induced by these peptides had similar dose/response profiles 
to those generated by HPV16 E6127-141 (figure 34). Nevertheless T-cells responded better 
against HPV16 E6127-141; 362.98pg/ml of IFNy was secreted in presence of BLCL loaded 
with 0 . 0 1 0  pg/ml, whereas no secretion or a very low secretion was observed for the two 
other peptides. As for belxl these results gave the basis for the next experiments with 
peptides from different HPV types.
HPV31. 52, 67:
All the responses induced by these peptides had exactly the same profile; a 
complete abolishment of the IFNy secretion. No IFNy secretion was observed even for 
the highest concentration of peptide.
HPV58 and 33:
The responses of belx2 to these two peptides were different from the previous 
peptides from other HPV types, in that they induced weak responses. Activation of T 
cells only occurred at peptide concentrations of 1 pg/ml and above, and the magnitude of 
the responses was much lower (30% of the HPV 16 peptide).
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Figure 34: IFNy ELISA performed on belx2. B-LCL cells were loaded with the peptide at different concentrations o f 
peptide during 1 hour at 37°C, then the cells were washed and co-cultured with belx2 CD4+ T-cells overnight at 37°C. 
The supernatants were collected and tested by IFNy ELISA. j ^
3-2-Impact of the substitutions in term of % of response:
In order to evaluate and compare the impact of each substitution on the response, 
IFNy ELISA were performed in triplicate and repeated three times. From these data a 
percentage of the response was calculated in comparison to the maximum response for 
each peptide, figure 34, and the T50 (concentration of peptide necessary to obtain 50% of 
the response) was determinated for each peptide, table 13.
The figure 36 summarizes the responses induced by each peptide; indeed for 
belxl and belx2 the peptides 9 and 10 had a similar profile to HPV 16 E6 127-141. 
Furthermore a later response could be observed for HPV33 and 58 nevertheless this 
response was lower than either the wild type or peptides 9 or 10, indeed the T50 for these 
two peptides were respectively 2.83 and 5.27 (tablel3). As the results were similar for 
peptide 10 and the wild type peptide and as all the study was started with the HPV 16 
E6 127-141, it was decided to use the wild type peptide as reference.
These results demonstrated the amino acids substitutions in the peptides had an 
effect on T-cell clone responses, different hypotheses could explain these results:
-the substitutions could induce some radical changes in the conformation, 
which could induce a different binding to MHC.
-the substitutions would allowed the binding of the peptide to the MHC, 
but this new complex could not be recognized by the TCR
-the peptide could bind the MHC and the complex could be recognized by 
the TCR but no positive intracellular signalling would be generated.
155
In order to address these different hypotheses a strategy was developed using to assess 
peptide binding to HLA-DR*0101 based on the functional inhibition of an influenza 
specific T cell clone (HC3).
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Figure 35: T-cell responses against the different variant peptides. Each peptide was tested at different 
concentrations by IFNy ELISA in triplicate. Each ELISA was performed three times and the % of 
response was calculated in function of the higher value of secreted IFNy for each peptide.
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Table 13: T50 o f HPV 16 E 6 1 2 7 - 1 4 1 ,  peptides 9, 10 and HPV variants.
T50 (pg/ml)
Peptides Belxl Belx 2
HPV 16 E6i2M4i
9
10 
HPV31 
HPV52 
HPV58 
HPV33 
HPV67
0.95
none
none
0.011
0.01
none
none
none none
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3-3-Binding of variant HPV peptides to HLA-DR1:
This assay was used to indirectly measure peptide binding to HLA-DR*0101. The 
principle of this assay was to load the BLCL with the HPV peptide at different 
concentrations. After 1 hour at 37°C the APC were washed and a constant concentration 
of influenza HA peptide, specifically recognised by the HC3 clone, was loaded on the 
same BLCL during 1 hour at 37°C. The cells were washed, co-cultured with the clone and 
an IFNy ELISA was performed on the supernatants.
An influenza HA (YDVPDYASLRSLVASS) specific T-cell clone was used for 
the experiment, indeed two flu clones (kindly provided by Dr Giovanna Lombardi and 
Saskia Yates, Kings College, London) were generated in London and each of them were 
known to recognise the Flu peptide via HLA-DR*0101. The first step was to test if these 
clones were able to secrete IFNy after stimulation by their peptides, in this goal a titration 
assay was performed (figure 36). BLCL were loaded with different concentrations of 
peptide during lhour and co-cultured with the clone HC3 or HC6 . The results showed 
HC3 secreted IFNy in response to its peptide loaded on BLCL, and had high avidity with 
a plateau reached for 0.1 pg/ml of peptide. The HC6  clone demonstrated very weak IFNy 
secretion against peptide (figure 36), and this could not be increased by stimulation with 
PMA. In parallel of this titration an IFNy ELISA assay was performed using HPV 16 
E6  127-141 peptide on HC3 and HC6  clones. No IFNy secretion was observed (figure 36), 
this confirmed the specificity of the clone for its peptide and the no cross-reactivity of the 
flu clone against HPV 16 E6 i27-i4i- From these results it was decided to use the HC3 clone 
for the inhibition assay, testing peptides for HPV16 E6127-141, HPV31, HPV52, HPV58, 
HPV33 and HPV67.
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Figure 36: IFNy ELISA performed on HC3 and HC6  clones. B-LCL cells were loaded with the 
peptide at different concentrations during 1 hour at 37°C, then the cells were washed and co-cultured 
with HC3 or HC6  CD4+ T cells overnight at 37°C. The supernatants were collected and tested by 
ELISA. The clones were tested against HPV 16 E6127-141 (p37) to check there was no cross-reactivity 
with the wild type peptide.
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From the dose/response experiments, a sub-optimum concentration o f 0.05pg/ml 
was chosen for the flu peptide to compete against the binding o f test HPV peptides from 
10 to 0.001 pg/ml. All the peptides could inhibit at the top dose (lOpg/ml) suggesting that 
could all bind. On the basis of the dose/response results two groups of peptides could be 
defined.
Weaker binders (HPV 16, HPV31, HPV52 and HPV67) that could inhibit the HC3 
T-cell response but only at high peptide concentration (superior or equal to 1 pg/ml). 
Stronger binders (HPV33 and HPV58) that could inhibit the HC3 T-cell response at 
lower peptide concentration (lower than 1 pg/ml) (figure 37). This was seen more clearly 
when the results were summarized in term of % of inhibition (figure 38).
Since all the HPV peptides inhibit the HC3 response to some degree, it indicated 
that all the HPV peptides could bind. Therefore the failure of HPV peptides to induce 
IFNy secretion by belxl or belx2 T-cells, was not due to problems in peptide binding.
3-4-Activation assays
The results in 3.3 suggested that the largely negative response against variant 
HPV peptides was due to interaction of the peptide with TCR and not MHC. To have a 
better understanding of the interaction between the peptides and the TCRs and potential 
effects in the cellular activation it was necessary to carry out some activation assays. The 
engagement of the TCR induces the activation of the cell (Geginat, Campagnaro et al. 
2002), which leads cells in the cellular cycle. These cellular activations can be measured 
by a proliferation assay using incorporation of thymidine.
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Figure 37: Inhibition assay with HC3 clone. B-LCL cells were loaded with different 
concentrations of peptide during 1 hour at 37°C. After this incubation cells were washed 
and loaded with 0.05pg/ml of influenza peptide (HA 100) during 1 hour at 37°C. Finally 
loaded B-LCL were co-cultured with HC3 clone overnight at 37°C. The supernatants were 
collected and tested by IFNy ELISA.
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Figure 38: % of inhibition of the different HPV variants. Each peptide was tested at 
different concentrations by IFNy ELISA in triplicate. Each ELISA was performed three 
times and the % of inhibition was calculated in function of the higher value of secreted 
IFNy for each peptide.
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3-4-1-Proliferation assays 
Belxl or belx2 cells were co-cultured with irradiated BLCL and a peptide at 
0 .1  pg/ml or 1 0 pg/ml, then tested for proliferation (figure 39). Unfortunately no 
significant differences were observed between each peptide or each concentration; all the 
peptides induced low level of proliferation of T-cell clones. It seemed this technique was 
not sensitive enough to determine differences in functional activation between peptides 
(several experiments were performed all gave the same result).
3-4-2-Calcium signalling assays 
Calcium (Ca2+) signals in cells of immune system participate in the regulation of 
cell differentiation; gene transcription and effector functions (figure 40). An increase in 
intracellular levels of Ca2+ ions results from the engagement of immunoreceptors, such as
the TCR (Feske 2007). Several studies have demonstrated that the engagement of the
2+TCR with various pMHC was able to induce different increases of intracellular Ca 
(Feske 2007). The goal of these experiments was to study the variations of intracellular 
Ca2+ after engagment o f the TCR by various peptides loaded on BLCL.
Ca2+ signalling on a cellular population:
In the first instance a model permitting the study of the variations of intracellular 
Ca2+ in a cellular population was used. The T-cells were loaded with a Ca2+ sensitive 
fluorescent probe Fura-2. Following this loading the T-cells were stimulated by the 
BLCL loaded with HPV16 E6127-141 at lOpg/ml and the variation of intracellular Ca2+ was 
measured straight away using the Fluorostar reader (figure 41).
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Figure 39: One representing proliferation assay. BLCL were loaded with different 
concentration of peptide during 1 hour and irradiated. After 3 washes the cells were co- 
cultured, in 96 well plates, with belxl and belx2  during 2 days. At 48 hours lpC of 
[methyl-3H]Thymidine was added in each well and the day after the cells were harvested 
and the radioactivity was measured. PMA was used as positive control for the 
proliferation assay. A negative control with the cells plus media (average of 200 cpm) 
was subtracted to each value.
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Figure 39: In resting T-cells, a steep gradient in Ca2+ concentrations exists between the cytoplasm and the extracellular space, as well as between the cytoplasm and the lumen o f  
the endoplasmic reticulum (ER). Antigen recognition through the TCR results in the activation o f  protein tyrosine kinases, such as LCK and ZAP70 (^-chain-associated protein 
kinase o f  70 kDa), which initiate phosphorylation events o f  adaptor proteins, such as SPL76 (SRC-homology-2-domain-containing leukocyte protein o f  76 kDa) and LAT 
(linker for activation o f  T-cells). This lead to the recruitment and activation o f  the TEC kinase ITK (interleukin-2-inducible T-cell kinase) and phospholipase Cyl (PLC yl ). 
Similarly, binding o f  G-protein-coupled chemokine receptors results in the activation o f  PLC(3. PLCp and PLCyl catalyse the hydrolysis o f  the membrane phospholipid 
phosphadylinositol-4,5-bisphosphate (PtdIns(4,5)P2) to inositol-1,4 ,5-trisphosphate (InsP3) and diacylglycerol (DAG). InsP3 to and opens InsP3 receptors (InsP3Rs) in the 
i— membrane o f  the ER, resulting in the release o f  Ca2+ from intracellular Ca2+ stores. A decrease in Ca2+ content o f  the ER is “sensed”by stromal interaction molecule 1 (STIM1),
*  which in turn activates calcium-release-activated calcium (CRAC) channels in the plasma membrane. Ca2+ influx though CRAC channels and elevated intracellular Ca2+
concentration activate Ca2+-dependent enzymes, such as calcineurin, and thereby transcription factors, such as NFAT (nuclear factor o f  activated T cells), NF-kB  (nuclear 
factor-icB) and CREB (cyclic-AMP-responsive-element-binding protein). cADPR (cyclic ADP ribose), CaMK (calmodulin-dependent kinase), GADS (growth-factor-receptor- 
bound-protein-2-related adaptor protein), IKK (inhibitor o f  NF-kB kinase), RYR3 (ryanodine receptor 3).
Unfortunately no significant variations were observed from these preliminary 
experiments, it appeared this technique was not sensitive enough to detect any variation. 
Nevertheless the controls showed that the cells were loaded with the probe and that the 
cells could be stimulated by ionomycin (figure 41). Indeed in presence of Triton X-100, a 
detergent, the cells generated a release of calcium (figure 41-A), which demonstrated that 
the cells were correctly loaded with the fluorescent probe. Furthermore this release of 
calcium was abolished in presence of EDTA, a chelater (figure 41-B). The stimulation by 
the ionomycin demonstrated that the T-cells were viable and could be stimulated, 
nevertheless the observed calcium wave was very small (figure 41-C). All these results 
suggested the signal was too small in magnitude to allow measurement of differences 
between peptides , indeed neither potent mitogens such as ionomycin nor activators such 
as OKT3 (anti-CD3 antibody which induces the activation of the cell by cross-linking to 
its target) could induce a strong calcium release. The stimulation of the T-cells by pMHC 
is likely to induce a smaller signal than the ionomycin or OKT3, so it may be below the 
threshold of detection for this assay system.
This technique allowed studying a T-cell population but it was likely that not all 
the population was stimulated in at same time by the ionomycin, the OKT3 or the pMHC. 
In order to continue the investigation on calcium release of the T-cells after stimulation it 
was decided to use a technique observing one cell.
Ca2+ signalling on a cell:
After these assays another model was used. The BLCL cells were loaded with 
10pg/ml of HPV16 E6127-141 and belx2 cells were loaded with a Ca2+ sensitive fluorescent 
probe Fura-2. With the help of Professor Hallett (Department of Surgery, Cardiff
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University) the BLCL were dropped on a slide and after few minutes, when the BLCL 
had adhered to the slide, the belx2 T-cells were added and the cellular interaction was 
observed under a fluorescent microscope, figure 41. The results showed a variation of the 
intracellular Ca2+ during the stimulation of belx2 by HPV16 E6127-141 loaded BLCL, 
nevertheless the intensity was too low and could not permit the study of intracellular Ca2+ 
signal difference induced by various peptides. Furthermore the chance to see an event 
was very low, indeed quite a few assays were necessary to obtain one cell in contact with 
another one. It was also very difficult to observe this type of signalling event because the 
activation of the cell was very fast (155 sec, figure 42).
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Figure 41: Calcium signalling in Belx2. BLCL were loaded with 10|ug/ml of HPV16 E6127-141 and added 
to belx2 cells preloaded with Ca2+ sensitive fluorescent fura-2 probe. A-Positive control for loading of 
the probe, the cells were in triton X-100 buffer. B-Cells in triton-XlOO buffer plus EDTA, which is a 
chelater of calcium. C-The cells were stimulated by ionomycin 1M. D-The cells were stimulated by 
ionomycine and EDTA was added in the buffer. E-Belx2 plus BLCL loaded with 10|*ig/ml of HPV16 
E6i27-i4i- F-Belx2 plus OKT3 antiboody, which is an anti-CD3 antibody.
5.6 sec 32.6 sec 47.3 sec
78 sec 124 sec 155 sec
0 .8 4 3 '
4 Time (second*,,
Figure 42: Calcium signalling in belx2. BLCL were loaded with 10pg/ml of HPV16 
E6127-141 and added to belx2  cells preloaded with Ca2+ sensitive fluorescent fura- 2  probe. 
BLCL were put on a slide. Few seconds later belx2 cells were added and contacting cells 
that were in contact were observed under fluorescent microscope at a magnification of 
200X.
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3-4-3-Study of down-regulation of the TCR
The previous results showed that it was very difficult to observe directly the 
activation of the T-cells by measuring proliferation or calcium signalling, therefore an 
indirect way had to be chosen to observe the activation of T-cells. The number TCR- 
CD3 complexes, on the surface of the T-cell, is maintained by an equilibrium between 
synthesis and secretion of new polypeptides, their internalization, recycling, and 
degradation. T-cell activation by antigen, anti-CD3 antibody or pharmacological 
activators of protein kinase C, results in increased TCR-CD3 internalization, followed by 
the down-regulation of TCR-CD3 complexes number on the surface (Alcover, 2000). 
The chosen strategy was to measure cell surface expression of the TCR after stimulation 
of the cells, BLCL were loaded with different concentration of HPV16 E6127-141 
(O.OOlpg/ml to 10pg/ml) and co-cultured with belx2 during 4 hours. Following this 
incubation a staining with an-CD4+ FITC antibody and an anti-TCR-PE antibody was 
performed, figure 42. The results o f this preliminary experiment showed a down- 
regulation of the TCR for the higher concentrations of peptide (Figure 43). Following 
this first experiment the effect of different HPV peptides was studied, BLCL cells were 
loaded with different peptides: HPV16 E6127-141, HPV31, HPV52, HPV58, HPV33 and 
HPV67 at various concentration (0.05pg/ml to lOpg/ml). After a co-culture of 4 hours 
the cells were stained with the same antibodies as previously, figure 44. It was decided to 
perform this experiment with be 1x2 because these cells had higher avidity than belxl, 
and could recognize soluble E6 protein (Gallagher, 2007). The lower concentrations of 
peptides were not tested because no difference in TCR down regulation was observed in 
the preliminary study. From these results two groups could be defined; one with HPV 16
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E6 127-141, HPV58, HPV33 and HPV67 with induced a down-regulation of the TCR from 
the cell surface, the second one which did not induced a significant down-regulation of 
the TCR. The second group contained the peptides from HPV31 and HPV52. In the first 
group HPV67 and HPV 16 E6127-141 induced a down-regulation of the TCR with low 
peptide concentrations suggesting a strong interaction between the TCR and pMHC. 
HPV58 and HPV33 induced a down-regulation of the TCR only for the higher 
concentrations of peptide suggesting a weak interaction between the TCR and the pMHC 
complex. The second group, which contained HPV52 and HPV31, did not induce a 
down-regulation of the TCR. This could suggest either there was not binding between the 
TCR and the pMHC or that there was a binding between the two molecules but this did 
not induce an activation of the T-cell.
To confirm the previous results an inhibition assay was performed using belx2 to 
investigate potential antagonistic activity. The APC were loaded with 10 pg/ml of variant 
peptides during 1 hour at 37°C. Following this incubation the cells were washed and 
loaded with various concentrations of HPV 16 E6127-141 (O.OOlpg/ml to lOpg/ml). The 
APC were co-cultured with belx2 clone overnight and an ELISA was performed on the 
supernatant, (figure 45). The results demonstrated that peptides HPV31, HPV52, HPV58 
and HPV33 were able to inhibit the T cell response against HPV16 E6127-141 in a dose 
dependent manner. This confirmed that all the peptides were able to bind to HLA- 
DR1*0101, and this would be predicted if the peptides had no antagonistic activity. By 
contrast the HPV67 peptide could induce a strong inhibition of the HPV 16 E6 127-141 
response even in the presence of much higher concentrations of the HPV 16 E6127-141  
peptide. This profile is consistent with the HPV67 peptide having antagonistic properties.
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Figure 44: Down-
regulation of the TCR in 
belx2 ells after exposure 
to peptide antigens. B- 
LCL cells were washed 
after this incubation and 
co-cultured with belx2 
during 4 hours at 37°C. 
Folliwing this incubation 
belx2 cells were stained 
with a mouse anti-human 
PAN TCR-PE antibody 
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CD4+-FITC antibody. 
The results were analysed 
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performed using FlowJo 
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3-5-Discussion
Initially, T-cell activation was thought to be an all or none event, i.e., recognition 
by T-cells either did or did not occur (Salzmann and Bachmann 1998). More recently, it 
became evident that T-cell activation is more complex than initially thought, indeed 
various observations suggested that signal transduction via the TCR may vary 
qualitatively, depending upon the nature of the ligand (Sette, Alexander et al. 1994). 
Some altered peptide ligands failed to stimulate the full spectrum of T-cell responses but 
triggered only a fraction of them, they were called T-cells agonists or partial T-cell 
agonists (Evavold, Sloan-Lancaster et al. 1993). In contrast to these T-cell agonists or 
partial T-cell agonists, some altered peptide ligands completely failed to activate T-cells 
and were able to inhibit responses triggered by full T-cell agonists. These inhibitory 
peptides were called T-cell antagonists or partial T-cell antagonist peptides (Sette, 
Alexander et al. 1994). In order to have a better understanding of the interactions between 
HPV 16 E6127-141 peptide, HLA-DR*0101 and TCR, different substitutions were 
performed in the peptide, the substitutions corresponding to peptide from E6 protein of 
other HPV types. Furthermore all these substitutions included amino acids which were 
either a putative TCR contact residues or putative MHC anchor residues.
In the goal to define if the substitution of amino acids could induce agonist, partial 
agonist, antagonist or partial antagonist responses and to understand how the molecular 
interactions between the peptide, MHC and TCR could interfere in the responses a 
strategy has been defined (figure 46). The first experiments, which were the titration of 
the IFNy secretion by belxl and belx2 in response to these peptides, provided a first level 
of screening. Indeed if the peptides induced IFNy they were considered as agonist or
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partial agonist depending of the level of secreted IFNy. The second set of experiments 
used an inhibition assay involving an influenza T-cell clone. In the case of no IFNy 
secretion these experiments determined whether the peptide was able to bind the HLA- 
DR*0101. The third set of experiments had to be an activation assay to determine any 
potential effect on the TCR. Different strategies have been used in this goal such as 
calcium signalling assays and TCR down regulation assays. Only the TCR down 
regulation assays were sensitive enough to provide usable data. These experiments 
generated information on the interactions between the pMHC and the TCR, indeed the 
engagement of the TCR with the pMHC complex induces an activation o f the T-cell and 
a down regulation of the TCR. The substitution of one or two amino acids may be 
sufficient to inhibit the binding to MHC, nevertheless the pMHC complexes with altered 
peptides could change the kinetic of signal transduction, the formation of immunological 
synapse, or induce negative signal (Ryan, McNeil et al. 2004) (Sette, Alexander et al. 
1996). Then the third set of experiments provided information on the cellular activation 
after contact with the TCR, and permitted to know if the peptide was a null peptide (no 
TCR down regulation) or a antagonist (down regulation or partial down regulation).
Two peptides were able to induce a secretion of IFNy, HPV58 and HPV33. This 
production of IFNy was observed for the higher concentrations of peptides and only for 
the clone belx2 that is why these peptides were named partial agonist (figure 47). 
Interestingly both peptides appeared to have stronger binding to HLA-DR*0101 than 
HPV 16 peptides, based on the HC3 inhibition assays (figure 38). Therefore the reduction 
in functional activity appears to be influenced by peptide/TCR interactions.
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Both HPV33 and HPV58 have a R—>S change at putative TCR residue (table 12). 
It is possible that the loss of a positive charge could reduce the affinity of TCR/peptide 
interactions. As might be predicted for weak/partial agonists, high concentrations of 
peptide were required to down-regulate the TCR compared to HPV 16 E6127-141 peptide 
(figure 44).
The three other peptides, HPV31, HPV52 and HPV67 did not induce the 
production of IFNy neither for belxl or belx2 (figure 47). All of them inhibited the 
binding between HA 100 (influenza peptide) and HLA-DR*0101. This inhibition was 
only for the highest concentration of peptide (lOpg/ml) in the case of HPV31 and 
HPV67, whereas inhibition could be seen for range of peptide concentrations for HPV52. 
This suggests that HPV31 and HPV67 were relatively weak binders to HLA-DR*0101. 
Only HPV67 induced a down regulation of TCR in the absence of any functional 
activation, which is a major characteristic of the antagonist peptides (Sette, Alexander et 
al. 1994). The other peptides induced minimal down regulation of the TCR suggesting 
that these peptides are “null peptides”, capable of binding to MHC but not able to activate 
or antagonise a functional response (figure 48). HPV31 has a R—>G change in a putative 
TCR contact residue. The change of a positively charged basic amino acid to an 
uncharged polar amino acid appears to have abolished T-cell activation. Similarly HPV52 
has a R— change, at the same location; here the change from a positively charged basic 
amino acid to a hydrophobic amino acid has also abolished T-cell activation. The effect 
of substitutions in that location is dependent on the amino acid, because the R—»S change 
for HPV58 and 33, still allow partial TCR activation. HPV67 was a very interesting 
peptide, because it had potent TCR down-regulation activity, similar to the HPV 16 E6127-
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141 peptide (figure 44), but weak binding to MHC (figure 38). However the original 
HPV 16 peptide would also be classified as a weak binding peptide according to the same 
assay (figure 38). The HPV67 peptide has R-*S change, similar to HPV33 (partial 
agonist) and a G^-N change at a putative MHC binding residue (table 12). The HPV67 
peptide is able to interact with the TCR (figure 44) to cause down-regulation, but this is 
insufficient to induce IFNy response of belx2, in the presence of high concentrations of 
HPV16 E6 127-141 peptide (figure 45). These results suggest that HPV67 is an antagonistic 
peptide.
All these data are summarized in the table 14. It is possible that by only assaying 
for IFNy secretion and TCR down-regulation, that other T-cell effector functions could 
have been missed. Therefore these peptides have been tested for their capacity to induce 
other types of cytokines, IL-4 and IL-10 ELISA were performed on belxl and belx2 (data 
not shown), but no secretion was observed. These data suggest that these peptides were 
not able induce changes in the cytokine profiles (Thl to Th2) of the specific T-cell 
clones.
The results in this chapter demonstrate that amino acids changes in putative TCR 
contact residues can have several effects; they can abolish (null peptide) or reduce T-cell 
activation (partial agonist). Alternatively they can cause an inhibition of T-cell responses 
by down-regulation of the TCR (antagonist). To investigate the interactions between the 
peptides and the TCR and the effect on the cellular activation it would be interesting to 
use a tetramer of HLA-DR*0101 associated with each peptide and to carry out binding 
assays. Earlier work had demonstrated that recombinant soluble HLA-DR*0101-CLIP 
complexes could be generated, and these could be used as the source material to make
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tetramers containing different variant peptides. Flourescently labelled tetramers could 
then be used for staining of HPV 16 E6127-141 specific T cells (table 15 summuraries all the 
data).
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Figure 48: A nalysis o f  the resu lts obtained for H PV 31, H PV 52 and H PV 67
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Table 14: List of the role of each variant peptide.
Peptides Agonist Partial agonist Antagonist Null
HPV16 E6i27-14i +++ - - -
HPV31 - - - +
HPV52 • + '
HPV58 - + - -
HPV33 - - -
HPV67 - - ++ -
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Table 15 : Summary of peptide activities
186
DISCUSSION
The main causative agent in the development of cervical cancer is HR HPV. 
However, the progression from persistent HPV infection to CIN and cervical cancer is a 
rare event and in nearly all cases the virus is effectively cleared. An important role for T- 
cell mediated immunity in the control of HPV infection has been inferred by a number o f 
observations from immunocompromised patients and studies of naturally regressing 
genital warts (Coleman, Birley et al. 1994) (Petry, Scheffel et al. 1994), and also animal 
studies (Nicholls, Moore et al. 2001). A number of studies have investigated the immune 
responses to HPV 16 and HPV 18 proteins in patients with CIN or cervical cancer 
(Bontkes, de Gruijl et al. 1999) (Bontkes, de Gruijl et al. 2000) (Bontkes, de Gruijl et al. 
1999) (de Jong, van Poelgeest et al. 2004) (Steele, Mann et al. 2005) (Welters, van der 
Logt et al. 2006) and more recently in healthy donors (de Jong, van der Burg et al. 2002) 
(Facchinetti, Seresini et al. 2005) (Welters, de Jong et al. 2003; Welters, van der Logt et 
al. 2006). The E6 and E7 proteins are constitutively expressed in both high grade CIN 
and cervical cancer, making them ideal tumour-specific antigens for study. In healthy 
women, memory T-cell responses tend to be directed at the E6 protein, with responses to 
the E7 protein being relatively rare (van der Burg, Ressing et al. 2001), (Welters, de Jong 
et al. 2003). As these women have successfully cleared viral infection, it is feasible that 
the epitopes against which the anti-viral immune response was generated could correlate 
with protection from persistent infection. The identification of such epitopes could 
potentially be useful in the development of T-cell based immunotherapeutic strategies. In 
this goal the previous studies of the laboratory have generated two T-cell clones specific 
for a peptide from HPV 16 E6 protein. Indeed ten healthy female donors were screened 
for T-cell responses against HPV 16 and HPV 18 E6 and E7 peptide pools. Five donors
188
made HPV E6  specific responses (as detected by IFNy ELISpot assay). Two T-cell lines 
were generated from one individual against the HPV 16 E6 (i27-i4 i) epitope. These lines 
exclusively express either TCR TRBV14 (belxl) or TCR TRBV4-2 (belx2) and 
TRAV17, and demonstrate differential cytokine secretion profiles in response to peptide 
re-stimulation. Furthermore it has been demonstrated HPV 16 E6 127-141 was exclusively 
presented by HLA-DR*0101 (Gallagher and Man 2007). It appeared that the differential 
cytokine secretion profiles observed for belxl and be 1x2 could be due to their TCR.
A central aim in this project was to study the interactions between the HLA- 
DR*0101-HPV16 E6 127-141 complexes and TCR. In order to evaluated the type of 
molecular interactions involved in this mechanism it was necessary to generate a HLA- 
DR*0101-HPV16 E6 127-141 tetramer, soluble TCRs and study their binding using 
BIAcore™. In order to produce HLA-DR*0101-HPV16 E6 127-141 tetramer different 
technologies have been used; baculovirus expression system and E. coli cells expression 
system. Unfortunately after severals attempts with the two expression systems and 
various conditions no tetramer could be obtained, and commercially produced tetramers 
did not appear to bind to specific T cells.
One explanation for this failure to produce soluble class II MHC associated with 
HPV peptide could be die stability of the complex. Class II molecules are non-covalent 
dimers of a  and p chains, which have a variable range of stability and solubility in 
solution. Peptides bind into a/p chain groove of class II based on specific interactions 
with amino acid side chains, which confer specificity, determining which peptides will 
bind which class II molecules (Nepom, Buckner et al. 2002). The stability of the 
molecule is dependant of the interaction between three factors; the a  chain, the p chain
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and the peptide; indeed peptide-free class II molecules are relatively unstable (Jensen, 
Weber et al. 1999). Even if HPV 16 E6127-141 peptide could be loaded on cells expressing 
stable HLA-DR*0101, and these complexes are able to activate specific T-cells via 
engagement of the TCR, the interactions and the stability of the HLA-DR*0101 and 
HPV 16 E6 127-141 stay unknown. Indeed if the peptide is not able to stabilise the molecule 
during its synthesis and refolding in-vivo (baculovirus expression system) or in-vitro (E. 
coli expression system) there will not be production of the molecule. Nevertheless 
previous studies in the laboratory have demonstrated the processing and presentation of 
this epitope by BLCL. APC have been incubated with soluble full-length E6  protein and 
co-cultured with belx2 T-cell clone overnight and an ELISpot assay has been carried out. 
Strong positive responses were detected against the epitope, which clearly indicated that 
the full length E6  protein could be processed and the epitope presented to belx2 
(Gallagher and Man 2007). These results indicated that the stability of the complex was 
sufficient for its formation and the processing mechanism occurs in the BLCL. However, 
it was not possible to assess the processing of this epitope in cervical carcinoma cells; 
there are no readily available HPV16+ cervical cancer cell lines expressing HLA- 
DR*0101, and previous attempts to transfect HLA-DR*0101 into HPV16+ CaSki cells 
were unsuccessful.
An alternative explanation for the failure to produce soluble HLA:HPV peptide 
complexes may be that there was inadequate assembly in the insect cells. Soon after 
synthesis in the ER, three a/p MHC class II dimers associate with a trimer of invariant 
(Ii) chains, which ensure that ER derived proteins do not bind to the ER membrane 
anchored MHC II molecule (Cresswell 1996) (Romagnoli, Layet et al. 1993). This
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nonameric complex exits the ER and pass through the Golgi apparatus before being 
transported to the endocytic pathway, under the influence of transport signals present in 
the cytoplasmic region of the Ii chain (Guermonprez, Valladeau et al. 2002). During the 
formation of these complexes, calnexin is present to add stability to the newly formed 
molecule (Anderson and Cresswell 1994). Ii has a second function, which starts with the 
dissociation of MHC II from calnexin and results in the transport of the MHC II molecule 
from the ER to endosomal compartments for peptide loading. In order for peptide loading 
to occur, Ii must be removed from the MHC II peptide-binding groove. This is mediated 
through the activities of cathepsin S (Villadangos, Bryant et al. 1999), which cleaves Ii in 
a number of steps. Ii is then released from the MHC II molecule through the actions of 
the class II associated invariant-chain peptide (CLIP), which performs the final Ii 
cleavage. This also releases the MHC II molecule from the membrane. In order for MHC 
II to bind to endosomally derived proteins, an MHC-like molecule called DM must first 
associate. This association leads to the dissociation of CLIP from the MHC II peptide- 
binding groove, allowing endosomally processed peptide fragments to bind. MHC DM 
(Kropshofer, Hammerling et al. 1999) also facilitates a process termed “peptide-editing”, 
which ensures that only stable MHC II peptide complexes are expressed and transported 
to the cell surface for potential TCR interactions (Busch, Doebele et al. 2000). All these 
mechanisms occur in the BLCL which are human cells even if they are transformed. In 
the insect cells it is not the similar system, indeed the expression and secretion of the 
soluble molecule is due to the infection by the cell of a recombinant virus which carries 
the correct DNA for the molecule. Indeed another explanation of the failure could be a 
major trouble in the DNA construction, nevertheless similar construction was used to
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produce HLA-DR*0101-CLIP and a low quantity was secreted. These results 
demonstrated that the DNA construction and cloning strategy were adequate, even if  this 
soluble molecule was produced in low quantity. It is possible that the production of HLA- 
DR*0101-CLIP was easier in insect cells than HLA-DR*0101-HPV16 E6 127-141 due to a 
complexity of the molecule or a better stability in insect cell environment.
Therefore to move the project forward, an HLA-DR*0101-HPV16 E6127-141 
ultimer was ordered from Pro-immune (Oxford, UK). This company has successfully 
synthesized other HLA-DR1 ultimers e.g. HLA-DR1 complexed to an Influenza 
hemagglutin peptide. Despite using several different conditions, no binding of the 
Proimmune ultimer to T-cells belxl or belx2 could be detected. It is possible that antigen 
specific T-cells are not stained by class II MHC tetramers because the TCR avidity for 
soluble MHC/peptide complexes is too weak (Vollers and Stem 2008). By contrast, TCR 
avidity for MHC/peptide complexes on live antigen specific cells may be influenced by 
other cell surface molecules. This might explain the lack of binding of the Proimmune 
ultimer, despite clear functional specificity of the tested cells. Another explanation was 
the production by Proimmune of unstable or incorrectly folded molecules due to an 
unstable binding between HLA-DR*0101 and HPV 16 E6 127-141. It was decided to 
investigate the functional difference between belxl and belx2  at a cellular level using in a 
first instance tmncated versions of HPV 16 E6127-141 and in a second instance variants 
from other HPV types.
The MHC-restricted recognition of antigen peptides by TCRs is a central event in 
the cellular immunity against pathogens and in the immune surveillance of cancer cells. 
In class II MHC polymorphic pockets in the binding site provide the basis for the
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preference of different alleles for different peptide sequence motifs (Stem, Brown et al. 
1994). Indeed class II molecule consists of an a-chain forming a l  and a2 domains and a 
P-chain forming p i and p2 domains. The MHC molecule firmly holds a peptide in a 
groove formed with two a-helices and a p-sheet floor and presents the peptide to T-cells 
(Tsurui and Takahashi 2007). These complexes class II MHC-peptide are recognized by 
the TCR, the V a domain recognizes the Cterminai side of the peptide with CDR1 and 3, and 
the a-helix of the p i domain with CDR2 ; and the Vp domain recognizes the N tenninai side 
of the peptide with CDR1 and 3, and the a  helix of the a l  domain with CDR2 (figure 
49). Belxl and belx2 are T-cell clones specific for HPV16 E6127-141 which differs by their 
TCR. In order to study the impact of the Cteiminai and Ntenninai ends of the peptide to the 
TCR and MHC binding various truncated peptides have been designed (table 16).
For the two clones, belxl and belx2, it was showed that the Germinal end had a 
greater impact on T-cell IFNy secretion than the Ntenninai end. Indeed the deletion of first 
three amino acids of the HPV16 E6127-141 peptide did not affect the response, similar 
profile of response and quantities of IFNy were observed in each case. The peptide 4 did 
not induce the same type of response for the two clones, for belxl the response was 
abolished, for belx2  the response required a higher concentration of peptide than the wild 
type. An explanation could be the impact of the deletion of the Q in P-2. Indeed 
following the identification of HLA-DR*0101 as the allotype responsible for HPV16 
E6127-141 (Gallagher and Man 2007), the peptide sequences was compared to the 
corresponding binding motifs (www.svfpeithi.de) . Peptide binding motifs for HLA- 
DR*0101 (Rammensee, Bachmann et al. 1999) have been defined but are often imprecise 
(Marsh 2000). The motifs are based upon the sequences of peptides that are known to
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bind, but do not form an exhaustive list of potential anchor residues for a given allotype.
It is therefore not uncommon for peptide epitopes to exhibit partial or no alignment with a
binding motif (Marsh 2000). For HLA-DR*0101 restricted peptides, 4 key anchor
positions (within the 9 amino acid core region) have been identified; PI, P4, P6  and P9.
The potential amino acids for each of the anchor residues are listed below (Rammensee,
Bachmann et al. 1999).
PI =Y, V, L, F, I, A, M, W 
P4 =L, A, I, V, M, N, Q 
P6  =A, G, S, T, C, P 
P9 =A, I, V, N, F, Y
The sequence of HPV16 E6127-141 can be aligned to complement PI, P4 and P6  as 
highlighted in bold and underlined in the following; D K K Q R F H N I R G R W T G .  
Based on this alignment it appears that HPV16 E6 127-141 is a conventional HLA-DR*0101 
restricted peptide. Using the SYFPEITHI predictive database (Rammensee, Bachmann et 
al. 1999) HPV16 E6127-141 is predicted to bind to HLA-DR*0101 molecules.
The residue in P-2 (Q) was a putative TCR contact residue. The major difference 
in belxl and belx2 was their TCRs, indeed the two clones had the same a  chain but not 
the same p chain. One of the characteristics of the TCRs is their ability to differ in their 
ap chain pairing, such that the pseudo Va/Vp twofold angle, which currently varies from
166° to 188°, can contribute to the variation in TCR orientation on the pMHC (Rudolph
and Wilson 2002), and potentially could have relevance to TCR signalling if  the pairing
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Table 16: List of all the peptides designed from the HPV16 E 6 1 2 7 - 1 4 1  epitope. 
Peptides Sequences
P-5 P-4 P-3 P-2 P-l PI P2 P3 P4 P5 P6 P7 P8 P9 P10
H6 E6127-141 D K K Q R F H N I R G R W T G
1 K K Q R F H N I R G R W T G
2 K Q R F H N 1 R G R W T G
3 Q R F H N I R G R W T G
4 R F H N I R G R W T G
5 D K K Q R F H N I R G R W T
6 D K K Q R F H N I R G R W
7 D K K Q R F H N I R G R
8 Q R F H N 1 R G R W T G
9 D K K K R F H N 1 R G R W T G
10 K R F H N I R G R W T G
HPV31 K R F H N I G G R W T G
HPV52 K R F H N I M G R w T G
HPV58 K R F H N I S G R w T G
HPV33 K R F H N I S G R w A G
HPV67 K R F H N I s N R w T G
R M
Putative TCR contact residues P utative  M H C  an ch o r resid u es
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changes propagate to the constant domains or are translated to accessory proteins (Garcia 
1999). Furthermore few studies have demonstrated that the Vp chain of the TCR 
recognizes the Ntenninai end of the peptide with CDR1 and 3 (Garcia 1999) (Garcia, Scott 
et al. 1996) (Garboczi, Ghosh et al. 1996) (Garcia and Teyton 1998) (Garcia 1999) 
(Reinherz, Tan et al. 1999) (Tsurui and Takahashi 2007). The deletion of the Q could 
generate a change in the twofold angle when the pMHC interacted with the TCR, only in 
presence of the Vpl6, and it could affect the intracellular signalling. It is possible that the 
Vp7 chain was less affected by the loss of the Q residue. A t the end, to answer to these 
questions it would be necessary to be able to produce the soluble molecules (TCRs and 
MHCs) and observe their interactions and affinity using BIAcore™ technology; 
nevertheless it was not possible to do this during the current study.
By contrast the deletion on the Cterminai end o f the HPV16 E6127-141 peptide had an 
important impact on the response of each clone. Each deletion was associated with either 
a putative TCR contact residue or a putative MHC anchor residue. The deletions 
generated peptides that potentially were not able to bind HLA-DR*0101 or to interact 
with the TCR. Furthermore the P10 position has been identified as minor or auxiliary 
anchor residues in several pMHC complexes (Ferrante and Gorski 2007).
Alignment o f the HPV16 E6127-141 sequence with the E6 protein sequences from 
five different HR HPVs revealed that residues in the core region involved in HLA-DR 
binding are relatively well conserved. In particular, the HPV16 E6127-141 anchor residues 
(at positions 1, 4, 6 and 9) are very well conserved in the E6 proteins from all the HR 
HPVs assessed. Furthermore, the putative TCR contact residues at P-l, P7 and P8 are
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also well conserved (Table 15). TCR recognition of pMHC is a highly sensitive ligand 
interaction whereby subtle changes in peptide can cause drastic variations in T-cell 
effector function (Ryan, McNeil et al. 2004). Indeed antagonist peptide can inhibit T-cell 
activation, and, similarly, engagement with a partial agonist elicits some, but not all, of 
the responses that characterize T-cell activation by fully agonistic ligand (Rudolph, 
Stanfield et al. 2006). In order to have a better understanding of the interactions between 
HPV16 E6127-141 peptide, HLA-DR*0101 and TCR, it was interesting to test the E6  
proteins from the five HR HPVs. Different substitutions were performed in the wild type 
peptide, and all o f them included amino acids which were either a putative TCR contact 
residues or putative MHC anchor residues. To define if  a peptide could be an agonist, a 
partial agonist, an antagonist, a partial antagonist or a null peptide several experiments 
including ELISA, inhibition assays and TCR down regulation were performed. The 
results showed the peptides from HPV58 and HPV33 were partial agonist, peptides from 
HPV31 and HPV52 were null peptides and peptide from HPV67 was an antagonist. 
Many models o f T-cell activation have been proposed to explain the differential effects of 
altered peptides. But no specific model is completely validated, few explanations are 
proposed. One possibility is that lowering peptide affinity reduces antigen dose by 
decreasing the number of potential pMHC complexes (Ryan, McNeil et al. 2004). An 
alternative explanation is that substitution at MHC contact positions shift the orientation 
of TCR-exposed side chains, thus affecting the recognition of ligand by TCR. Indeed the 
TCR itself seems to adapt to small changes in the pMHC ligand by small conformational 
changes or rearrangements of its central CDR loops (Rudolph and Wilson 2002). The 
dissociation rate o f pMHC complexes could also prove to be a critical variable in
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dictating T-cell responses levels. It is possible too that those substitutions at MHC- 
contact positions shift the orientation o f TCR-exposed side chains, thus affecting the 
recognition o f ligand by the TCR. It is also formally possible that alteration of MHC 
anchor residues could change the conformation of the MHC a-helices. Nevertheless the 
mechanism by which antagonist peptides inhibit T cell activation remains incompletely 
understood and few studies have been performed, and even the crystal structures of 
several agonist and antagonist complexes, could not predict their biological behaviour 
because such similar structure can not resolve the subtle differences in kinetic and 
thermodynamic properties that lead to such different signalling outcomes (Rudolph and 
Wilson 2002).
These results suggested that it is important to evaluate the therapeutic potential of 
altered peptide ligands. Indeed no therapeutic vaccine exist for the moment, although 
clinical trials involving viral vectors, peptides, prime boost, DNA or DC have been 
performed (see table 3). In the chapter 5 it was demonstrated that the substitution of two 
amino acids in the wild type peptide was enough to produce an antagonist peptide which 
could inhibit the response induced by HPV16 E6127- 141.
This finding illustrates a potential mechanism for turning off a T cell response 
against a particular peptide epitope and suggests that this should be investigated for other 
peptide epitopes. It also suggests that care must be taken when modifying peptide 
sequences for vaccines because modification might result in a peptide that turns off the 
response.
It has been demonstrated that different factors are necessary for full malignant 
transformation (Campo 1998) and the mechanism of escape by the virus could be one of
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them. HPV infects the keratinocytes within the cervical epithelium. Within the cervical 
epithelia, the primary cell population responsible for antigen presentation is the LC. 
These cells are thought to endocytose HPV antigen within the epithelia and upon 
activation, migrate to the lymph nodes where they present the processed peptide in the 
context of HLA class II molecules to the CD4+ T-cells (Kupper and Fuhlbrigge 2004). 
Subsequent to T-cell priming, the HPV-specific activated CD4+ T-cell population may 
then migrate from the lymph node and enter the infected cervical tissue. Local re­
stimulation o f the T-cells either by infected keratinocytes or other APC such as DCs and 
macrophages presenting the cognate peptide, stimulates the T-cells to produce cytokines 
such as IL-2 and IFNy. The local production of these immunomodulatory cytokines 
could have several beneficial effects. Firstly IFNy is a potent anti-viral cytokine which 
could limit viral spread and also activate macrophages resulting in the production of 
potent cytotoxic compounds such as NO and reactive oxygen species. The production of 
IL-2 would positively effect the development of the CD8 + CTL response, which in other 
systems is known to play a crucial role in the clearance of virally infected or transformed 
cells. The principles of this model are based on a recent report which described a vital 
role for CD4+ T-cells (through collaboration with macrophages) in the control of a 
primary immune response against a HLA class II negative tumour in mice (Corthay, 
Skovseth et al. 2005). The presentation of an antagonist peptide by the APC to the T-cells 
could induce a tolerance of the organism to the viruses. Indeed an antagonist peptide 
could either down-regulate the TCR (as peptide variant from HPV67) or bind the TCR 
and leave less site free for the binding o f agonist peptides. Furthermore if a person, 
infected by HPV 16, is infected by HPV67 this could result in the abolishment o f the
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responses against HPV 16 due to a tolerance induced by the new infection. Indeed a 
model could be established in HPV infection or co-infection (figure 50). This model 
could take place in young women who are more likely to regularly encounter different 
HPV types as a result of high levels of sexual activity. Young women could be infected 
by a first type of HPV, such as HPV 16, in this case either the immune system will 
eradicate the infection in the 3 following years (about 80% of the infected population) or 
there will be a persistence of the infection which could drive to lesions and cancer. In the 
case of a clearance a naive immune response takes place and is followed by a adaptive 
immune response. During the establishment of the immune response if a co-infection 
takes place with a virus, such as HPV67, this co-infection could inhibit the response 
induced by HPV 16 and then allows a persistence of the first virus, which could generate a 
persistent infection that could lead to cancer. These kinds of events could be an 
explanation for the evasion of a virus type from the immune system. Furthermore it has 
been demonstrated that HPV67 is a HR HPV, and associated with HPV31 is able to 
induce the development o f squamous cell carcinoma, an explanation could be the 
antagonistic role of the peptide from one virus which allow the evasion of the other virus.
In the future various studies could help a better understanding of the responses 
against HPVs. The purification of HLA-DR*0101-CLIP, from transfected insect cells, 
needs to be improved, using a column carrying L243 antibody to obtain a higher yield 
and realise a peptide exchange. Indeed a few studies have already used this technique 
which consists in the production of a class II MHC tetramer associated with CLIP peptide 
and the exchange of the CLIP peptide by the target peptide (Day, Seth et al. 2003). The 
technique has the advantage to allow the production of several different HLA:peptide
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complexes starting from the same HLA:CLIP source. From this it could be possible to 
exchange CLIP peptide by the wild type or the variant peptides and to study the 
interaction between pMHC and T-cells. Animal studies could be another aspect of the 
future studies.Using HPV16 E6127-141 and the variants it could be interesting to observe if 
the in-vitro results could be correlated to in-vivo results. Indeed it could be interesting to 
test the responses induced by HPV 16 E6127-141 on T-cells from severals samples of 
DRl+ve tumour at different grades of infection. These observations could allow to have a 
better understanding of the immune responses against HPV 16 and to observe, in the case 
of co-infection, if  there is a potential inhibition o f the T-cell response.
This study was based on two T-cell clones generated from one healthy donor, it 
could be interesting in the future to generate other clones, against HPV 16 E 6127-141, from 
other DR1 healthy donors in order to generalize these data. Previous data (Gallagher and 
Man, 2007) showed that different epitope from HPV 16 E 6 could be presented by other 
HLA-DR (for example HPV 16 E 619.33 is potentially presented by HLA-DR*0104 or 
*0115). Based on these results it could be interesting to generate other T-cell clones 
against different epitopes from HPV 16 E 6 and to compare the responses against the 
different clones, this kind o f studies could help the understanding of molecular interaction 
between TCR and pMHC. Finally, study the responses against HPV 18 E 6127-141 by belxl 
and belx2  could permit to observe if there is a cross-presentation or reactivity between 
the two viruses, which contribute to a significant proportion o f disease worldwide.
Over the last few years severals studies have demonsrated the efficacy of the 
prophylactic vaccines against HPV such as Gardasil (Govan 2008), nevertheless these 
vaccines are not therapeutic vaccines and they cannot be used in patient already infected
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with HPV. In the future it seems likely that the most effective immunotherapeutic 
approaches will need to combine several different strategies in order to overcome many 
of the problems presented by the cervical cancer environment. As an example, the 
provision of additional pro-inflammatory molecules such as IFNy or TNFa, along with an 
HPV vaccine construct could facilitate the generation of an appropriately polarised and 
effective T-cell response. Recent advances in soluble TCR technology (Laugel, Boulter 
et al. 2005) may soon permit the targeting of pro-inflammatory cytokines specifically to 
the infected/transformed tissue by attaching them to viral-specific soluble TCRs (which 
have been modified to increase their avidity). Such an approach could also help to 
decrease the occurrence of unpleasant side effects that are suffered as a result of systemic 
injection with these cytokines. In animal tumour models, the depletion of T-regulatory 
cells has yielded some positive results (Jones, Dahm-Vicker et al. 2002), and it is possible 
that such an approach may be effective in the treatment of HPV-mediated disease (van 
der Burg, Piersma et al. 2007). Thus the understanding of the activation of HPV specific 
T-cells is still important for development of immunotherapy and the current study shows 
the potential for poorly designed peptide vaccines, to make disease worse rather than 
better.
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